Philip Morris International (PM) 10-Q 25 Jul 24 2024 Q2 Quarterly report Financial data

Cover Page

Cover Page - shares	6 Months Ended
	Jun. 30, 2024	Jul. 19, 2024
Document Information [Line Items]
Document Type	10-Q
Document Quarterly Report	true
Document Period End Date	Jun. 30, 2024
Document Transition Report	false
Entity File Number	001-33708
Entity Registrant Name	Philip Morris International Inc.
Entity Incorporation, State or Country Code	VA
Entity Tax Identification Number	13-3435103
Entity Address, Address Line One	677 Washington Blvd, Suite 1100
Entity Address, City or Town	Stamford
Entity Address, State or Province	CT
Entity Address, Postal Zip Code	06901
City Area Code	(203)
Local Phone Number	905-2410
Entity Current Reporting Status	Yes
Entity Interactive Data Current	Yes
Entity Filer Category	Large Accelerated Filer
Entity Small Business	false
Entity Emerging Growth Company	false
Entity Shell Company	false
Entity Common Stock, Shares Outstanding		1,554,801,534
Entity Central Index Key	0001413329
Current Fiscal Year End Date	--12-31
Document Fiscal Year Focus	2024
Document Fiscal Period Focus	Q2
Amendment Flag	false
Common Stock
Document Information [Line Items]
Title of 12(b) Security	Common Stock, no par value
Trading Symbol	PM
Security Exchange Name	NYSE
0.625% Notes due 2024
Document Information [Line Items]
Title of 12(b) Security	0.625% Notes due 2024
Trading Symbol	PM24B
Security Exchange Name	NYSE
3.250% Notes due 2024
Document Information [Line Items]
Title of 12(b) Security	3.250% Notes due 2024
Trading Symbol	PM24A
Security Exchange Name	NYSE
2.750% Notes due 2025
Document Information [Line Items]
Title of 12(b) Security	2.750% Notes due 2025
Trading Symbol	PM25
Security Exchange Name	NYSE
3.375% Notes due 2025
Document Information [Line Items]
Title of 12(b) Security	3.375% Notes due 2025
Trading Symbol	PM25A
Security Exchange Name	NYSE
2.750% Notes due 2026
Document Information [Line Items]
Title of 12(b) Security	2.750% Notes due 2026
Trading Symbol	PM26A
Security Exchange Name	NYSE
2.875% Notes due 2026
Document Information [Line Items]
Title of 12(b) Security	2.875% Notes due 2026
Trading Symbol	PM26
Security Exchange Name	NYSE
0.125% Notes due 2026
Document Information [Line Items]
Title of 12(b) Security	0.125% Notes due 2026
Trading Symbol	PM26B
Security Exchange Name	NYSE
3.125% Notes due 2027
Document Information [Line Items]
Title of 12(b) Security	3.125% Notes due 2027
Trading Symbol	PM27
Security Exchange Name	NYSE
3.125% Notes due 2028
Document Information [Line Items]
Title of 12(b) Security	3.125% Notes due 2028
Trading Symbol	PM28
Security Exchange Name	NYSE
2.875% Notes due 2029
Document Information [Line Items]
Title of 12(b) Security	2.875% Notes due 2029
Trading Symbol	PM29
Security Exchange Name	NYSE
3.375% Notes due 2029
Document Information [Line Items]
Title of 12(b) Security	3.375% Notes due 2029
Trading Symbol	PM29A
Security Exchange Name	NYSE
3.750% Notes due 2031
Document Information [Line Items]
Title of 12(b) Security	3.750% Notes due 2031
Trading Symbol	PM31B
Security Exchange Name	NYSE
0.800% Notes due 2031
Document Information [Line Items]
Title of 12(b) Security	0.800% Notes due 2031
Trading Symbol	PM31
Security Exchange Name	NYSE
3.125% Notes due 2033
Document Information [Line Items]
Title of 12(b) Security	3.125% Notes due 2033
Trading Symbol	PM33
Security Exchange Name	NYSE
2.000% Notes due 2036
Document Information [Line Items]
Title of 12(b) Security	2.000% Notes due 2036
Trading Symbol	PM36
Security Exchange Name	NYSE
1.875% Notes due 2037
Document Information [Line Items]
Title of 12(b) Security	1.875% Notes due 2037
Trading Symbol	PM37A
Security Exchange Name	NYSE
6.375% Notes due 2038
Document Information [Line Items]
Title of 12(b) Security	6.375% Notes due 2038
Trading Symbol	PM38
Security Exchange Name	NYSE
1.450% Notes due 2039
Document Information [Line Items]
Title of 12(b) Security	1.450% Notes due 2039
Trading Symbol	PM39
Security Exchange Name	NYSE
4.375% Notes due 2041
Document Information [Line Items]
Title of 12(b) Security	4.375% Notes due 2041
Trading Symbol	PM41
Security Exchange Name	NYSE
4.500% Notes due 2042
Document Information [Line Items]
Title of 12(b) Security	4.500% Notes due 2042
Trading Symbol	PM42
Security Exchange Name	NYSE
3.875% Notes due 2042
Document Information [Line Items]
Title of 12(b) Security	3.875% Notes due 2042
Trading Symbol	PM42A
Security Exchange Name	NYSE
4.125% Notes due 2043
Document Information [Line Items]
Title of 12(b) Security	4.125% Notes due 2043
Trading Symbol	PM43
Security Exchange Name	NYSE
4.875% Notes due 2043
Document Information [Line Items]
Title of 12(b) Security	4.875% Notes due 2043
Trading Symbol	PM43A
Security Exchange Name	NYSE
4.250% Notes due 2044
Document Information [Line Items]
Title of 12(b) Security	4.250% Notes due 2044
Trading Symbol	PM44
Security Exchange Name	NYSE

Condensed Consolidated Statemen

Condensed Consolidated Statements of Earnings - USD ($) $ in Millions	3 Months Ended				6 Months Ended
	Jun. 30, 2024		Jun. 30, 2023		Jun. 30, 2024		Jun. 30, 2023
Income Statement [Abstract]
Net revenues	$ 9,468	[1],[2]	$ 8,967	[1],[2]	$ 18,261	[3],[4]	$ 16,986	[3],[4]
Cost of sales	3,345		3,228		6,540		6,266
Gross profit	6,123		5,739		11,721		10,720
Marketing, administration and research costs (Notes 4 & 7)	2,679	[5]	2,508	[5]	5,232	[6]	4,758	[6]
Impairment of goodwill (Note 4)	0		665		0		665
Operating income	3,444		2,566		6,489		5,297
Interest expense, net	329		297		628		527
Pension and other employee benefit costs (Note 3)	14		6		29		28
Earnings before income taxes	3,101		2,263		5,832		4,742
Provision for income taxes	734		560		1,410		988
Equity investments and securities (income)/loss, net	(161)		21		(352)		(30)
Net earnings	2,528		1,682		4,774		3,784
Net earnings attributable to noncontrolling interests	122		114		220		221
Net earnings attributable to PMI	$ 2,406		$ 1,568		$ 4,554		$ 3,563
Per share data (Note 6):
Basic earnings per share (in dollars per share)	$ 1.54		$ 1.01		$ 2.92		$ 2.29
Diluted earnings per share (in dollars per share)	$ 1.54		$ 1.01		$ 2.92		$ 2.29
[1]Includes net revenues from related parties of $961 million and $901 million for the three months ended June 30, 2024 and 2023, respectively.[2]Net of excise taxes of $12,923 million and $12,749 million for the three months ended June 30, 2024 and 2023, respectively.[3]Includes net revenues from related parties of $1,821 million and $1,774 million for the six months ended June 30, 2024 and 2023, respectively.[4]Net of excise tax on products of $24,762 million and $24,048 million for the six months ended June 30, 2024 and 2023, respectively.[5]Includes the South Korea indirect tax charge of $204 million for the three months ended June 30, 2023. For further details, see Note 7. Segment Reporting. Segment Reporting.

Condensed Consolidated Statem_2

Condensed Consolidated Statements of Earnings (Parenthetical) - USD ($) $ in Millions	3 Months Ended				6 Months Ended
	Jun. 30, 2024		Jun. 30, 2023		Jun. 30, 2024		Jun. 30, 2023
Net revenues, related parties	$ 9,468	[1],[2]	$ 8,967	[1],[2]	$ 18,261	[3],[4]	$ 16,986	[3],[4]
Excise tax	12,923		12,749		24,762		24,048
EA, AU & PMI DF
Net revenues, related parties	1,673		1,680		3,357		3,200
Korea | EA, AU & PMI DF
Non-cash pre-tax charge			204				204
Related Party
Net revenues, related parties	$ 961		$ 901		$ 1,821		$ 1,774
[1]Includes net revenues from related parties of $961 million and $901 million for the three months ended June 30, 2024 and 2023, respectively.[2]Net of excise taxes of $12,923 million and $12,749 million for the three months ended June 30, 2024 and 2023, respectively.[3]Includes net revenues from related parties of $1,821 million and $1,774 million for the six months ended June 30, 2024 and 2023, respectively.[4]Net of excise tax on products of $24,762 million and $24,048 million for the six months ended June 30, 2024 and 2023, respectively.

Condensed Consolidated Statem_3

Condensed Consolidated Statements of Comprehensive Earnings - USD ($) $ in Millions	3 Months Ended		6 Months Ended
	Jun. 30, 2024	Jun. 30, 2023	Jun. 30, 2024	Jun. 30, 2023
Statement of Comprehensive Income [Abstract]
Net earnings	$ 2,528	$ 1,682	$ 4,774	$ 3,784
Change in currency translation adjustments:
Unrealized gains (losses), net of income taxes	(123)	(572)	365	(827)
(Gains)/losses transferred to earnings, net of income taxes	113	2	155	2
Change in net loss and prior service cost:
Net gains (losses) and prior service costs, net of income taxes	0	(2)	0	0
Amortization of net losses, prior service costs and net transition costs, net of income taxes	33	16	67	41
Change in fair value of derivatives accounted for as hedges:
Gains (losses) recognized, net of income taxes	108	187	286	246
(Gains) losses transferred to earnings, net of income taxes	(48)	(75)	(94)	(104)
Other comprehensive earnings (losses), net of income taxes	83	(444)	779	(642)
Total comprehensive earnings	2,611	1,238	5,553	3,142
Less comprehensive earnings (losses) attributable to:
Noncontrolling interests	70	101	114	65
Comprehensive earnings attributable to PMI	$ 2,541	$ 1,137	$ 5,439	$ 3,077

Condensed Consolidated Statem_4

Condensed Consolidated Statements of Comprehensive Earnings (Parenthetical) - USD ($) $ in Millions	3 Months Ended		6 Months Ended
	Jun. 30, 2024	Jun. 30, 2023	Jun. 30, 2024	Jun. 30, 2023
Statement of Comprehensive Income [Abstract]
Change in foreign currency translation adjustments, unrealized gains (losses), tax	$ (28)	$ 31	$ (130)	$ 83
Change in currency translation adjustments, transferred to earnings, tax	0	0	0	0
Net gains (losses) and prior service costs, tax	0	1	0	0
Amortization of net losses, prior service costs and net transition costs, tax	(9)	(7)	(18)	(14)
Change in fair value of derivatives accounted for as hedges, gains (losses) recognized, tax	(16)	(32)	(55)	(48)
Change in fair value of derivatives accounted for as hedges, (gains) losses transferred to earnings, tax	$ 7	$ 16	$ 23	$ 22

Condensed Consolidated Balance

Condensed Consolidated Balance Sheets - USD ($) $ in Millions		Jun. 30, 2024	Dec. 31, 2023
ASSETS
Cash and cash equivalents		$ 4,807	$ 3,060
Trade receivables (less allowances of $54 in 2024 and $79 in 2023) (1)	[1]	4,240	3,461
Other receivables (less allowances of $21 in 2024 and $35 in 2023)		877	930
Inventories:
Leaf tobacco		1,920	1,942
Other raw materials		2,359	2,293
Finished product		5,103	6,539
Total inventory, net		9,382	10,774
Other current assets		1,722	1,530
Total current assets		21,028	19,755
Property, plant and equipment, at cost		16,736	17,080
Less: accumulated depreciation		9,472	9,564
Total property, plant and equipment, net		7,264	7,516
Goodwill (Note 4)		16,819	16,779
Other intangible assets, net (Note 4)		12,171	9,864
Equity investments (Note 12)		4,961	4,929
Deferred income taxes		918	814
Other assets (less allowances of $24 in 2024 and $25 in 2023) (Note 18)		2,621	5,647
TOTAL ASSETS		65,782	65,304
LIABILITIES
Short-term borrowings (Note 10)		139	1,968
Current portion of long-term debt (Note 10)		4,353	4,698
Accounts payable		3,591	4,143
Accrued liabilities:
Marketing and selling		961	862
Taxes, except income taxes		6,826	7,514
Employment costs		1,052	1,262
Dividends payable		2,040	2,041
Other		2,453	2,737
Income taxes		1,001	1,158
Total current liabilities		22,416	26,383
Long-term debt (Note 10)		44,647	41,243
Deferred income taxes		2,651	2,335
Employment costs		2,823	3,046
Income taxes and other liabilities		1,187	1,743
Total liabilities		73,724	74,750
Contingencies (Note 8)
STOCKHOLDERS’ (DEFICIT) EQUITY
Common stock, no par value (2,109,316,331 shares issued in 2024 and 2023)		0	0
Additional paid-in capital		2,249	2,285
Earnings reinvested in the business		34,582	34,090
Accumulated other comprehensive losses (Note 11)		(10,930)	(11,815)
Total stockholders' equity before treasury stock		25,901	24,560
Less: cost of repurchased stock (554,559,782 and 556,891,800 shares in 2024 and 2023, respectively)		35,645	35,785
Total PMI stockholders’ deficit		(9,744)	(11,225)
Noncontrolling interests		1,802	1,779
Total stockholders’ deficit		(7,942)	(9,446)
TOTAL LIABILITIES AND STOCKHOLDERS’ (DEFICIT) EQUITY		$ 65,782	$ 65,304
[1] Includes trade receivables from related parties of $834 million and $710 million as of June 30, 2024, and December 31, 2023, respectively. For further details, see Note 12. Related Parties - Equity Investments and Other.

Condensed Consolidated Balanc_2

Condensed Consolidated Balance Sheets (Parenthetical) - USD ($) $ in Millions		Jun. 30, 2024	Dec. 31, 2023
Trade receivables, allowances		$ 54	$ 79
Other receivables, allowances		21	35
Other assets, allowances		$ 24	$ 25
Common stock, issued (in shares)		2,109,316,331	2,109,316,331
Repurchased stock (in shares)		554,559,782	556,891,800
Trade receivables, related parties	[1]	$ 4,240	$ 3,461
Related Party
Trade receivables, related parties		$ 834	$ 710
[1] Includes trade receivables from related parties of $834 million and $710 million as of June 30, 2024, and December 31, 2023, respectively. For further details, see Note 12. Related Parties - Equity Investments and Other.

Condensed Consolidated Statem_5

Condensed Consolidated Statements of Cash Flows - USD ($)		6 Months Ended
		Jun. 30, 2024	Jun. 30, 2023
CASH PROVIDED BY (USED IN) OPERATING ACTIVITIES
Net earnings		$ 4,774,000,000	$ 3,784,000,000
Adjustments to reconcile net earnings to operating cash flows:
Depreciation and amortization expense		812,000,000	600,000,000
Impairment of goodwill and other intangibles (Note 4)		27,000,000	680,000,000
Deferred income tax (benefit) provision		59,000,000	(211,000,000)
Asset impairment and exit costs, net of cash paid (Note 15)		136,000,000	85,000,000
Cash effects of changes, net of the effects from acquired companies:
Receivables, net	[1]	(978,000,000)	(292,000,000)
Inventories		1,047,000,000	(74,000,000)
Accounts payable		(145,000,000)	(414,000,000)
Accrued liabilities and other current assets		(341,000,000)	(1,603,000,000)
Income taxes		(329,000,000)	(509,000,000)
Pension plan contributions (Note 3)		(55,000,000)	(72,000,000)
Other		(134,000,000)	513,000,000
Net cash provided by (used in) operating activities		4,873,000,000	2,487,000,000
CASH PROVIDED BY (USED IN) INVESTING ACTIVITIES
Capital expenditures		(787,000,000)	(639,000,000)
Acquisitions, net of acquired cash (Note 18)		44,000,000	0
Equity investments		(113,000,000)	(91,000,000)
Collateral posted/settlements for derivatives, (paid)/returned (Note 5)		439,000,000	(342,000,000)
Other		(113,000,000)	(2,000,000)
Net cash provided by (used in) investing activities		(530,000,000)	(1,074,000,000)
Short-term borrowing activity by original maturity:
Net issuances (repayments) - maturities of 90 days or less		(1,463,000,000)	2,356,000,000
Issuances - maturities longer than 90 days		100,000,000	712,000,000
Repayments - maturities longer than 90 days		(433,000,000)	(180,000,000)
Repayments under credit facilities related to Swedish Match AB acquisition		0	(4,430,000,000)
Long-term debt proceeds		5,194,000,000	7,652,000,000
Long-term debt repaid		(1,812,000,000)	(2,034,000,000)
Dividends paid		(4,064,000,000)	(3,964,000,000)
Collateral received/settlements for derivatives, received/(returned)		350,000,000	(5,000,000)
Payments to acquire Swedish Match AB noncontrolling interests		0	(883,000,000)
Noncontrolling interests activity and Other (Note 18)		(269,000,000)	(144,000,000)
Net cash provided by (used in) financing activities		(2,397,000,000)	(920,000,000)
Effect of exchange rate changes on cash, cash equivalents and restricted cash		(216,000,000)	(198,000,000)
Cash, cash equivalents and restricted cash:
Increase (Decrease)	[2]	1,730,000,000	295,000,000
Balance at beginning of period	[2]	3,146,000,000	3,217,000,000
Balance at end of period	[2]	$ 4,876,000,000	$ 3,512,000,000
[1]Includes amounts from related parties of $(142) million and $(134) million for June 30, 2024 and 2023, respectively[2] The amounts for cash, cash equivalents and restricted cash shown above include restricted cash of $69 million and $20 million as of June 30, 2024 and 2023, respectively, and $86 million and $10 million as of December 31, 2023 and 2022, respectively, which were included in other current assets in the condensed consolidated balance sheets.

Condensed Consolidated Statem_6

Condensed Consolidated Statements of Cash Flows (Parenthetical) - USD ($) $ in Millions		6 Months Ended
		Jun. 30, 2024	Jun. 30, 2023	Dec. 31, 2023	Dec. 31, 2022
Receivables, net	[1]	$ (978)	$ (292)
Restricted cash		69	20	$ 86	$ 10
Related Party
Receivables, net		$ (142)	$ (134)
[1]Includes amounts from related parties of $(142) million and $(134) million for June 30, 2024 and 2023, respectively

Condensed Consolidated Statem_7

Condensed Consolidated Statements of Stockholders' (Deficit) Equity - USD ($) $ in Millions	Total	Common Stock	Additional Paid-in Capital	Earnings Reinvested in the Business	Accumulated Other Comprehensive Losses	Cost of Repurchased Stock	Noncontrolling Interests
Beginning balance at Dec. 31, 2022	$ (6,311)	$ 0	$ 2,230	$ 34,289	$ (9,559)	$ (35,917)	$ 2,646
Increase (Decrease) in Stockholders' Equity [Roll Forward]
Net earnings	3,784			3,563			221
Other comprehensive earnings (losses), net of income taxes	(642)				(665)		23
Issuance of stock awards	115		(11)			126
Dividends declared	(3,959)			(3,959)
Dividends paid to noncontrolling interests	(318)						(318)
Sale (purchase) of subsidiary shares to/(from) noncontrolling interests	(629)		21		179		(829)
Ending balance at Jun. 30, 2023	(7,960)	0	2,240	33,893	(10,045)	(35,791)	1,743
Beginning balance at Mar. 31, 2023	(7,053)	0	2,188	34,303	(9,614)	(35,801)	1,871
Increase (Decrease) in Stockholders' Equity [Roll Forward]
Net earnings	1,682			1,568			114
Other comprehensive earnings (losses), net of income taxes	(444)				(431)		(13)
Issuance of stock awards	62		52			10
Dividends declared	(1,978)			(1,978)
Dividends paid to noncontrolling interests	(225)						(225)
Sale (purchase) of subsidiary shares to/(from) noncontrolling interests	(4)						(4)
Ending balance at Jun. 30, 2023	(7,960)	0	2,240	33,893	(10,045)	(35,791)	1,743
Beginning balance at Dec. 31, 2023	(9,446)	0	2,285	34,090	(11,815)	(35,785)	1,779
Increase (Decrease) in Stockholders' Equity [Roll Forward]
Net earnings	4,774			4,554			220
Other comprehensive earnings (losses), net of income taxes	779				885		(106)
Issuance of stock awards	104		(36)			140
Dividends declared	(4,062)			(4,062)
Dividends paid to noncontrolling interests	(262)						(262)
Acquisitions (Note 18)	159						159
Sale (purchase) of subsidiary shares to/(from) noncontrolling interests	12						12
Ending balance at Jun. 30, 2024	(7,942)	0	2,249	34,582	(10,930)	(35,645)	1,802
Beginning balance at Mar. 31, 2024	(8,563)	0	2,205	34,208	(11,065)	(35,657)	1,746
Increase (Decrease) in Stockholders' Equity [Roll Forward]
Net earnings	2,528			2,406			122
Other comprehensive earnings (losses), net of income taxes	83				135		(52)
Issuance of stock awards	56		44			12
Dividends declared	(2,032)			(2,032)
Dividends paid to noncontrolling interests	(186)						(186)
Acquisitions (Note 18)	159						159
Sale (purchase) of subsidiary shares to/(from) noncontrolling interests	13						13
Ending balance at Jun. 30, 2024	$ (7,942)	$ 0	$ 2,249	$ 34,582	$ (10,930)	$ (35,645)	$ 1,802

Condensed Consolidated Statem_8

Condensed Consolidated Statements of Stockholders' (Deficit) Equity (Parenthetical) - $ / shares	3 Months Ended		6 Months Ended
	Jun. 30, 2024	Jun. 30, 2023	Jun. 30, 2024	Jun. 30, 2023
Statement of Stockholders' Equity [Abstract]
Dividends declared (in dollars per share)	$ 1.30	$ 1.27	$ 2.60	$ 2.54

Background and Basis of Present

Background and Basis of Presentation:	6 Months Ended
	Jun. 30, 2024
Organization, Consolidation and Presentation of Financial Statements [Abstract]
Background and Basis of Presentation:	Background and Basis of Presentation: Background Philip Morris International Inc. is a holding company incorporated in Virginia, U.S.A. (also referred to herein as the U.S., the United States or the United States of America), whose subsidiaries and affiliates and their licensees are primarily engaged in the manufacture and sale of cigarettes and smoke-free products. Throughout these financial statements, the term "PMI" refers to Philip Morris International Inc. and its subsidiaries. Smoke-Free Business ("SFB”) is the term PMI uses to refer to all of its smoke-free products. SFB also includes wellness and healthcare products, as well as consumer accessories, such as lighters and matches. Smoke-free products (also referred to herein as "SFPs") is the term PMI uses to refer to all of its products that provide nicotine without combusting tobacco, such as heat-not-burn, e-vapor, and oral smokeless, and that therefore generate far lower levels of harmful chemicals. As such, these products have the potential to present less risk of harm versus continued smoking. "Platform 1" is the term PMI uses to refer to PMI’s smoke-free products that use a precisely controlled heating device into which a specially designed and proprietary tobacco unit is inserted and heated to generate an aerosol. Basis of Presentation The interim condensed consolidated financial statements of PMI are unaudited. These interim condensed consolidated financial statements have been prepared in conformity with accounting principles generally accepted in the United States of America ("U.S. GAAP") and such principles are applied on a consistent basis. Certain information and footnote disclosures normally included in annual financial statements prepared in accordance with U.S.GAAP have been omitted. It is the opinion of PMI’s management that all adjustments necessary for a fair statement of the interim results presented have been reflected therein. All such adjustments were of a normal recurring nature. Net revenues and net earnings attributable to PMI for any interim period are not necessarily indicative of results that may be expected for the entire year. Following the combination and the progress in 2023 toward the integration of the Swedish Match business into PMI's existing regional structure, PMI updated in January 2024 its segment reporting by including the former Swedish Match segment results into the four existing geographical segments. The four existing geographical segments are as follows: Europe Region; South and Southeast Asia, Commonwealth of Independent States, Middle East and Africa Region ("SSEA, CIS & MEA"); East Asia, Australia, and PMI Duty Free Region ("EA, AU & PMI DF"); and Americas Region. The Wellness and Healthcare ("W&H") segment remained unchanged. Certain prior years' amounts have been reclassified to conform with the current year's presentation as a result of the new segment structure discussed above. See Note 4. Goodwill and Other Intangible Assets, net, Note 7. Segment Reporting and Note 15. Asset Impairment and Exit Costs for further details. These reclassifications did not impact PMI’s consolidated financial position, results of operations or cash flows in any of the periods presented. These statements should be read in conjunction with the audited consolidated financial statements and related notes, which appear in PMI’s Annual Report on Form 10-K for the year ended December 31, 2023.

Stock Plans_

Stock Plans:	6 Months Ended
	Jun. 30, 2024
Share-Based Payment Arrangement [Abstract]
Stock Plans:	Stock Plans: In May 2022, PMI’s shareholders approved the Philip Morris International Inc. 2022 Performance Incentive Plan (the “2022 Plan”). Under the 2022 Plan, PMI may grant to eligible employees restricted shares and restricted share units, performance-based cash incentive awards and performance-based equity awards. Up to 25 million shares of PMI’s common stock may be issued under the 2022 Plan. At June 30, 2024, shares available for grant under the 2022 Plan were 19,161,366. In May 2017, PMI’s shareholders approved the Philip Morris International Inc. 2017 Stock Compensation Plan for Non-Employee Directors (the “2017 Non-Employee Directors Plan”). A non-employee director is defined as a member of the PMI Board of Directors who is not a full-time employee of PMI or of any corporation in which PMI owns, directly or indirectly, stock possessing at least 50% of the total combined voting power of all classes of stock entitled to vote in the election of directors in such corporation. Up to 1 million shares of PMI common stock may be awarded under the 2017 Non-Employee Directors Plan. At June 30, 2024, shares available for grant under the plan were 855,920. Restricted share unit (RSU) awards During the six months ended June 30, 2024 and 2023, shares granted to eligible employees and the weighted-average grant date fair value per share related to RSU awards were as follows: Number of Weighted-Average Grant Date Fair Value Per RSU Award Granted 2024 1,976,920 $ 89.05 2023 1,752,050 $ 101.98 Compensation expense related to RSU awards was as follows: Compensation Expense Related to RSU Awards (in millions) For the Six Months Ended June 30, For the Three Months Ended June 30, 2024 $ 84 $ 37 2023 $ 86 $ 36 As of June 30, 2024, PMI had $228 million of total unrecognized compensation cost related to non-vested RSU awards. The cost is recognized over the original restriction period of the awards, which is typically three years after the date of the award, or upon death, disability or reaching the age of 58. During the six months ended June 30, 2024, 1,741,966 RSU awards vested. The grant date fair value of all the vested awards was approximately $148 million. The total fair value of RSU awards that vested during the six months ended June 30, 2024 was approximately $159 million. Performance share unit (PSU) awards During the six months ended June 30, 2024 and 2023, PMI granted PSU awards to certain executives. The PSU awards require the achievement of certain performance metrics, which are predetermined at the time of grant, typically over a three-year performance cycle. The performance metrics for such PSU's granted during the six months ended June 30, 2023 consisted of PMI's Total Shareholder Return ("TSR") relative to a predetermined peer group and on an absolute basis (40% weight), PMI’s currency-neutral compound annual adjusted diluted earnings per share growth rate (30% weight), and a Sustainability Index, which consists of two drivers: • Product Sustainability (20% weight) measuring progress primarily on PMI's efforts to maximize the benefits of smoke-free products, purposefully phase out cigarettes, and reduce post-consumer waste; and • Operational Sustainability (10% weight) measuring progress on PMI's efforts to tackle climate change, preserve nature, improve the quality of life of people in its supply chain, and foster an empowered, and inclusive workplace. The performance metrics, targets and relative weights for the PSU’s granted during the six months ended June 30, 2024 were the same as the PSU’s granted during the six months ended June 30, 2023, with the exception of adjustments made to certain components of the Sustainability Index intended to address PMI's developing sustainability strategy and reporting. The PSU performance metrics may be adjusted if appropriate to reflect the impact of unusual or infrequently occurring events, including, to the extent significant, corporate transactions, accounting or tax law changes, asset write-downs, litigation or claim adjustments, foreign exchange gains and losses, unbudgeted capital expenditures and other such events. The aggregate of the weighted performance factors for the three metrics in each such PSU award determines the percentage of PSUs that will vest at the end of the three-year performance cycle. The minimum percentage of such PSUs that can vest is zero, with a target percentage of 100 and a maximum percentage of 200. Each such vested PSU entitles the participant to one share of common stock. An aggregate weighted PSU performance factor of 100 will result in the targeted number of PSUs being vested. At the end of the performance cycle, participants are entitled to an amount equivalent to the accumulated dividends paid on common stock during the performance cycle for the number of shares earned. During the six months ended June 30, 2024 and 2023, shares granted to eligible employees and the grant date fair value per share related to PSU awards were as follows: Number of Shares Granted Weighted- Weighted- (Per Share) (Per Share) 2024 543,560 $ 89.01 $ 85.72 2023 482,360 $ 102.02 $ 133.54 The grant date fair value of the PSU awards subject to the other performance factors was determined by using the market price of PMI’s stock on the date of the grant. The grant date fair value of the PSU market-based awards subject to the TSR performance factor was determined by using the Monte Carlo simulation model. The following assumptions were used to determine the grant date fair value of the PSU awards subject to the TSR performance factor: 2024 2023 Average risk-free interest rate (a) 4.2 % 4.1 % Average expected volatility (b) 19.9 % 24.3 % (a) Based on the U.S. Treasury yield curve. (b) Determined using the observed historical volatility. Compensation Expense Related to PSU Awards (in millions) For the Six Months Ended June 30, For the Three Months Ended June 30, 2024 $ 49 $ 18 2023 $ 45 $ 18 As of June 30, 2024, PMI had $55 million of total unrecognized compensation cost related to non-vested PSU awards. The cost is recognized over the performance cycle of the awards, or upon death, disability or reaching the age of 58. During the six months ended June 30, 2024, 916,452 PSU awards vested. The grant date fair value of all the vested awards was approximately $86 million. The total fair value of PSU awards that vested during the six months ended June 30, 2024 was approximately $83 million.

Benefit Plans_

Benefit Plans:	6 Months Ended
	Jun. 30, 2024
Retirement Benefits [Abstract]
Benefit Plans:	Benefit Plans: Pension coverage for employees of PMI’s subsidiaries is provided, to the extent deemed appropriate, through separate plans, many of which are governed by local statutory requirements. In addition, PMI provides health care and other benefits to certain U.S. retired employees and certain non-U.S. retired employees. In general, health care benefits for non-U.S. retired employees are covered through local government plans. Pension and other employee benefit costs per the condensed consolidated statements of earnings consisted of the following: For the Six Months Ended June 30, For the Three Months Ended June 30, (in millions) 2024 2023 2024 2023 Net pension costs (income) $ (39) $ (37) $ (20) $ (25) Net postemployment costs 62 59 31 29 Net postretirement costs 6 6 3 2 Total pension and other employee benefit costs $ 29 $ 28 $ 14 $ 6 Pension Plans Components of Net Periodic Benefit Cost Net periodic pension cost consisted of the following: Pension (1) For the Six Months Ended June 30, For the Three Months Ended June 30, (in millions) 2024 2023 2024 2023 Service cost $ 109 $ 85 $ 54 $ 42 Interest cost 116 129 57 63 Expected return on plan assets (200) (181) (99) (91) Amortization: Net loss 46 16 23 4 Prior service cost (credit) (1) (1) (1) (1) Net periodic pension cost $ 70 $ 48 $ 34 $ 17 (1) Primarily non-U.S. based defined benefit retirement plans. Employer Contributions PMI makes, and plans to make, contributions, to the extent that they are tax deductible and meet specific funding requirements of its funded pension plans. Employer contributions of $55 million were made to the pension plans during the six months ended June 30, 2024. Currently, PMI anticipates making additional contributions during the remainder of 2024 of approximately $66 million to its pension plans, based on current tax and benefit laws. However, this estimate is subject to change as a result of changes in tax and other benefit laws, as well as asset performance significantly above or below the assumed long-term rate of return on pension assets, or changes in interest and currency rates.

Goodwill and Other Intangible A

Goodwill and Other Intangible Assets, net:	6 Months Ended
	Jun. 30, 2024
Goodwill and Intangible Assets Disclosure [Abstract]
Goodwill and Other Intangible Assets, net:	Goodwill and Other Intangible Assets, net: 2024 Annual impairment review of goodwill and non-amortizable intangible assets During the second quarter of 2024, PMI completed its annual review of goodwill and non-amortizable intangible assets for potential impairment using a quantitative assessment for all of its reporting units and non-amortizable intangible assets. As a result of this review, no impairment charges were required. Each of PMI's reporting units had fair values substantially in excess of their carrying values with the exception of the Wellness & Healthcare reporting unit, which had less than 20% excess of fair value over its carrying value. PMI will continue to monitor this reporting unit as any changes in assumptions and estimates, unfavorable clinical trial results, failure to obtain regulatory approvals or other market factors could result in additional future goodwill and other intangible asset impairments. In addition, there are still risks related to PMI’s Russian reporting unit’s assets as the fair value of these assets is difficult to predict due to the current economic, political, regulatory and social conditions as well as the volatility in foreign currency and commodity markets. As of June 30, 2024, our Russian operations had approximately $2.8 billion in total assets, excluding intercompany balances, of which approximately $0.7 billion consisted of cash and cash equivalents held mostly in local currency (Russian rubles). Additionally, we hold a 23% equity interest in Megapolis Distribution B.V., the holding company of JSC TK Megapolis, PMI's distributor in Russia. For further details, see Note 8. Contingencies and Note 12. Related Parties – Equity Investments and Other . Goodwill The movements in goodwill were as follows: (in millions) Europe SSEA, CIS & MEA EA, AU & PMI DF Americas Wellness & Healthcare Total Balances at December 31, 2023 $ 4,173 $ 2,877 $ 492 $ 8,847 $ 390 $ 16,779 Changes due to: Acquisitions — 510 — — — 510 Currency (228) (159) (27) (49) (7) (470) Balances, June 30, 2024 $ 3,945 $ 3,228 $ 465 $ 8,798 $ 383 $ 16,819 As discussed in Note 1. Background and Basis of Presentation , PMI updated in January 2024 its segment reporting by including the former Swedish Match segment results into its geographical segments. As a result, the December 31, 2023 goodwill balance in the table above included the reclassification of the former Swedish Match segment to the Europe and Americas segments. The increase in goodwill was due to the preliminary purchase price allocation of PMI's acquisition in Egypt of United Tobacco Company in the second quarter of 2024, partially offset by currency movements. For further details on the acquisition in Egypt, see Note 18. Acquisitions . At June 30, 2024, goodwill primarily reflects PMI’s acquisitions of Swedish Match AB, Fertin Pharma A/S and Vectura Group plc., as well as acquisitions in Egypt, Greece, Indonesia, Mexico, the Philippines and Serbia. Other Intangible Assets Details of other intangible assets were as follows: June 30, 2024 December 31, 2023 (in millions) Weighted-Average Remaining Useful Life Gross Carrying Amount Accumulated Amortization Net Gross Carrying Amount Accumulated Amortization Net Non-amortizable intangible assets $ 4,541 $ 4,541 $ 4,543 $ 4,543 Amortizable intangible assets: Trademarks 16 years 2,179 $ 812 1,367 2,267 $ 784 1,483 Reacquired commercialization rights for IQOS in the U.S. 5 years 2,777 93 2,684 — — — Developed technology, including patents 6 years 750 349 401 774 329 445 Customer relationships and other 11 years 3,757 579 3,178 3,843 450 3,393 Total other intangible assets $ 14,004 $ 1,833 $ 12,171 $ 11,427 $ 1,563 $ 9,864 Non-amortizable intangible assets substantially consist of the ZYN trademarks and other trademarks related to acquisitions in Indonesia and Mexico, as well as the tobacco manufacturing license associated with the preliminary purchase price allocation of PMI's acquisition in Egypt in the second quarter of 2024 (see Note 18. Acquisitions for further details). The decrease since December 31, 2023 was mainly due to currency movements of $181 million and a pre-tax impairment charge in the first quarter of 2024 of $27 million primarily for an in-process research and development project in the Wellness and Healthcare segment, partially offset by the recognition of the Egyptian tobacco manufacturing license. The pre-tax impairment charge of $27 million was recorded in marketing, administration and research costs on PMI's condensed consolidated statements of earnings during the six months ended June 30, 2024. The increase in the gross carrying amount of amortizable intangible assets from December 31, 2023, was primarily due to the classification of the IQOS commercialization rights in the U.S. on the acquisition date (May 1, 2024) as Other intangible assets, net (see Note 18. Acquisitions ), partially offset by currency movements of $203 million. The change in the accumulated amortization from December 31, 2023, was mainly due to the 2024 amortization of $332 million, partially offset by currency movements of $62 million. The amortization of intangibles for the six months ended June 30, 2024 was recorded in cost of sales ($32 million) and in marketing, administration and research costs ($300 million) on PMI's condensed consolidated statements of earnings. Amortization expense for each of the next five years is estimated to be approximately $1,031 million or less, assuming no additional transactions occur that require the amortization of intangible assets. This amount includes amortization of IQOS commercialization rights in the U.S. (see Note 18, Acquisitions ). 2023 Annual impairment review of goodwill and non-amortizable intangible assets During the second quarter of 2023, as a result of the completion of PMI's annual review of goodwill and non-amortizable intangible assets for potential impairment, it was determined that the estimated fair value of the Wellness and Healthcare reporting unit was lower than its carrying value. Consequently, PMI recorded a goodwill impairment charge of $665 million in the consolidated statements of earnings for the six months and three months ended June 30, 2023, reflecting the impact of reduced estimated future cash flows, which were primarily attributable to unfavorable clinical trial results that became available in June 2023 for an inhalable aspirin product being developed by the Wellness and Healthcare business. Additionally, as a result of the impairment test of non-amortizable intangible assets, PMI recorded a pre-tax impairment charge of $15 million for an in-process research and development project related to one of PMI's 2021 acquisitions. This pre-tax impairment charge of $15 million was recorded within marketing, administration and research costs in the consolidated statements of earnings for the six months and three months ended June 30, 2023.

Financial Instruments_

Financial Instruments:	6 Months Ended
	Jun. 30, 2024
Derivative Instruments and Hedging Activities Disclosure [Abstract]
Financial Instruments:	Financial Instruments: Overview PMI operates globally with manufacturing and sales facilities in various locations around the world and is exposed to risks such as changes in foreign currency exchange rates and interest rates. As a result, PMI uses deliverable and non-deliverable forward foreign exchange contracts, foreign currency swaps and foreign currency options, (collectively referred to as "foreign exchange contracts"), and interest rate contracts to mitigate its exposure to changes in foreign currency exchange and interest rates related to net investments in foreign operations, third-party and intercompany actual and forecasted transactions. The primary currencies to which PMI is exposed include the Euro, Egyptian pound, Indonesian rupiah, Japanese yen, Mexican peso, Philippine peso, Russian ruble and Swiss franc. Additionally, certain materials that PMI uses in the manufacturing of its products are exposed to market price risks. PMI uses commodity derivative contracts (“commodity contracts") to manage its exposure to the market price volatility of certain commodity components of these materials. These foreign exchange contracts, interest rate contracts and commodity contracts are collectively referred to as "derivative contracts". PMI is not a party to leveraged derivatives and, by policy, does not use derivative financial instruments for speculative purposes. Substantially all of PMI's derivative financial instruments are subject to master netting arrangements, whereby the right to offset occurs in the event of default by a participating party. While these contracts contain the enforceable right to offset through close-out netting rights, PMI elects to present them on a gross basis in the condensed consolidated balance sheets. Collateral associated with these arrangements is in the form of cash and is unrestricted. Changes in collateral posted are included in cash flows from investing activities and changes in collateral received are included in cash flows from financing activities. Financial instruments qualifying for hedge accounting must maintain a specified level of effectiveness between the hedging instrument and the item being hedged, both at inception and throughout the hedged period. PMI formally documents the nature and relationships between the hedging instruments and hedged items, as well as its risk-management objectives, strategies for undertaking the various hedge transactions and method of assessing hedge effectiveness. Additionally, for hedges of forecasted transactions, the significant characteristics and expected terms of the forecasted transaction must be specifically identified, and it must be probable that each forecasted transaction will occur. If it were deemed probable that the forecasted transaction would not occur, the gain or loss would be recognized in earnings. The gross notional amounts for outstanding derivatives at the end of each period were as follows: (in millions) At June 30, 2024 At December 31, 2023 Derivative contracts designated as hedging instruments: Foreign exchange contracts $ 22,826 $ 21,987 Interest rate contracts 1,000 3,600 Commodity contracts 13 20 Derivative contracts not designated as hedging instruments: Foreign exchange contracts 17,540 17,658 Total $ 41,379 $ 43,265 The fair value of PMI’s derivative contracts included in the condensed consolidated balance sheets as of June 30, 2024 and December 31, 2023, were as follows: Derivative Assets Derivative Liabilities Fair Value Fair Value At At At At (in millions) Balance Sheet Classification June 30, 2024 December 31, 2023 Balance Sheet Classification June 30, 2024 December 31, 2023 Derivative contracts designated as hedging instruments: Foreign exchange contracts Other current assets $ 590 $ 345 Other accrued liabilities $ 50 $ 249 Other assets 292 153 Income taxes and other liabilities 167 449 Interest rate contracts Other current assets — 1 Other accrued liabilities 41 78 Other assets — — Income taxes and other liabilities 16 18 Commodity contracts Other current assets — — Other accrued liabilities 3 5 Other assets — — Income taxes and other liabilities — 1 Derivative contracts not designated as hedging instruments: Foreign exchange contracts Other current assets 144 85 Other accrued liabilities 61 425 Other assets 2 — Income taxes and other liabilities 99 143 Total gross amount derivatives contracts presented in the condensed consolidated balance sheets $ 1,028 $ 584 $ 437 $ 1,368 Gross amounts not offset in the condensed consolidated balance sheets Financial instruments (352) (374) (352) (374) Cash collateral received/pledged (483) (109) (48) (551) Net amount $ 193 $ 101 $ 37 $ 443 PMI assesses the fair value of its derivative contracts using standard valuation models that use, as their basis, readily observable market inputs. The fair value of PMI’s foreign exchange forward contracts, foreign currency swaps and interest rate contracts is determined by using the prevailing foreign exchange spot rates and interest rate differentials, and the respective maturity dates of the instruments. The fair value of PMI’s currency options is determined by using a Black-Scholes methodology based on foreign exchange spot rates and interest rate differentials, currency volatilities and maturity dates. The fair value of PMI’s commodity contracts is determined by using the prevailing market spot and futures prices and the respective maturity dates of the instruments. PMI’s derivative contracts have been classified within Level 2 at June 30, 2024 and December 31, 2023. For the six months ended June 30, 2024 and 2023, PMI's derivative contracts impacted the condensed consolidated statements of earnings and comprehensive earnings as follows: (pre-tax, in millions) For the Six Months Ended June 30, Amount of Gain/(Loss) Recognized in Other Comprehensive Earnings/(Losses) on Derivatives Statement of Earnings Amount of Gain/(Loss) Reclassified from Other Comprehensive Earnings/(Losses) into Earnings Amount of Gain/(Loss) Recognized in Earnings 2024 2023 2024 2023 2024 2023 Derivative contracts designated as hedging instruments: Cash flow hedges: Foreign exchange contracts $ 288 $ 223 Net revenues $ 90 $ 39 Cost of sales — — Marketing, administration and research costs 7 71 Interest expense, net (5) (6) Interest rate contracts 54 72 Interest expense, net 25 22 Commodity contracts (1) (1) Cost of sales — — Fair value hedges: Interest rate contracts Interest expense, net (a) $ (17) $ (14) Net investment hedges (b) : Foreign exchange contracts 578 (439) Interest expense, net (c) 147 127 Derivative contracts not designated as hedging instruments: Foreign exchange contracts Interest expense, net 99 152 Marketing, administration and research costs (d) 432 (104) Total $ 919 $ (145) $ 117 $ 126 $ 661 $ 161 (a) The gains (losses) from these contracts are offset by the changes in the fair value of the hedged item (b) Amount of gains (losses) on hedges of net investments principally related to changes in foreign currency exchange and interest rates between the Euro and U.S. dollar (c) Represent the gains for amounts excluded from the effectiveness testing (d) The gains (losses) from these contracts attributable to changes in foreign currency exchange rates are partially offset by the (losses) and gains generated by the underlying intercompany and third-party loans being hedged For the three months ended June 30, 2024 and 2023, PMI's derivative contracts impacted the condensed consolidated statements of earnings and comprehensive earnings as follows: (pre-tax, in millions) For the Three Months Ended June 30, Amount of Gain/(Loss) Recognized in Other Comprehensive Earnings/(Losses) on Derivatives Statement of Earnings Amount of Gain/(Loss) Reclassified from Other Comprehensive Earnings/(Losses) into Earnings Amount of Gain/(Loss) Recognized in Earnings 2024 2023 2024 2023 2024 2023 Derivative contracts designated as hedging instruments: Cash flow hedges: Foreign exchange contracts $ 122 $ 213 Net revenues $ 61 $ 27 Cost of sales — — Marketing, administration and research costs (17) 55 Interest expense, net (2) (3) Interest rate contracts — 7 Interest expense, net 13 12 Commodity contracts 2 (1) Cost of sales — — Fair value hedges: Interest rate contracts Interest expense, net (a) $ (6) $ (17) Net investment hedges (b) : Foreign exchange contracts 125 (181) Interest expense, net (c) 75 64 Derivative contracts not designated as hedging instruments: Foreign exchange contracts Interest expense, net 55 62 Marketing, administration and research costs (d) (80) (88) Total $ 249 $ 38 $ 55 $ 91 $ 44 $ 21 (a) The gains (losses) from these contracts are offset by the changes in the fair value of the hedged item (b) Amount of gains (losses) on hedges of net investments principally related to changes in foreign currency exchange and interest rates between the Euro and U.S. dollar (c) Represent the gains for amounts excluded from the effectiveness testing (d) The gains (losses) from these contracts attributable to changes in foreign currency exchange rates are partially offset by the (losses) and gains generated by the underlying intercompany and third-party loans being hedged Cash Flow Hedges PMI has entered into derivative contracts to hedge the foreign currency exchange, interest rate and commodity price risks related to certain forecasted transactions. Gains and losses associated with qualifying cash flow hedge contracts are deferred as components of accumulated other comprehensive losses until the underlying hedged transactions are reported in PMI’s condensed consolidated statements of earnings. As of June 30, 2024, PMI has hedged forecasted transactions with derivative contracts expiring at various dates through May 2028. Premiums paid for, and settlements of, the derivative contracts designated as cash flow hedges are included primarily in cash flows from operating activities on PMI’s condensed consolidated statements of cash flows. Fair Value Hedges PMI has entered into fixed-to-floating interest rate contracts, designated as fair value hedges to minimize exposure to changes in the fair value of fixed rate U.S. dollar-denominated debt that results from fluctuations in benchmark interest rates. For derivative contracts that are designated and qualify as fair value hedges, the gain or loss on the derivative, as well as the offsetting gain or loss on the hedged items attributable to the hedged risk, is recognized in current earnings. The carrying amount of the debt hedged, which includes the cumulative adjustment for fair value gains/losses, as of June 30, 2024 was $941 million, of which $336 million was recorded in current portion of long-term debt and $605 million was recorded in long-term debt in the condensed consolidated balance sheets. The cumulative amount of fair value gains/(losses) included in the carrying amount of the debt hedged was $57 million as of June 30, 2024. Hedges of Net Investments in Foreign Operations PMI designates derivative contracts and certain foreign currency denominated debt and other financial instruments as net investment hedges, primarily of its Euro net assets. For the six months ended June 30, 2024 and 2023, the amount of pre-tax gain/(loss) related to the non-derivative financial instruments, that was reported as a component of accumulated other comprehensive losses within currency translation adjustments, was $5 million and $24 million, respectively. For the three months ended June 30, 2024 and 2023, the amount of pre-tax gain/(loss) related to the non-derivative financial instruments, that was reported as a component of accumulated other comprehensive losses within currency translation adjustments, was nil and $23 million, respectively. Settlements of the derivative contracts designated as net investment hedges are included in cash flows from investing activities on PMI’s condensed consolidated statements of cash flows. Other Derivatives PMI has entered into derivative contracts to hedge the foreign currency exchange and interest rate risks related to intercompany loans between certain subsidiaries and third-party loans. While effective as economic hedges, no hedge accounting is applied for these contracts; therefore, the gains (losses) relating to these contracts are reported in PMI’s condensed consolidated statements of earnings. Settlements of other derivative contracts are included primarily in cash flows from investing activities on PMI's condensed consolidated statements of cash flows. Qualifying Hedging Activities Reported in Accumulated Other Comprehensive Losses Derivative gains or losses reported in accumulated other comprehensive losses are a result of qualifying hedging activity. Transfers of these gains or losses to earnings are offset by the corresponding gains or losses on the underlying hedged item. Hedging activity affected accumulated other comprehensive losses, net of income taxes, as follows: (in millions) For the Six Months Ended June 30, For the Three Months Ended June 30, 2024 2023 2024 2023 Gain/(loss) as of beginning of period, $ 241 $ 266 $ 373 $ 296 Derivative (gains)/losses transferred to earnings (94) (104) (48) (75) Change in fair value 286 246 108 187 Gain/(loss) as of June 30, $ 433 $ 408 $ 433 $ 408 At June 30, 2024, PMI expects $197 million of derivative gains that are included in accumulated other comprehensive losses to be reclassified to the condensed consolidated statement of earnings within the next 12 months. These gains are expected to be substantially offset by the statement of earnings impact of the respective hedged transactions. Contingent Features PMI’s derivative instruments do not contain contingent features. Credit Exposure and Credit Risk PMI is exposed to credit loss in the event of non-performance by counterparties. While PMI does not anticipate non-performance, its risk is limited to the fair value of the financial instruments less any cash collateral received or pledged. PMI actively monitors its exposure to credit risk through the use of credit approvals and credit limits and by selecting and continuously monitoring a diverse group of major international banks and financial institutions as counterparties. Other Investments

Earnings Per Share_

Earnings Per Share:	6 Months Ended
	Jun. 30, 2024
Earnings Per Share [Abstract]
Earnings Per Share:	Earnings Per Share: Basic and diluted earnings per share (“EPS”) were calculated using the following: (in millions) For the Six Months Ended June 30, For the Three Months Ended June 30, 2024 2023 2024 2023 Net earnings attributable to PMI $ 4,554 $ 3,563 $ 2,406 $ 1,568 Less distributed and undistributed earnings attributable to share-based payment awards 14 11 7 5 Net earnings for basic and diluted EPS $ 4,540 $ 3,552 $ 2,399 $ 1,563 Weighted-average shares for basic EPS 1,554 1,552 1,555 1,552 Plus contingently issuable performance stock units (PSUs) (1) 2 1 1 1 Weighted-average shares for diluted EPS 1,556 1,553 1,556 1,553 (1) Including rounding adjustment Unvested share-based payment awards that contain non-forfeitable rights to dividends or dividend equivalents are participating securities and therefore are included in PMI’s earnings per share calculation pursuant to the two-class method. For the 2024 and 2023 computations, there were no antidilutive stock awards.

Segment Reporting_

Segment Reporting:	6 Months Ended
	Jun. 30, 2024
Segment Reporting [Abstract]
Segment Reporting:	Segment Reporting: PMI’s subsidiaries and affiliates are primarily engaged in the manufacture and sale of cigarettes and smoke-free products, including heat-not-burn, e-vapor and oral nicotine products. Excluding the Wellness and Healthcare segment, PMI's segments are generally organized by geographic region and managed by segment managers who are responsible for the operating and financial results of the regions inclusive of combustible tobacco and smoke-free product categories sold in the region. As discussed in Note 1. Background and Basis of Presentation , PMI updated in January 2024 its segment reporting by including the former Swedish Match segment results into the four existing geographical segments. The four existing geographical segments are as follows: Europe Region; South and Southeast Asia, Commonwealth of Independent States, Middle East and Africa Region ("SSEA, CIS & MEA"); East Asia, Australia, and PMI Duty Free Region ("EA, AU & PMI DF"); and Americas Region. The Wellness and Healthcare segment remained unchanged. PMI’s chief operating decision maker evaluates geographical segment performance and allocates resources based on regional operating income, which includes results from all product categories sold in each region, excluding Wellness and Healthcare products. Business operations in the Wellness and Healthcare segment are evaluated separately. PMI disaggregates its net revenues from contracts with customers by product category for each of PMI's four geographical segments. For the Wellness and Healthcare business, Vectura Fertin Pharma, net revenues from contracts with customers are included in the Wellness and Healthcare segment. PMI believes this best depicts how the nature, amount, timing and uncertainty of its revenue and cash flows are affected by economic factors. Segment data were as follows: (in millions) For the Six Months Ended June 30, For the Three Months Ended June 30, 2024 2023 2024 2023 Net revenues: Europe $ 7,180 $ 6,642 $ 3,815 $ 3,574 SSEA, CIS & MEA 5,429 5,145 2,771 2,668 EA, AU & PMI DF 3,357 3,200 1,673 1,680 Americas 2,125 1,837 1,129 969 Wellness and Healthcare 170 162 80 76 Net revenues $ 18,261 $ 16,986 $ 9,468 $ 8,967 Operating income (loss): Europe $ 3,116 $ 2,834 $ 1,660 $ 1,619 SSEA, CIS & MEA 1,663 1,614 891 880 EA, AU & PMI DF 1,516 1,194 753 557 Americas 282 426 183 243 Wellness and Healthcare (88) (771) (43) (733) Operating income $ 6,489 $ 5,297 $ 3,444 $ 2,566 PMI's net revenues by product category were as follows: (in millions) For the Six Months Ended June 30, For the Three Months Ended June 30, 2024 2023 2024 2023 Net revenues: Combustible tobacco: Europe $ 4,145 $ 3,924 $ 2,214 $ 2,108 SSEA, CIS & MEA 4,778 4,504 2,432 2,350 EA, AU & PMI DF 1,217 1,412 620 724 Americas 1,126 1,173 592 608 Total combustible tobacco 11,265 11,013 5,858 5,790 Smoke-free: Smoke-free excluding Wellness and Healthcare: Europe 3,035 2,718 1,601 1,466 SSEA, CIS & MEA 651 641 339 318 EA, AU & PMI DF 2,140 1,788 1,053 956 Americas 999 664 537 361 Total Smoke-free excluding Wellness and Healthcare 6,826 5,811 3,530 3,101 Wellness and Healthcare 170 162 80 76 Total Smoke-free 6,996 5,973 3,610 3,177 Total PMI net revenues $ 18,261 $ 16,986 $ 9,468 $ 8,967 Note: Sum of product categories or Regions might not foot to total PMI due to roundings. Items affecting the comparability of results from operations were as follows: • Asset impairment and exit costs – See Note 15. Asset Impairment and Exit Costs for a breakdown of these costs by segment for the six months ended June 30, 2024 and 2023. • Termination of distribution arrangement in the Middle East – In the first quarter of 2023, PMI recorded a pre-tax charge of $80 million following the termination of a distribution arrangement in the Middle East. This pre-tax charge was recorded as a reduction of net revenues in the condensed consolidated statements of earnings, and was included in the SSEA, CIS & MEA segment results for the six months ended June 30, 2023. • Swedish Match AB acquisition accounting related items – In the first quarter of 2023, PMI recorded $18 million pre-tax purchase accounting adjustments related to the sale of acquired inventories stepped up to fair value included in the Americas segment. • Impairment of goodwill and other intangibles – For the six months and three months ended June 30, 2023, PMI recorded $680 million of goodwill and non-amortizable intangible assets impairment charges that was included in the Wellness and Healthcare segment. For further details, see Note 4. Goodwill and Other Intangible Assets, net . • South Korea indirect tax charge – On July 13, 2023, PMI's South Korean subsidiary, PM Korea, received an adverse ruling from the Supreme Court of South Korea related to cases alleging underpayment of excise taxes in connection with a 2015 excise tax increase and subsequent audit by the South Korean Board of Audit and Inspection. The Supreme Court ruling reversed previous decisions that were in PM Korea’s favor at the trial and appellate levels. As a result of the ruling, we concluded that an adverse outcome was probable. Consequently, we recorded a non-cash pre-tax charge of $204 million in marketing, administration and research costs in the condensed consolidated statements of earning, reflecting the full amount previously paid by PM Korea, which was included in the EA, AU & PMI DF segment for the six months and three months ended June 30, 2023. Net revenues related to combustible tobacco refer to the operating revenues generated from the sale of these products, including shipping and handling charges billed to customers, net of sales and promotion incentives, and excise taxes. These net revenue amounts consist of the sale of PMI's cigarettes and other tobacco products that are combusted. Other tobacco products primarily include roll-your-own and make-your-own cigarettes, pipe tobacco, cigars and cigarillos, and do not include smoke-free products. Net revenues related to smoke-free, excluding wellness and healthcare, refer to the operating revenues generated from the sale of these products, including shipping and handling charges billed to customers, net of sales and promotion incentives, and excise taxes, if applicable. These net revenue amounts consist of the sale of PMI's products that are not combustible tobacco products, such as heat-not-burn, e-vapor, and oral products, as well as consumer accessories. Net revenues related to wellness and healthcare consist of operating revenues generated from the sale of products primarily associated with inhaled therapeutics, and oral and intra-oral delivery systems that are included in the operating results of PMI's Wellness and Healthcare business, Vectura Fertin Pharma.

Contingencies_

Contingencies:	6 Months Ended
	Jun. 30, 2024
Commitments and Contingencies Disclosure [Abstract]
Contingencies:	Contingencies: Tobacco and/or Nicotine-Related Litigation Legal proceedings covering a wide range of matters are pending or threatened against us, and/or our subsidiaries, and/or our indemnitees in various jurisdictions. Our indemnitees include distributors, licensees, and others that have been named as parties in certain cases and that we have agreed to defend, as well as to pay costs and some or all of judgments, if any, that may be entered against them. Pursuant to the terms of the Distribution Agreement between Altria Group, Inc. (“Altria”) and PMI, PMI will indemnify Altria and Philip Morris USA Inc. (“PM USA”), a U.S. tobacco subsidiary of Altria, for tobacco product claims based in substantial part on products manufactured by PMI or contract manufactured for PMI by PM USA, and PM USA will indemnify PMI for tobacco product claims based in substantial part on products manufactured by PM USA, excluding tobacco products contract manufactured for PMI. It is possible that there could be adverse developments in pending cases against us and our subsidiaries. An unfavorable outcome or settlement of pending tobacco or nicotine-related litigation could encourage the commencement of additional litigation. Damages claimed in some of the tobacco-related litigation are significant and, in certain cases in Canada and Nigeria, range into the billions of U.S. dollars. The variability in pleadings in multiple jurisdictions, together with the actual experience of management in litigating claims, demonstrate that the monetary relief that may be specified in a lawsuit bears little relevance to the ultimate outcome. While, as discussed below, we have to date been largely successful in defending tobacco-related litigation, litigation is subject to uncertainty. Additionally, as reported further below, beginning in March 2024, litigation related to oral nicotine products was filed against us and our subsidiary before certain courts in the United States. We and our subsidiaries record provisions in the consolidated financial statements for pending litigation when we determine that an unfavorable outcome is probable and the amount of the loss can be reasonably estimated. At the present time, except as stated otherwise in this Note 8. Contingencies, it is reasonably possible that an unfavorable outcome in a case may occur. Legal defense costs are expensed as incurred. It is possible that our consolidated financial statements, including our results of operations, cash flows or financial position could be materially affected in a particular fiscal quarter or fiscal year by an unfavorable outcome or settlement of certain pending litigation. Nevertheless, although litigation is subject to uncertainty, we and each of our subsidiaries named as a defendant believe, and each has been so advised by counsel handling the respective cases, that we have valid defenses to the litigation pending against us, as well as valid bases for appeal of adverse verdicts. All such cases are, and will continue to be, vigorously defended. However, we and our subsidiaries may enter into settlement discussions in particular cases if we believe it is in our best interests to do so. After assessing the information available to it, except as stated otherwise in this Note 8. Contingencies , (i) management has not concluded that it is probable that a loss has been incurred in any of the pending combustible tobacco product-related cases; (ii) management is unable to estimate the possible loss or range of loss for any of the pending combustible tobacco product-related cases; and (iii) accordingly, no estimated loss has been accrued in the consolidated financial statements for unfavorable outcomes in these cases, if any. CCAA Proceedings and Stay of Combustible Tobacco Product-Related Cases Pending in Canada As a result of the Court of Appeal of Quebec’s decision in both the Létourneau and Blais cases described below, our subsidiary, Rothmans, Benson & Hedges Inc. (“RBH”), and the other defendants, JTI Macdonald Corp., and Imperial Tobacco Canada Limited, sought protection in the Ontario Superior Court of Justice under the Companies’ Creditors Arrangement Act (“CCAA”) on March 22, March 8, and March 12, 2019, respectively. CCAA is a Canadian federal law that permits a Canadian business to restructure its affairs while carrying on its business in the ordinary course. The initial CCAA order made by the Ontario Superior Court on March 22, 2019 authorizes RBH to pay all expenses incurred in carrying on its business in the ordinary course after the CCAA filing, including obligations to employees, vendors, and suppliers. RBH's financial results have been deconsolidated from our consolidated financial statements since March 22, 2019. As part of the CCAA proceedings, there is currently a comprehensive stay up to and including September 30, 2024 of all combustible tobacco product-related litigation pending in Canada against RBH and the other defendants, including PMI and our indemnitees (PM USA and Altria), namely, the smoking and health class actions filed in various Canadian provinces and health care cost recovery actions. These proceedings are presented below under the caption “ Stayed Litigation — Canada .” Ernst & Young Inc. has been appointed as monitor of RBH in the CCAA proceedings. In accordance with the CCAA process, as the parties work towards a plan of arrangement or compromise in a confidential mediation, it is anticipated that the court will set additional hearings and further extend the stay of proceedings. On April 17, 2019, the Ontario Superior Court ruled that RBH and the other defendants will not be allowed to file an application to the Supreme Court of Canada for leave to appeal the Court of Appeal’s decision in the Létourneau and the Blais cases so long as the comprehensive stay of all combustible tobacco product-related litigation in Canada remains in effect and that the time period to file the application would be extended by the stay period. While RBH believes that the findings of liability and damages in both Létourneau and the Blais cases were incorrect, the CCAA proceedings will provide a forum for RBH to seek resolution through a plan of arrangement or compromise of all combustible tobacco product-related litigation pending in Canada. It is not possible to predict the resolution of the underlying legal proceedings or the length of the CCAA process. Stayed Litigation — Canada Smoking and Health Litigation — Canada In the first class action pending in Canada, Conseil Québécois Sur Le Tabac Et La Santé and Jean-Yves Blais v. Imperial Tobacco Canada Ltd., Rothmans, Benson & Hedges Inc. and JTI-Macdonald Corp., Quebec Superior Court, Canada , filed in November 1998, RBH and other Canadian cigarette manufacturers (Imperial Tobacco Canada Ltd. and JTI-Macdonald Corp.) are defendants (the " Blais Class Action"). The plaintiffs, an anti-smoking organization and an individual smoker, sought compensatory and punitive damages for each member of the class who suffers allegedly from certain smoking-related diseases. The class was certified in 2005. The trial court issued its judgment on May 27, 2015. The trial court found RBH and two other Canadian manufacturers liable and found that the class members’ compensatory damages totaled approximately CAD 15.5 billion (approximately $11.3 billion), including pre-judgment interest. The trial court awarded compensatory damages on a joint and several liability basis, allocating 20% to our subsidiary (approximately CAD 3.1 billion (approximately $2.3 billion) including pre-judgment interest). In addition, the trial court awarded CAD 90,000 (approximately $65,000) in punitive damages, allocating CAD 30,000 (approximately $22,000) to RBH. The trial court estimated the disease class at 99,957 members. RBH appealed to the Court of Appeal of Quebec. In October 2015, the Court of Appeal ordered RBH to furnish security totaling CAD 226 million (approximately $164 million) to cover both the Létourneau and Blais cases, which RBH has paid in installments through March 2017. The Court of Appeal ordered Imperial Tobacco Canada Ltd. to furnish security totaling CAD 758 million (approximately $551 million) in installments through June 2017. JTI Macdonald Corp. was not required to furnish security in accordance with plaintiffs’ motion. The Court of Appeal ordered that the security is payable upon a final judgment of the Court of Appeal affirming the trial court’s judgment or upon further order of the Court of Appeal. On March 1, 2019, the Court of Appeal issued a decision largely affirming the trial court’s findings of liability and the compensatory and punitive damages award while reducing the total amount of compensatory damages to approximately CAD 13.5 billion (approximately $9.8 billion), including interest due to the trial court’s error in the calculation of interest. The compensatory damages award is on a joint and several basis with an allocation of 20% to RBH (approximately CAD 2.7 billion (approximately $2.0 billion), including pre-judgment interest). The Court of Appeal upheld the trial court’s findings that defendants violated the Civil Code of Quebec, the Quebec Charter of Human Rights and Freedoms, and the Quebec Consumer Protection Act by failing to warn adequately of the dangers of smoking and by conspiring to prevent consumers from learning of the dangers of smoking. The Court of Appeal further held that the plaintiffs either need not prove, or had adequately proven, that these faults were a cause of the class members’ injuries. In accordance with the judgment, defendants were required to deposit their respective portions of the damages awarded in both the Létourneau case described below and the Blais case, approximately CAD 1.1 billion (approximately $799 million), into trust accounts within 60 days. RBH’s share of the deposit was approximately CAD 257 million (approximately $194 million). PMI recorded a pre-tax charge of $194 million in its consolidated results, representing $142 million net of tax, as tobacco litigation-related expense, in the first quarter of 2019. The charge reflects PMI’s assessment of the portion of the judgment that represents probable and estimable loss prior to the deconsolidation of RBH and corresponds to the trust account deposit required by the judgment. In the second class action pending in Canada, Cecilia Létourneau v. Imperial Tobacco Ltd., Rothmans, Benson & Hedges Inc. and JTI-Macdonald Corp., Quebec Superior Court, Canada, filed in September 1998, RBH and other Canadian cigarette manufacturers (Imperial Tobacco Canada Ltd. and JTI-Macdonald Corp.) are defendants (the " Létourneau Class Action"). The plaintiff, an individual smoker, sought compensatory and punitive damages for each member of the class who is deemed addicted to smoking. The class was certified in 2005. The trial court issued its judgment on May 27, 2015. The trial court found RBH and two other Canadian manufacturers liable and awarded a total of CAD 131 million (approximately $95 million) in punitive damages, allocating CAD 46 million (approximately $33 million) to RBH. The trial court estimated the size of the addiction class at 918,000 members but declined to award compensatory damages to the addiction class because the evidence did not establish the claims with sufficient accuracy. The trial court found that a claims process to allocate the awarded punitive damages to individual class members would be too expensive and difficult to administer. On March 1, 2019, the Court of Appeal issued a decision largely affirming the trial court’s findings of liability and the total amount of punitive damages awarded allocating CAD 57 million (approximately $41 million), including interest to RBH. See the Blais description above for further detail concerning the security order pertaining to both Létourneau and Blais cases and the impact of the decision on PMI’s financial statements. RBH and PMI believe the findings of liability and damages in both Létourneau and the Blais cases were incorrect and in contravention of applicable law on several grounds including, the following: (i) defendants had no obligation to warn class members who knew, or should have known, of the risks of smoking; (ii) defendants cannot be liable to class members who would have smoked regardless of what warnings were given; and (iii) defendants cannot be liable to all class members given the individual differences among class members. In the third class action pending in Canada, Kunta v. Canadian Tobacco Manufacturers' Council, et al., The Queen's Bench, Winnipeg, Canada , filed June 12, 2009, we, RBH, and our indemnitees (PM USA and Altria), and other members of the industry are defendants. The plaintiff, an individual smoker, alleges her own addiction to tobacco products and chronic obstructive pulmonary disease (“COPD”), severe asthma, and mild reversible lung disease resulting from the use of tobacco products. She is seeking compensatory and punitive damages on behalf of a proposed class comprised of all smokers, their estates, dependents and family members, as well as restitution of profits, and reimbursement of government health care costs allegedly caused by tobacco products. In the fourth class action pending in Canada, Adams v. Canadian Tobacco Manufacturers' Council, et al., The Queen's Bench, Saskatchewan, Canada , filed July 10, 2009, we, RBH, and our indemnitees (PM USA and Altria), and other members of the industry are defendants. The plaintiff, an individual smoker, alleges her own addiction to tobacco products and COPD resulting from the use of tobacco products. She is seeking compensatory and punitive damages on behalf of a proposed class comprised of all smokers who have smoked a minimum of 25,000 cigarettes and have allegedly suffered, or suffer, from COPD, emphysema, heart disease, or cancer, as well as restitution of profits. In the fifth class action pending in Canada, Semple v. Canadian Tobacco Manufacturers' Council, et al., The Supreme Court (trial court), Nova Scotia, Canada , filed June 18, 2009, we, RBH, and our indemnitees (PM USA and Altria), and other members of the industry are defendants. The plaintiff, an individual smoker, alleges his own addiction to tobacco products and COPD resulting from the use of tobacco products. He is seeking compensatory and punitive damages on behalf of a proposed class comprised of all smokers, their estates, dependents and family members, as well as restitution of profits, and reimbursement of government health care costs allegedly caused by tobacco products. In the sixth class action pending in Canada, Dorion v. Canadian Tobacco Manufacturers' Council, et al., The Queen's Bench, Alberta, Canada, filed June 15, 2009, we, RBH, and our indemnitees (PM USA and Altria), and other members of the industry are defendants. The plaintiff, an individual smoker, alleges her own addiction to tobacco products and chronic bronchitis and severe sinus infections resulting from the use of tobacco products. She is seeking compensatory and punitive damages on behalf of a proposed class comprised of all smokers, their estates, dependents and family members, restitution of profits, and reimbursement of government health care costs allegedly caused by tobacco products. To date, we, our subsidiaries, and our indemnitees have not been properly served with the complaint. In the seventh class action pending in Canada, McDermid v. Imperial Tobacco Canada Limited, et al., Supreme Court, British Columbia, Canada , filed June 25, 2010, we, RBH, and our indemnitees (PM USA and Altria), and other members of the industry are defendants. The plaintiff, an individual smoker, alleges his own addiction to tobacco products and heart disease resulting from the use of tobacco products. He is seeking compensatory and punitive damages on behalf of a proposed class comprised of all smokers who were alive on June 12, 2007, and who suffered from heart disease allegedly caused by smoking, their estates, dependents and family members, plus disgorgement of revenues earned by the defendants from January 1, 1954, to the date the claim was filed. In the eighth class action pending in Canada, Bourassa v. Imperial Tobacco Canada Limited, et al., Supreme Court, British Columbia, Canada , filed June 25, 2010, we, RBH, and our indemnitees (PM USA and Altria), and other members of the industry are defendants. The plaintiff, the heir to a deceased smoker, alleges that the decedent was addicted to tobacco products and suffered from emphysema resulting from the use of tobacco products. She is seeking compensatory and punitive damages on behalf of a proposed class comprised of all smokers who were alive on June 12, 2007, and who suffered from chronic respiratory diseases allegedly caused by smoking, their estates, dependents and family members, plus disgorgement of revenues earned by the defendants from January 1, 1954, to the date the claim was filed. In December 2014, plaintiff filed an amended statement of claim. In the ninth class action pending in Canada, Suzanne Jacklin v. Canadian Tobacco Manufacturers' Council, et al., Ontario Superior Court of Justice, filed June 20, 2012, we, RBH, and our indemnitees (PM USA and Altria), and other members of the industry are defendants. The plaintiff, an individual smoker, alleges her own addiction to tobacco products and COPD resulting from the use of tobacco products. She is seeking compensatory and punitive damages on behalf of a proposed class comprised of all smokers who have smoked a minimum of 25,000 cigarettes and have allegedly suffered, or suffer, from COPD, heart disease, or cancer, as well as restitution of profits. Health Care Cost Recovery Litigation — Canada In the first health care cost recovery case pending in Canada, Her Majesty the Queen in Right of British Columbia v. Imperial Tobacco Limited, et al., Supreme Court, British Columbia, Vancouver Registry, Canada, filed January 24, 2001, we, RBH, our indemnitee (PM USA), and other members of the industry are defendants. The plaintiff, the government of the province of British Columbia, brought a claim based upon legislation enacted by the province authorizing the government to file a direct action against cigarette manufacturers to recover the health care costs it has incurred, and will incur, resulting from a “tobacco related wrong.” In the second health care cost recovery case filed in Canada, Her Majesty the Queen in Right of New Brunswick v. Rothmans Inc., et al., Court of Queen's Bench of New Brunswick, Trial Court, New Brunswick, Fredericton, Canada, filed March 13, 2008, we, RBH, our indemnitees (PM USA and Altria), and other members of the industry are defendants. The claim was filed by the government of the province of New Brunswick based on legislation enacted in the province. This legislation is similar to the law introduced in British Columbia that authorizes the government to file a direct action against cigarette manufacturers to recover the health care costs it has incurred, and will incur, as a result of a “tobacco related wrong.” In the third health care cost recovery case filed in Canada, Her Majesty the Queen in Right of Ontario v. Rothmans Inc., et al., Ontario Superior Court of Justice, Toronto, Canada , filed September 29, 2009, we, RBH, our indemnitees (PM USA and Altria), and other members of the industry are defendants. The claim was filed by the government of the province of Ontario based on legislation enacted in the province. This legislation is similar to the laws introduced in British Columbia and New Brunswick that authorize the government to file a direct action against cigarette manufacturers to recover the health care costs it has incurred, and will incur, as a result of a “tobacco related wrong.” In the fourth health care cost recovery case filed in Canada, Attorney General of Newfoundland and Labrador v. Rothmans Inc., et al., Supreme Court of Newfoundland and Labrador, St. Johns, Canada , filed February 8, 2011, we, RBH, our indemnitees (PM USA and Altria), and other members of the industry are defendants. The claim was filed by the government of the province of Newfoundland and Labrador based on legislation enacted in the province that is similar to the laws introduced in British Columbia, New Brunswick and Ontario. The legislation authorizes the government to file a direct action against cigarette manufacturers to recover the health care costs it has incurred, and will incur, as a result of a “tobacco related wrong.” In the fifth health care cost recovery case filed in Canada, Attorney General of Quebec v. Imperial Tobacco Limited, et al., Superior Court of Quebec, Canada , filed June 8, 2012, we, RBH, our indemnitee (PM USA), and other members of the industry are defendants. The claim was filed by the government of the province of Quebec based on legislation enacted in the province that is similar to the laws enacted in several other Canadian provinces. The legislation authorizes the government to file a direct action against cigarette manufacturers to recover the health care costs it has incurred, and will incur, as a result of a “tobacco related wrong.” In the sixth health care cost recovery case filed in Canada, Her Majesty in Right of Alberta v. Altria Group, Inc., et al., Supreme Court of Queen's Bench Alberta, Canada , filed June 8, 2012, we, RBH, our indemnitees (PM USA and Altria), and other members of the industry are defendants. The claim was filed by the government of the province of Alberta based on legislation enacted in the province that is similar to the laws enacted in several other Canadian provinces. The legislation authorizes the government to file a direct action against cigarette manufacturers to recover the health care costs it has incurred, and will incur, as a result of a “tobacco related wrong.” In the seventh health care cost recovery case filed in Canada, Her Majesty the Queen in Right of the Province of Manitoba v. Rothmans, Benson & Hedges, Inc., et al., The Queen's Bench, Winnipeg Judicial Centre, Canada , filed May 31, 2012, we, RBH, our indemnitees (PM USA and Altria), and other members of the industry are defendants. The claim was filed by the government of the province of Manitoba based on legislation enacted in the province that is similar to the laws enacted in several other Canadian provinces. The legislation authorizes the government to file a direct action against cigarette manufacturers to recover the health care costs it has incurred, and will incur, as a result of a “tobacco related wrong.” In the eighth health care cost recovery case filed in Canada, The Government of Saskatchewan v. Rothmans, Benson & Hedges Inc., et al., Queen's Bench, Judicial Centre of Saskatchewan, Canada , filed June 8, 2012, we, RBH, our indemnitees (PM USA and Altria), and other members of the industry are defendants. The claim was filed by the government of the province of Saskatchewan based on legislation enacted in the province that is similar to the laws enacted in several other Canadian provinces. The legislation authorizes the government to file a direct action against cigarette manufacturers to recover the health care costs it has incurred, and will incur, as a result of a “tobacco related wrong.” In the ninth health care cost recovery case filed in Canada, Her Majesty the Queen in Right of the Province of Prince Edward Island v. Rothmans, Benson & Hedges Inc., et al., Supreme Court of Prince Edward Island (General Section), Canada , filed September 10, 2012, we, RBH, our indemnitees (PM USA and Altria), and other members of the industry are defendants. The claim was filed by the government of the province of Prince Edward Island based on legislation enacted in the province that is similar to the laws enacted in several other Canadian provinces. The legislation authorizes the government to file a direct action against cigarette manufacturers to recover the health care costs it has incurred, and will incur, as a result of a “tobacco related wrong.” In the tenth health care cost recovery case filed in Canada, Her Majesty the Queen in Right of the Province of Nova Scotia v. Rothmans, Benson & Hedges Inc., et al., Supreme Court of Nova Scotia, Canada , filed January 2, 2015, we, RBH, our indemnitees (PM USA and Altria), and other members of the industry are defendants. The claim was filed by the government of the province of Nova Scotia based on legislation enacted in the province that is similar to the laws enacted in several other Canadian provinces. The legislation authorizes the government to file a direct action against cigarette manufacturers to recover the health care costs it has incurred, and will incur, as a result of a “tobacco related wrong.” Combustible tobacco products litigation Since 1995, 622 combustible tobacco product-related cases, including Smoking and Health, Label-Related, Health Care Cost Recovery, and Public Civil Actions, have been filed against a PMI entity, 552 of those cases have been terminated in our favor, and the balance of 70 remains pending. Of those pending cases, four were initially decided in favor of plaintiffs and remain on appeal, or are subject to an appeal. These four cases include the Blais Class Action and the Létourneau Class Action, described above under the caption " Smoking and Health Litigation — Canada, " and two individual cases where final resolution in the amount of the verdict would not have a material adverse effect on our consolidated financial statements, including our results of operations, cash flows, or financial position. Pending claims related to combustible tobacco products generally fall within the following categories: Smoking and Health Litigation: These cases primarily allege personal injury and are brought by individual plaintiffs or on behalf of a class or purported class of individual plaintiffs. Plaintiffs' allegations of liability in these cases are based on various theories of recovery, including negligence, gross negligence, strict liability, fraud, misrepresentation, design defect, failure to warn, breach of express and implied warranties, violations of deceptive trade practice laws and consumer protection statutes. Plaintiffs in these cases seek various forms of relief, including compensatory and other damages, and injunctive and equitable relief. Defenses raised in these cases include licit activity, failure to state a claim, lack of defect, lack of proximate cause, assumption of the risk, contributory negligence, and statute of limitations. As of June 30, 2024, there were a number of smoking and health cases pending against us, our subsidiaries or indemnitees, as follows: • 39 cases brought by individual plaintiffs in Argentina (27), Canada (2), Chile (9), and Turkey (1), compared with 50 such cases on June 30, 2023; and • 9 cases brought on behalf of classes of individual plaintiffs, compared with 9 such cases on June 30, 2023. The class actions pending in Canada are described above under the caption “ Smoking and Health Litigation — Canada. ” Health Care Cost Recovery Litigation: These cases, brought by governmental and non-governmental plaintiffs, seek reimbursement of health care cost expenditures allegedly caused by tobacco products. Plaintiffs' allegations of liability in these cases are based on various theories of recovery including unjust enrichment, negligence, negligent design, strict liability, breach of express and implied warranties, violation of a voluntary undertaking or special duty, fraud, negligent misrepresentation, conspiracy, public nuisance, defective product, failure to warn, sale of cigarettes to minors, and claims under statutes governing competition and deceptive trade practices. Plaintiffs in these cases seek various forms of relief including compensatory and other damages, and injunctive and equitable relief. Defenses raised in these cases include lack of proximate cause, remoteness of injury, failure to state a claim, adequate remedy at law, “unclean hands” (namely, that plaintiffs cannot obtain equitable relief because they participated in, and benefited from, the sale of cigarettes), and statute of limitations. As of June 30, 2024, there were 17 health care cost recovery cases pending against us, our subsidiaries or indemnitees in Brazil (1), Canada (10), Korea (1) and Nigeria (5), compared with 17 such cases on June 30, 2023. The health care cost recovery actions pending in Canada are described above under the caption “ Health Care Cost Recovery Litigation — Canada. ” In the health care cost recovery case in Brazil, The Attorney General of Brazil v. Souza Cruz Ltda., et al., Federal Trial Court, Porto Alegre, Rio Grande do Sul, Brazil , filed May 21, 2019, we, our subsidiaries, and other members of the industry are defendants. Plaintiff seeks reimbursement for the cost of treating alleged smoking-related diseases in certain prior years, payment of anticipated costs of treating future alleged smoking-related diseases, and moral damages. Defendants filed answers to the complaint in May 2020. In the first health care cost recovery case in Nigeria, The Attorney General of Lagos State v. British American Tobacco (Nigeria) Limited, et al., High Court of Lagos State, Lagos, Nigeria, filed March 13, 2008, we and other members of the industry are defendants. Plaintiff seeks reimbursement for the cost of treating alleged smoking-related diseases for the past 20 years, payment of anticipated costs of treating alleged smoking-related diseases for the next 20 years, various forms of injunctive relief, plus punitive damages. We are in the process of making challenges to service and the court's jurisdiction. Currently, the case is stayed in the trial court pending the appeals of certain co-defendants relating to service objections. In the second health care cost recovery case in Nigeria, The Attorney General of Kano State v. British American Tobacco (Nigeria) Limited, et al., High Court of Kano State, Kano, Nigeria, filed May 9, 2007, we and other members of the industry are defendants. Plaintiff seeks reimbursement for the cost of treating alleged smoking-related diseases for the past 20 years, payment of anticipated costs of treating alleged smoking-related diseases for the next 20 years, various forms of injunctive relief, plus punitive damages. We are in the process of challenging the court's jurisdiction. Currently, the case is stayed in the trial court pending the appeals of certain co-defendants relating to service objections. In the third health care cost recovery case in Nigeria, The Attorney General of Gombe State v. British American Tobacco (Nigeria) Limited, et al., High Court of Gombe State, Gombe, Nigeria, filed October 17, 2008, we and other members of the industry are defendants . Plaintiff seeks reimbursement for the cost of treating alleged smoking-related diseases for the past 20 years, payment of anticipated costs of treating alleged smoking-related diseases for the next 20 years, various forms of injunctive relief, plus punitive damages. In February 2011, the court ruled that the plaintiff had not complied with the procedural steps necessary to serve us. As a result of this ruling, plaintiff must re-serve its claim. We have not yet been re-served. In the fourth health care cost recovery case in Nigeria, The Attorney General of Oyo State, et al., v. British American Tobacco (Nigeria) Limited, et al., High Court of Oyo State, Ibadan, Nigeria, filed May 25, 2007, we and other members of the industry are defendants . Plaintiffs seek reimbursement for the cost of treating alleged smoking-related diseases for the past 20 years, payment of anticipated costs of treating alleged smoking-related diseases for the next 20 years, various forms of injunctive relief, plus punitive damages. We challenged service as improper. In June 2010, the court ruled that plaintiffs did not have leave to serve the writ of summons on the defendants and that they must re-serve the writ. We have not yet been re-served. In the fifth health care cost recovery case in Nigeria, The Attorney General of Ogun State v. British American Tobacco (Nigeria) Limited, et al., High Court of Ogun State, Abeokuta, Nigeria , filed February 26, 2008, we and other members of the industry are defendants. Plaintiff seeks reimbursement for the cost of treating alleged smoking-related diseases for the past 20 years, payment of anticipated costs of treating alleged smoking-related diseases for the next 20 years, various forms of injunctive relief, plus punitive damages. In May 2010, the trial court rejected our objections to the court's jurisdiction.

Income Taxes_

Income Taxes:	6 Months Ended
	Jun. 30, 2024
Income Tax Disclosure [Abstract]
Income Taxes:	Income Taxes: Income tax provisions for jurisdictions outside the United States of America, as well as state and local income tax provisions, were determined on a separate company basis, and the related assets and liabilities were recorded in PMI’s condensed consolidated balance sheets. PMI’s effective tax rates for the six months and three months ended June 30, 2024 were 24.2% and 23.7%, respectively. PMI’s effective tax rates for the six months and three months ended June 30, 2023 were 20.8% and 24.7%, respectively. The effective tax rate for the six months ended June 30, 2024, was unfavorably impacted by a deferred tax charge for unrealized foreign currency gains on intercompany loans related to the Swedish Match acquisition financing reflected in the condensed consolidated statements of earnings ($142 million), while the underlying pre-tax foreign currency movements fully offset in the condensed consolidated statements of earnings and were reflected as currency translation adjustments in its condensed consolidated statements of stockholders' (deficit) equity, and an increase in deferred tax liabilities related to the fair value adjustment of equity securities held by PMI ($77 million), partially offset by a U.S. tax benefit for a worthless stock deduction under section 165(g) of the Internal Revenue Code related to PMI's investment in C.A. Tabacalera Nacional, a wholly owned foreign corporation incorporated in Venezuela ($47 million). For further details on PMI's ceased operations in Venezuela, see Note 15. Asset Impairment and Exit Costs . Changes in the tax laws of foreign jurisdictions could arise as a result of the Base Erosion and Profit Shifting project undertaken by the Organisation for Economic Co-operation and Development (“OECD”), which recommended changes to numerous long- standing tax principles. Many countries have enacted the OECD’s framework on a global minimum tax (referred to as “Pillar Two”), effective for taxable years beginning after December 31, 2023. PMI has determined that Pillar Two should not have a material impact on its 2024 consolidated financial statements. The effective tax rate for the six months ended June 30, 2023, was unfavorably impacted by the non-deductible Wellness and Healthcare goodwill impairment charge, partially offset by a deferred tax benefit for unrealized foreign currency losses on intercompany loans related to the Swedish Match acquisition financing reflected in the condensed consolidated statements of earnings ($96 million), while the underlying pre-tax foreign currency movements fully offset in the condensed consolidated statements of earnings and were reflected as currency translation adjustments in its condensed consolidated statements of stockholders' (deficit) equity. PMI is regularly examined by tax authorities around the world and is currently under examination in a number of jurisdictions. The U.S. federal statute of limitations remains open for the years 2019 and onward. Foreign and U.S. state jurisdictions have statutes of limitations generally ranging from 3 to 5 years after the filing of a return. Subsidiaries of PMI in Indonesia, principally PT Hanjaya Mandala Sampoerna Tbk ("HMS"), have recorded income tax receivables in the amount of 3.9 trillion Indonesian rupiah (approximately $238 million) relating to corporate income tax assessments paid to avoid potential penalties, primarily for domestic and other intercompany transactions for the years 2015 to 2020. Objection letters have been filed with the Tax Office and these assessments are being challenged at various levels in court. These income tax receivables are included in other assets in PMI’s condensed consolidated balance sheets at June 30, 2024 and December 31, 2023. It is reasonably possible that within the next 12 months certain tax examinations will close, which could result in a change in unrecognized tax benefits along with related interest and penalties. An estimate of any possible change cannot be made at this time.

Indebtedness_

Indebtedness:	6 Months Ended
	Jun. 30, 2024
Debt Disclosure [Abstract]
Indebtedness:	Indebtedness: Short-term Borrowings: At June 30, 2024 and December 31, 2023, PMI’s short-term borrowings and related average interest rates consisted of the following: June 30, 2024 December 31, 2023 (in millions) Amount Outstanding Average Rate Amount Outstanding Average Rate Commercial paper $ — — % $ 1,685 5.6 % Bank loans 139 11.6 283 8.9 $ 139 $ 1,968 Given the mix of PMI's legal entities and their respective local economic environments, the average interest rate for bank loans above can vary significantly from day to day and country to country. The fair values of PMI’s short-term borrowings, based on current market interest rates, approximate carrying value. Long-term Debt: At June 30, 2024 and December 31, 2023, PMI’s long-term debt consisted of the following: (in millions) June 30, 2024 December 31, 2023 U.S. dollar notes, 0.875% to 6.375% (average interest rate 4.572%), due through 2044 $ 34,059 $ 30,272 Foreign currency obligations: Euro notes, 0.125% to 3.750% (average interest rate 1.921%), due through 2039 8,103 8,526 Swiss franc note, 1.625%, due 2024 — 299 Euro credit facility borrowings related to Swedish Match AB acquisition, (average interest rate 4.194%), due through 2027 5,887 6,121 Swedish krona notes, 1.395% to 2.710% (average interest rate 2.016%), due through 2029 224 236 Other (average interest rate 6.131%), due through 2032 (a) 727 487 Carrying value of long-term debt 49,000 45,941 Less current portion of long-term debt 4,353 4,698 $ 44,647 $ 41,243 (a) Includes long-term bank loans at subsidiaries, as well as $43 million and $53 million in finance leases at June 30, 2024 and December 31, 2023, respectively. The fair value of PMI’s outstanding long-term debt, which is utilized solely for disclosure purposes, is determined using quotes and market interest rates currently available to PMI for issuances of debt with similar terms and remaining maturities. At June 30, 2024, the fair value of PMI's outstanding long-term debt, excluding the aforementioned finance leases, was as follows: (in millions) June 30, 2024 Level 1 $ 40,607 Level 2 6,693 For a description of the fair value hierarchy and the three levels of inputs used to measure fair values, see Item 8, Note 2. Summary of Significant Accounting Policies of PMI's Annual Report on Form 10-K for the year ended December 31, 2023. Credit Facilities related to the Financing of the Swedish Match Acquisition In connection with PMI's all-cash recommended public offer to the shareholders of Swedish Match, on May 11, 2022, PMI entered into a credit agreement relating to a 364-day senior unsecured bridge facility. The facility provided for borrowings up to an aggregate principal amount of $17 billion, expiring 364 days after the occurrence of certain events unless extended. On June 23, 2022, PMI entered into a €5.5 billion (approximately $5.8 billion at the date of signing) senior unsecured term loan credit agreement consisting of a €3.0 billion (approximately $3.2 billion at the date of signing) tranche expiring three years after the occurrence of certain events and a €2.5 billion (approximately $2.6 billion at the date of signing) tranche expiring on June 23, 2027. In connection with the term loan facility, the aggregate principal amount of commitments under the 364-day senior unsecured bridge facility was reduced from $17 billion to $11 billion. On November 11, 2022, PMI acquired a controlling interest of 85.87% of the total issued shares in Swedish Match and acquired 94.81% of its outstanding shares as of December 31, 2022. In accordance with the Swedish Companies Act, PMI subsequently exercised its right to compulsorily redeem the remaining shares for which acceptances were not received and obtained legal title to 100% of the shares in Swedish Match on February 17, 2023. PMI borrowed $8.4 billion under the bridge facility by delivering notices of borrowing for advances of $7.9 billion and $0.5 billion on November 7, 2022 and November 10, 2022, respectively. On November 21, 2022 and February 17, 2023, PMI repaid $4.0 billion and $4.4 billion, respectively, under the bridge facility. Effective February 20, 2023, the remaining outstanding commitments under the bridge facility were fully canceled and the bridge facility agreement was terminated in accordance with its terms. On November 7, 2022, PMI also delivered notices of borrowing for advances totaling €5.5 billion under the term loan facility, of which €3.0 billion will become due on November 9, 2025 and €2.5 billion will become due on June 23, 2027 unless prepaid pursuant to the terms of the credit agreement. As of June 30, 2024 and December 31, 2023, the €5.5 billion (approximately $6 billion) term loan facility was fully drawn and remained outstanding. The proceeds under the bridge facility and the term loan facility were used, directly or indirectly, to finance the acquisition, including, the payment of related fees and expenses. Debt Issuances PMI's debt issuances in the first six months of 2024 were as follows: (in millions) Type Face Value Interest Rate Issuance Maturity U.S. dollar notes (a) $750 4.750% February 2024 February 2027 U.S. dollar notes (a) $1,000 4.875% February 2024 February 2029 U.S. dollar notes (a) $1,250 5.125% February 2024 February 2031 U.S. dollar notes (a) $1,750 5.250% February 2024 February 2034 Euro notes (b) (c) €500 (approximately $543) 3.750% June 2024 January 2031 (a) Interest is payable semi-annually, commencing in August 2024 (b) Interest is payable annually, commencing in January 2025 (c) USD equivalents for foreign currency notes were calculated based on exchange rates on the date of issuance. The net proceeds from the sale of the securities listed in the table above have been or will be used for general corporate purposes, including working capital requirements, repayment of commercial paper and to refinance certain of our outstanding notes due in 2024. Revolving Credit Facilities: At June 30, 2024, PMI's total committed revolving credit facilities were as follows: (in billions) Type Committed 364-day revolving credit, expiring January 28, 2025 $ 1.7 Multi-year revolving credit, expiring February 10, 2026 (1) 2.0 Multi-year revolving credit, expiring September 29, 2026 (2) (3) 2.5 Total facilities $ 6.2 (1) On January 28, 2022, PMI entered into an agreement, effective February 10, 2022, to amend and extend the term of its $2.0 billion multi-year revolving credit facility, for an additional year covering the period February 11, 2026 to February 10, 2027, in the amount of $1.9 billion. (2) Includes pricing adjustments that may result in the reduction or increase in both the interest rate and commitment fee under the credit agreement if PMI achieves, or fails to achieve, certain specified targets. (3) On September 20, 2022, PMI entered into an agreement, effective September 29, 2022, to amend and extend the term of its $2.5 billion multi-year revolving credit facility, for an additional year covering the period September 30, 2026 to September 29, 2027, in the amount of $2.3 billion. On September 20, 2023, PMI entered into an agreement, effective September 29, 2023, to amend and further extend the term to September 29, 2028. At June 30, 2024, there were no borrowings under these committed revolving credit facilities, and the entire committed amounts were available for borrowing.

Accumulated Other Comprehensive

Accumulated Other Comprehensive Losses:	6 Months Ended
	Jun. 30, 2024
Accumulated Other Comprehensive Income (Loss), Net of Tax [Abstract]
Accumulated Other Comprehensive Losses:	Accumulated Other Comprehensive Losses: PMI’s accumulated other comprehensive losses, net of taxes, consisted of the following: (Losses) Earnings At At At (in millions) June 30, 2024 December 31, 2023 June 30, 2023 Currency translation adjustments $ (8,841) $ (9,467) $ (8,678) Pension and other benefits (2,522) (2,589) (1,775) Derivatives accounted for as hedges 433 241 408 Total accumulated other comprehensive losses $ (10,930) $ (11,815) $ (10,045) Reclassifications from Other Comprehensive Earnings The movements in accumulated other comprehensive losses and the related tax impact, for each of the components above, that are due to current period activity and reclassifications to the income statement, are shown on the condensed consolidated statements of comprehensive earnings for the six months and three months ended June 30, 2024 and 2023. For additional information, see Note 3. Benefit Plans for disclosures related to PMI's pension and other benefits, Note 5. Financial Instruments for disclosures related to derivative financial instruments, as well as Note 15. Asset Impairment and Exit Costs and Note 18. Acquisitions

Related Parties - Equity Invest

Related Parties - Equity Investments and Other:	6 Months Ended
	Jun. 30, 2024
Equity Method Investments and Joint Ventures [Abstract]
Related Parties - Equity Investments and Other:	Related Parties - Equity Investments and Other: Equity Method Investments: At June 30, 2024 and December 31, 2023, PMI had total equity method investments of $1,145 million and $1,309 million, respectively. Equity method investments are initially recorded at cost. Under the equity method of accounting, the investment is adjusted for PMI's proportionate share of earnings or losses, dividends, capital contributions, changes in ownership interests and movements in currency translation adjustments. The carrying value of our equity method investments at June 30, 2024 and December 31, 2023, exceeded our share of the investees' book value by $1,075 million and $907 million, respectively. The difference between the investment carrying value and the amount of underlying equity in net assets is mainly attributable to equity method goodwill, convertible debt instruments, and definite-lived intangible assets and other assets. The difference related to the definite-lived intangibles and other assets at June 30, 2024 and December 31, 2023 of $153 million and $31 million, respectively, is amortized on a straight-line basis and is included in Equity investments and securities (income)/loss, net on the condensed consolidated statements of earnings. At June 30, 2024, PMI received no year-to-date dividends from equity method investees. At December 31, 2023, PMI received year-to-date dividends from equity method investees of $57 million. PMI holds a 23% equity interest in Megapolis Distribution B.V. ("MDBV"), the holding company of JSC TK Megapolis (formerly CJSC TK Megapolis), PMI's distributor in Russia (SSEA, CIS & MEA segment), which as of June 30, 2024 had a carrying value of $431 million. Additionally, there was approximately $540 million of cumulative foreign currency translation losses associated with MDBV reflected in accumulated other comprehensive losses in the condensed consolidated statement of stockholders’ equity as of June 30, 2024. In June 2024, the Russian government included JSC TK Megapolis in the list of economically significant organizations that may be subject to forced localization under applicable Russian law, which refers to the mandatory removal of a foreign holding company from the shareholding structure. If a forced localization were to occur, MDBV’s shares in JSC TK Megapolis will be transferred to JSC TK Megapolis and may subsequently be transferred to its indirect shareholders. On July 18, 2024, the Ministry of Industry and Trade (given standing to initiate the claim under the law) filed a petition before the Arbitrazh Court of Moscow seeking the forced localization of JSC TK Megapolis. The court scheduled a hearing on August 8, 2024. While as of June 30, 2024, there have been no impairment indicators based on the business’ performance or legal status, there are still risks related to this investment and our associated economic and control rights as the fair value of these assets with their associated rights is difficult to predict due to the current economic, political, regulatory, legal and social conditions as well as the volatility in foreign currency and commodity markets. PMI holds a 49% equity interest in United Arab Emirates-based Emirati Investors-TA (FZC) (“EITA”). PMI holds an approximate 25% economic interest in Société des Tabacs Algéro-Emiratie (“STAEM”), an Algerian joint venture that is 51% owned by EITA and 49% by the Algerian state-owned enterprise Management et Développement des Actifs et des Ressources Holding ("MADAR Holding"), which manufactures and distributes under license some of PMI’s brands (SSEA, CIS & MEA segment). In April 2023, PMI acquired an approximate economic interest of 25% in United Tobacco Company ("UTC"). UTC is an entity incorporated in Egypt which manufactures products under license for PMI’s Egyptian subsidiary. On May 16, 2024, PMI acquired a controlling interest in UTC. For further details, see Note 18. Acquisitions . In May 2024, PMI acquired an indirect economic interest of 14.7% in Eastern Company (“Eastern"), Egypt’s largest cigarette manufacturer which also includes cigars and pipe tobacco, among others, in its portfolio. PMI accounted for its investment in Eastern under the equity method of accounting as it has the indirect ability to participate in Eastern's policy making processes. As of June 30, 2024, PMI has not finalized the basis difference allocation resulting from the investment. The initial investments in Megapolis Distribution BV, EITA, Eastern and UTC (up to the acquisition of controlling interest in UTC on May 16, 2024) have been recorded at cost and are included in equity investments on the consolidated balance sheets. Transactions between these equity method investees and PMI subsidiaries are considered to be related-party transactions and are included in the tables below. Equity securities: On March 22, 2019, PMI’s wholly owned subsidiary in Canada, Rothmans, Benson & Hedges Inc. (“RBH”) obtained an initial order from the Ontario Superior Court of Justice granting it protection under the Companies’ Creditors Arrangement Act ("CCAA"), which is a Canadian federal law that permits a Canadian business to restructure its affairs while carrying on its business in the ordinary course with minimal disruption to its customers, suppliers and employees. The administration of the CCAA process, principally relating to the powers provided to the court under the CCAA and the oversight provided by the court appointed monitor, removes certain elements of control of the business from both PMI and RBH. As a result, PMI determined that it no longer had a controlling financial interest over RBH as defined in ASC 810 (Consolidation), and deconsolidated RBH as of the date of the CCAA filing. For further details, see Note 8. Contingencies . Since the deconsolidation of RBH on March 22, 2019, PMI has accounted for its continuing investment in RBH in accordance with ASC 321 (Investments-Equity Securities) as an equity security, without readily determinable fair value, and recorded its continuing investment in RBH at fair value of $3,280 million at the date of deconsolidation, within equity investments. Developments in the CCAA process, including resolution through a plan of arrangement or compromise of some or all tobacco-related litigation pending in Canada may have a material adverse impact on the fair value of PMI’s continuing investment in RBH and may result in impairment charges. Transactions between PMI and RBH are considered to be related-party transactions from the date of deconsolidation and are included in the tables below. The fair value of PMI’s other equity securities, which have been classified within Level 1, was $694 million at June 30, 2024. Unrealized pre-tax gain (loss) of $319 million ($242 million net of tax) on these equity securities was recorded in equity investments and securities (income)/loss, net on the condensed consolidated statements of earnings for the six months ended June 30, 2024. Other related parties: United Arab Emirates-based Trans-Emirates Trading and Investments (FZC) ("TTI") holds a 33% non-controlling interest in Philip Morris Misr LLC ("PMM"), an entity incorporated in Egypt which is consolidated in PMI’s financial statements in the SSEA, CIS & MEA segment. PMM sells, under license, PMI brands in Egypt through an exclusive distribution agreement with a local entity that is also controlled by TTI. Godfrey Phillips India Ltd ("GPI") is one of the non-controlling interest holders in IPM India, which is a 56.3% owned PMI consolidated subsidiary in the SSEA, CIS & MEA segment. GPI also acts as contract manufacturer and distributor for IPM India. Financial activity with the above related parties: PMI’s net revenues and expenses with the above related parties were as follows: For the Six Months Ended June 30, For the Three Months Ended June 30, (in millions) 2024 2023 2024 2023 Net revenues: Megapolis Group $ 1,096 $ 1,184 $ 576 $ 596 Other 725 590 385 305 Net revenues (a) $ 1,821 $ 1,774 $ 961 $ 901 Expenses: Other $ 73 $ 113 $ 33 $ 63 Expenses $ 73 $ 113 $ 33 $ 63 (a) Net revenues exclude excise taxes and VAT billed to customers. PMI’s balance sheet activity with the above related parties was as follows: (in millions) At June 30, 2024 At December 31, 2023 Receivables: Megapolis Group $ 535 $ 474 Other 299 236 Receivables $ 834 $ 710 Payables: Other $ 28 $ 18 Payables $ 28 $ 18

Sale of Accounts Receivable_

Sale of Accounts Receivable:	6 Months Ended
	Jun. 30, 2024
Sale of Accounts Receivable [Abstract]
Sale of Accounts Receivable:	Sale of Accounts Receivable: To mitigate risk and enhance cash and liquidity management, PMI sells trade receivables to unaffiliated financial institutions. These arrangements allow PMI to sell, on an ongoing basis, certain trade receivables without recourse. The trade receivables sold are generally short-term in nature and are removed from the condensed consolidated balance sheets. PMI sells trade receivables under two types of arrangements, servicing and non-servicing. For servicing arrangements, PMI continues to service the sold trade receivables on an administrative basis and does not act on behalf of the unaffiliated financial institutions. When applicable, a servicing liability is recorded for the estimated fair value of the servicing. The amounts associated with the servicing liability were not material as of June 30, 2024 and June 30, 2023. Under the non-servicing arrangements, PMI does not provide any administrative support or servicing after the trade receivables have been sold to the unaffiliated financial institutions. Cumulative trade receivables sold, including excise taxes, for the six months ended June 30, 2024 and 2023, were $5.6 billion and $6.1 billion, respectively. PMI’s operating cash flows were positively impacted by the amount of the trade receivables sold and derecognized from the condensed consolidated balance sheets, which remained outstanding with the unaffiliated financial institutions. The trade receivables sold that remained outstanding under these arrangements as of June 30, 2024 and 2023 were $0.7 billion. The net proceeds received are included in cash provided by operating activities in the condensed consolidated statements of cash flows. The difference between the carrying amount of the trade receivables sold and the sum of the cash received is recorded as a loss on sale of trade receivables within marketing, administration and research costs in the condensed consolidated statements of earnings. The loss on sale of trade receivables was as follows: (in millions) For the Six Months Ended June 30, For the Three Months Ended June 30, 2024 $ 22 $ 10 2023 $ 24 $ 14

Product Warranty_

Product Warranty:	6 Months Ended
	Jun. 30, 2024
Guarantees and Product Warranties [Abstract]
Product Warranty:	Product Warranty: PMI's heat-not-burn devices and e-vapor products are subject to standard product warranties generally for a period of 12 months from the date of purchase or such other periods as required by law. PMI generally provides in cost of sales for the estimated cost of warranty in the period the related revenue is recognized. PMI assesses the adequacy of its accrued product warranties and adjusts the amounts as necessary based on actual experience and changes in future estimates. Factors that affect product warranties may vary across markets but typically include device version mix, product failure rates, logistics and service delivery costs, and warranty policies. PMI accounts for its product warranties within other accrued liabilities. At June 30, 2024 and December 31, 2023, these amounts were as follows: (in millions) As of and For the Six Months Ended June 30, 2024 As of and For the Year Ended December 31, 2023 Balance at beginning of period $ 80 $ 104 Changes due to: Warranties issued 45 60 Settlements (38) (83) Currency/Other — (1) Balance at end of period $ 87 $ 80

Asset Impairment and Exit Costs

Asset Impairment and Exit Costs:	6 Months Ended
	Jun. 30, 2024
Restructuring and Related Activities [Abstract]
Asset Impairment and Exit Costs:	Asset Impairment and Exit Costs: For the six months ended June 30, 2024 and 2023, PMI recorded total pre-tax asset impairment and exit costs of $168 million and $109 million, respectively, related to restructuring activities. These 2024 and 2023 pre-tax charges were included in marketing, administration and research costs in the condensed consolidated statements of earnings. For the three months ended June 30, 2024 and 2023, PMI did not record any charges for asset impairment and exit costs related to restructuring activities. During the six months ended June 30, 2024, PMI recorded a pre-tax impairment charge on other intangibles of $27 million within the Wellness and Healthcare segment. During the six months and three months ended June 30, 2023, PMI recorded a pre-tax impairment charge on goodwill and other intangibles of $680 million within the Wellness and Healthcare segment. For further details on these impairment charges, see Note 4. Goodwill and Other Intangible Assets, net . Platform 1 (IQOS) products sourcing for the U.S. market On February 1, 2024, a subsidiary of PMI entered into a settlement agreement (the “Settlement Agreement”) with Nicoventures Trading Limited (“NTV”), an affiliate of British American Tobacco p.l.c. (“BAT”). In accordance with its terms, the parties to the Settlement Agreement filed a joint motion to rescind the limited exclusion order and the cease-and-desist order issued by the International Trade Commission (“ITC”) on September 29, 2021, which was granted on March 11, 2024. Prior to their rescission, the orders prohibited the importation and sales of imported Platform 1 products to the United States of America (for further details of the Settlement Agreement, ITC order and its rescission, see Note 8. Contingencies ). As a result, PMI has initiated a project in the first quarter of 2024 to restructure the sourcing of Platform 1 products to commercialize IQOS in the United States. For further details on IQOS commercialization in the U.S. and the related agreement with Altria Group, Inc (“Altria”), see Note 8. Contingencies and Note 18. Acquisitions . During the first quarter of 2024, PMI recorded pre-tax asset impairment and exit costs of $121 million related to this restructuring activity. This amount included contract termination costs with suppliers of $61 million, including prepaid commitments of $20 million. The amount also included asset impairment costs of $60 million, primarily related to machinery and equipment and other assets, which were non-cash charges. Venezuela In the first quarter of 2024, PMI ceased its operations in Venezuela and as a result, recorded pre-tax asset impairment and exit costs of $47 million. The amount primarily included non-cash charges related to the reclassification of accumulated foreign currency translation losses from other comprehensive losses of $38 million and asset impairment charge of $5 million related to land and buildings. This amount also included contract termination, severance and other related costs of $4 million, which were paid in cash. For details on the income tax impact of the transaction, see Note 9. Income Taxes . e-Vapor Products Manufacturing Optimization In the first quarter of 2023, PMI initiated a project to fully outsource and restructure the manufacturing of e-vapor devices and consumables. As a result, PMI recorded pre-tax asset impairment and exit costs of $109 million. This amount included contract termination costs for suppliers of $78 million, including $21 million of embedded finance lease terminations, payable in cash. This amount also included asset impairment costs of $31 million, primarily related to machinery and equipment, which were non-cash charges. Asset Impairment and Exit Costs by Segment PMI recorded the following pre-tax asset impairment and exit costs by segment: (in millions) For the Six Months Ended June 30, 2024 2023 Reclassification of accumulated foreign currency translation losses from other comprehensive losses: Americas $ 38 $ — Total reclassification of accumulated foreign currency translation losses from other comprehensive losses 38 — Contract termination charges: Europe — 34 SSEA, CIS & MEA — 23 EA, AU & PMI DF — 14 Americas 65 7 Total contract termination charges 65 78 Asset impairment charges: Europe — 13 SSEA, CIS & MEA — 9 EA, AU & PMI DF — 5 Americas 65 4 Total asset impairment charges 65 31 Asset impairment and exit costs $ 168 $ 109 Movement in Exit Cost Liabilities The movement in exit cost liabilities for the six months ended June 30, 2024 was as follows: (in millions) Liability balance, January 1, 2024 $ 29 Charges, net 65 Cash spent (32) Prepaid commitments (20) Currency/other 1 Liability balance, June 30, 2024 $ 43 Future cash payments for exit costs incurred to date are anticipated to be substantially paid by the end of 2025, with approximately $32 million expected to be paid in the remainder of 2024.

Leases_

Leases:	6 Months Ended
	Jun. 30, 2024
Leases [Abstract]
Leases:	Leases: The components of PMI’s lease cost were as follows for the six months and three months ended June 30, 2024 and 2023: For the Six Months Ended June 30, For the Three Months Ended June 30, (in millions) 2024 2023 2024 2023 Operating lease cost $ 138 $ 133 $ 72 $ 66 Finance lease cost: Amortization of right-of-use assets 37 28 12 14 Interest on lease liabilities 1 — 1 — Short-term lease cost 32 29 16 15 Variable lease cost 13 14 6 7 Total lease cost $ 221 $ 204 $ 107 $ 102
Leases:	Leases: The components of PMI’s lease cost were as follows for the six months and three months ended June 30, 2024 and 2023: For the Six Months Ended June 30, For the Three Months Ended June 30, (in millions) 2024 2023 2024 2023 Operating lease cost $ 138 $ 133 $ 72 $ 66 Finance lease cost: Amortization of right-of-use assets 37 28 12 14 Interest on lease liabilities 1 — 1 — Short-term lease cost 32 29 16 15 Variable lease cost 13 14 6 7 Total lease cost $ 221 $ 204 $ 107 $ 102

Supply Chain Financing_

Supply Chain Financing:	6 Months Ended
	Jun. 30, 2024
Payables and Accruals [Abstract]
Supply Chain Financing:	Supply Chain Financing:

Acquisitions_

Acquisitions:	6 Months Ended
	Jun. 30, 2024
Business Combination, Asset Acquisition, and Joint Venture Formation [Abstract]
Acquisitions:	Acquisitions: Transactions With Noncontrolling Interests - Turkey In the first quarter of 2022, PMI acquired the remaining 25% stake of its holding in Philip Morris Tütün Mamulleri Sanayi ve Ticaret A.Ş. ("PMTM") (formerly Philsa Philip Morris Sabanci Sigara ve Tütüncülük Sanayi ve Ticaret A.Ş.) and 24.75% stake in Philip Morris Pazarlama ve Satiş A.Ş. ("PMPS") (formerly Philip Morris SA, Philip Morris Sabanci Pazarlama ve Satiş A.Ş.) from its Turkish partners, Sabanci Holding for a total acquisition price including transaction costs and remaining dividend entitlements of approximately $223 million. As a result of this acquisition, PMI owned 100% of these Turkish subsidiaries as of December 31, 2022. The purchase of the remaining stakes in these holdings resulted in a decrease to PMI's additional paid-in capital of $30 million and an increase to accumulated other comprehensive losses of $171 million primarily following the reclassification of accumulated currency translation losses from noncontrolling interests to PMI’s accumulated other comprehensive losses during the first quarter of 2022. In January 2023, PMI sold the acquired stakes of its holdings in PMTM and PMPS to Pioneers Tutun Yatirim Anonim Sirketi (“Pioneers”) for a consideration of approximately $258 million, including transaction costs and dividend entitlements. The sale resulted in an increase to PMI's additional paid-in capital of $36 million and a decrease to accumulated other comprehensive losses of $179 million, following the reclassification of accumulated other comprehensive losses from PMI’s accumulated other comprehensive losses to noncontrolling interests. Altria Group, Inc. Agreement On October 20, 2022, PMI announced that it had reached an agreement with Altria Group, Inc. ("Altria") to end the companies' relationship regarding the IQOS commercialization rights in the U.S. as of April 30, 2024. As a result of PMI reacquiring these rights, effective May 1, 2024 ("acquisition date"), PMI holds the full rights to commercialize IQOS in the U.S. As part of the agreement, PMI agreed to pay a total cash consideration of approximately $2.8 billion, including interest, of which $1.0 billion was paid at the inception of the agreement and the remaining $1.8 billion was paid on July 14, 2023. The cash consideration paid was accounted for within Other assets in PMI's condensed consolidated balance sheets as of December 31, 2023. On the acquisition date and as of June 30, 2024, the reacquired rights were classified as Other intangible assets, net in PMI's condensed consolidated balance sheets, and will be amortized over their useful life of 5 years. For further details on PMI's agreement with Altria, see Note 8. Contingencies . United Tobacco Company In April 2023, PMI acquired 66.73% of Egyptian Investment Holding (“EIH”), a United Arab Emirates based company and as a result, acquired an approximate economic interest of 25% in United Tobacco Company ("UTC"), which was accounted for using the equity method of accounting. In May 2024, PMI increased its indirect economic interest and acquired a controlling interest of 54.25% in UTC. UTC is an entity incorporated in Egypt and manufactures products under license for Philip Morris Misr LLC (“PMM”), PMI’s Egyptian subsidiary. The acquisition builds on PMI’s existing investments in Egypt and increases the manufacturing synergies between PMM and UTC. As a result of PMI obtaining control over UTC, PMI’s previously held 25% economic interest in UTC was remeasured to its fair value by applying the guideline transaction method adjusted for a discount for lack of control. The difference between the book value of $312 million, including related cumulative translation losses balance of $112 million, which was reclassified from accumulated other comprehensive losses and the fair value of PMI’s previously held interest in UTC was not material. The total purchase price for the incremental equity interest of $315 million included cash consideration of $30 million, contingent consideration of $22 million and $263 million of assumed bank loan liabilities. The following table summarizes the preliminary purchase price allocation for the fair value of assets acquired and liabilities assumed as of the date of the acquisition, which includes previously held interest: (in millions) Cash and cash equivalent $ 74 Current assets, including receivables and inventories 11 Other intangible assets - Tobacco manufacturing license 211 Other non-current assets, including property, plant and equipment 16 Current liabilities (8) Identifiable net assets acquired 304 Noncontrolling interest (159) Goodwill 510 Acquisition fair value $ 655 Goodwill is primarily attributable to future growth opportunities, anticipated synergies in the manufacturing processes and intangible assets that did not qualify for separate recognition. The fair value of the noncontrolling interest was estimated based on the enterprise value of UTC, adjusted for a discount for lack of control. The manufacturing license, which relates to the manufacturing of both smoke-free and combustible tobacco products, was valued using the multi-period excess earnings method and has been determined to have an indefinite life. The purchase price allocation is preliminary and continues to be subject to refinement. PMI is evaluating the deductibility of goodwill for income tax purposes. UTC's results of operations from May 16, 2024, through June 30, 2024, were included in PMI's consolidated statements of earnings and were not material. Pro forma results of operations for the business combination have not been presented as the aggregate impact is not material to PMI's consolidated statements of earnings.

New Accounting Standards

New Accounting Standards	6 Months Ended
	Jun. 30, 2024
Accounting Changes and Error Corrections [Abstract]
New Accounting Standards	New Accounting Standards: Improvements to Reportable Segment Disclosures On November 27, 2023, the Financial Accounting Standards Board (“FASB”) issued Accounting Standards Update ASU 2023-07, “Improvements to Reportable Segment Disclosures” (“ASU 2023-07”). ASU 2023-07 improves reportable segment disclosures, primarily through enhanced disclosures about significant segment expenses regularly provided to the chief operating decision maker that impact segment profit or loss. The amendments are effective for fiscal years beginning after December 15, 2023, and for interim periods within fiscal years beginning after December 15, 2024, on a retrospective basis, with early adoption permitted. PMI is currently evaluating the impact of ASU 2023-07 on its disclosures. Improvements to Income Tax Disclosures On December 14, 2023, the FASB issued Accounting Standards Update ASU 2023-09, “Improvements to Income Tax Disclosures” (“ASU 2023-09”). ASU 2023-09 enhances the transparency of income tax disclosures, primarily by requiring public business entities to disclose specific categories in the rate reconciliation tabular presentation, as well as by providing additional information for reconciling items that meet a quantitative threshold. The ASU also requires disaggregated disclosures of federal, state and foreign income taxes paid.

Pay vs Performance Disclosure

Pay vs Performance Disclosure - USD ($) $ in Millions	3 Months Ended		6 Months Ended
	Jun. 30, 2024	Jun. 30, 2023	Jun. 30, 2024	Jun. 30, 2023
Pay vs Performance Disclosure
Net Income (Loss) Attributable to Parent	$ 2,406	$ 1,568	$ 4,554	$ 3,563

Insider Trading Arrangements

Insider Trading Arrangements	3 Months Ended
	Jun. 30, 2024
Trading Arrangements, by Individual
Rule 10b5-1 Arrangement Adopted	false
Non-Rule 10b5-1 Arrangement Adopted	false
Rule 10b5-1 Arrangement Terminated	false
Non-Rule 10b5-1 Arrangement Terminated	false

Background and Basis of Prese_2

Background and Basis of Presentation: (Policies)	6 Months Ended
	Jun. 30, 2024
Organization, Consolidation and Presentation of Financial Statements [Abstract]
Basis of Presentation	The interim condensed consolidated financial statements of PMI are unaudited. These interim condensed consolidated financial statements have been prepared in conformity with accounting principles generally accepted in the United States of America ("U.S. GAAP") and such principles are applied on a consistent basis. Certain information and footnote disclosures normally included in annual financial statements prepared in accordance with U.S.GAAP have been omitted. It is the opinion of PMI’s management that all adjustments necessary for a fair statement of the interim results presented have been reflected therein. All such adjustments were of a normal recurring nature. Net revenues and net earnings attributable to PMI for any interim period are not necessarily indicative of results that may be expected for the entire year.
Derivatives	PMI operates globally with manufacturing and sales facilities in various locations around the world and is exposed to risks such as changes in foreign currency exchange rates and interest rates. As a result, PMI uses deliverable and non-deliverable forward foreign exchange contracts, foreign currency swaps and foreign currency options, (collectively referred to as "foreign exchange contracts"), and interest rate contracts to mitigate its exposure to changes in foreign currency exchange and interest rates related to net investments in foreign operations, third-party and intercompany actual and forecasted transactions. The primary currencies to which PMI is exposed include the Euro, Egyptian pound, Indonesian rupiah, Japanese yen, Mexican peso, Philippine peso, Russian ruble and Swiss franc. Additionally, certain materials that PMI uses in the manufacturing of its products are exposed to market price risks. PMI uses commodity derivative contracts (“commodity contracts") to manage its exposure to the market price volatility of certain commodity components of these materials.
Fair Value of Financial Instruments	PMI assesses the fair value of its derivative contracts using standard valuation models that use, as their basis, readily observable market inputs. The fair value of PMI’s foreign exchange forward contracts, foreign currency swaps and interest rate contracts is determined by using the prevailing foreign exchange spot rates and interest rate differentials, and the respective maturity dates of the instruments. The fair value of PMI’s currency options is determined by using a Black-Scholes methodology based on foreign exchange spot rates and interest rate differentials, currency volatilities and maturity dates.
New Accounting Standards	Improvements to Reportable Segment Disclosures On November 27, 2023, the Financial Accounting Standards Board (“FASB”) issued Accounting Standards Update ASU 2023-07, “Improvements to Reportable Segment Disclosures” (“ASU 2023-07”). ASU 2023-07 improves reportable segment disclosures, primarily through enhanced disclosures about significant segment expenses regularly provided to the chief operating decision maker that impact segment profit or loss. The amendments are effective for fiscal years beginning after December 15, 2023, and for interim periods within fiscal years beginning after December 15, 2024, on a retrospective basis, with early adoption permitted. PMI is currently evaluating the impact of ASU 2023-07 on its disclosures. Improvements to Income Tax Disclosures On December 14, 2023, the FASB issued Accounting Standards Update ASU 2023-09, “Improvements to Income Tax Disclosures” (“ASU 2023-09”). ASU 2023-09 enhances the transparency of income tax disclosures, primarily by requiring public business entities to disclose specific categories in the rate reconciliation tabular presentation, as well as by providing additional information for reconciling items that meet a quantitative threshold. The ASU also requires disaggregated disclosures of federal, state and foreign income taxes paid.

Stock Plans_ (Tables)

Stock Plans: (Tables)	6 Months Ended
	Jun. 30, 2024
Share-Based Payment Arrangement [Abstract]
Disclosure of Share-Based Compensation Arrangements by Payment Award	During the six months ended June 30, 2024 and 2023, shares granted to eligible employees and the weighted-average grant date fair value per share related to RSU awards were as follows: Number of Weighted-Average Grant Date Fair Value Per RSU Award Granted 2024 1,976,920 $ 89.05 2023 1,752,050 $ 101.98 Compensation expense related to RSU awards was as follows: Compensation Expense Related to RSU Awards (in millions) For the Six Months Ended June 30, For the Three Months Ended June 30, 2024 $ 84 $ 37 2023 $ 86 $ 36 During the six months ended June 30, 2024 and 2023, shares granted to eligible employees and the grant date fair value per share related to PSU awards were as follows: Number of Shares Granted Weighted- Weighted- (Per Share) (Per Share) 2024 543,560 $ 89.01 $ 85.72 2023 482,360 $ 102.02 $ 133.54 Compensation Expense Related to PSU Awards (in millions) For the Six Months Ended June 30, For the Three Months Ended June 30, 2024 $ 49 $ 18 2023 $ 45 $ 18
Schedule of Assumptions Used to Determine the Grant Date Fair Value of the PSU Awards Subject to the TSR Performance Metric	The following assumptions were used to determine the grant date fair value of the PSU awards subject to the TSR performance factor: 2024 2023 Average risk-free interest rate (a) 4.2 % 4.1 % Average expected volatility (b) 19.9 % 24.3 % (a) Based on the U.S. Treasury yield curve. (b) Determined using the observed historical volatility.

Benefit Plans_ (Tables)

Benefit Plans: (Tables)	6 Months Ended
	Jun. 30, 2024
Retirement Benefits [Abstract]
Components of Pension and Other Employee Benefit Costs	Pension and other employee benefit costs per the condensed consolidated statements of earnings consisted of the following: For the Six Months Ended June 30, For the Three Months Ended June 30, (in millions) 2024 2023 2024 2023 Net pension costs (income) $ (39) $ (37) $ (20) $ (25) Net postemployment costs 62 59 31 29 Net postretirement costs 6 6 3 2 Total pension and other employee benefit costs $ 29 $ 28 $ 14 $ 6
Components of Net Periodic Benefit Cost	Net periodic pension cost consisted of the following: Pension (1) For the Six Months Ended June 30, For the Three Months Ended June 30, (in millions) 2024 2023 2024 2023 Service cost $ 109 $ 85 $ 54 $ 42 Interest cost 116 129 57 63 Expected return on plan assets (200) (181) (99) (91) Amortization: Net loss 46 16 23 4 Prior service cost (credit) (1) (1) (1) (1) Net periodic pension cost $ 70 $ 48 $ 34 $ 17 (1) Primarily non-U.S. based defined benefit retirement plans.

Goodwill and Other Intangible_2

Goodwill and Other Intangible Assets, net: (Tables)	6 Months Ended
	Jun. 30, 2024
Goodwill and Intangible Assets Disclosure [Abstract]
Schedule of Movements in Goodwill	The movements in goodwill were as follows: (in millions) Europe SSEA, CIS & MEA EA, AU & PMI DF Americas Wellness & Healthcare Total Balances at December 31, 2023 $ 4,173 $ 2,877 $ 492 $ 8,847 $ 390 $ 16,779 Changes due to: Acquisitions — 510 — — — 510 Currency (228) (159) (27) (49) (7) (470) Balances, June 30, 2024 $ 3,945 $ 3,228 $ 465 $ 8,798 $ 383 $ 16,819
Schedule of Amortizable Intangible Assets	Details of other intangible assets were as follows: June 30, 2024 December 31, 2023 (in millions) Weighted-Average Remaining Useful Life Gross Carrying Amount Accumulated Amortization Net Gross Carrying Amount Accumulated Amortization Net Non-amortizable intangible assets $ 4,541 $ 4,541 $ 4,543 $ 4,543 Amortizable intangible assets: Trademarks 16 years 2,179 $ 812 1,367 2,267 $ 784 1,483 Reacquired commercialization rights for IQOS in the U.S. 5 years 2,777 93 2,684 — — — Developed technology, including patents 6 years 750 349 401 774 329 445 Customer relationships and other 11 years 3,757 579 3,178 3,843 450 3,393 Total other intangible assets $ 14,004 $ 1,833 $ 12,171 $ 11,427 $ 1,563 $ 9,864
Schedule of Non-Amortizable Intangible Assets	Details of other intangible assets were as follows: June 30, 2024 December 31, 2023 (in millions) Weighted-Average Remaining Useful Life Gross Carrying Amount Accumulated Amortization Net Gross Carrying Amount Accumulated Amortization Net Non-amortizable intangible assets $ 4,541 $ 4,541 $ 4,543 $ 4,543 Amortizable intangible assets: Trademarks 16 years 2,179 $ 812 1,367 2,267 $ 784 1,483 Reacquired commercialization rights for IQOS in the U.S. 5 years 2,777 93 2,684 — — — Developed technology, including patents 6 years 750 349 401 774 329 445 Customer relationships and other 11 years 3,757 579 3,178 3,843 450 3,393 Total other intangible assets $ 14,004 $ 1,833 $ 12,171 $ 11,427 $ 1,563 $ 9,864

Financial Instruments_ (Tables)

Financial Instruments: (Tables)	6 Months Ended
	Jun. 30, 2024
Derivative Instruments and Hedging Activities Disclosure [Abstract]
Schedule of Notional Amounts of Outstanding Derivative Positions	The gross notional amounts for outstanding derivatives at the end of each period were as follows: (in millions) At June 30, 2024 At December 31, 2023 Derivative contracts designated as hedging instruments: Foreign exchange contracts $ 22,826 $ 21,987 Interest rate contracts 1,000 3,600 Commodity contracts 13 20 Derivative contracts not designated as hedging instruments: Foreign exchange contracts 17,540 17,658 Total $ 41,379 $ 43,265
Fair Value of Derivative Contracts	The fair value of PMI’s derivative contracts included in the condensed consolidated balance sheets as of June 30, 2024 and December 31, 2023, were as follows: Derivative Assets Derivative Liabilities Fair Value Fair Value At At At At (in millions) Balance Sheet Classification June 30, 2024 December 31, 2023 Balance Sheet Classification June 30, 2024 December 31, 2023 Derivative contracts designated as hedging instruments: Foreign exchange contracts Other current assets $ 590 $ 345 Other accrued liabilities $ 50 $ 249 Other assets 292 153 Income taxes and other liabilities 167 449 Interest rate contracts Other current assets — 1 Other accrued liabilities 41 78 Other assets — — Income taxes and other liabilities 16 18 Commodity contracts Other current assets — — Other accrued liabilities 3 5 Other assets — — Income taxes and other liabilities — 1 Derivative contracts not designated as hedging instruments: Foreign exchange contracts Other current assets 144 85 Other accrued liabilities 61 425 Other assets 2 — Income taxes and other liabilities 99 143 Total gross amount derivatives contracts presented in the condensed consolidated balance sheets $ 1,028 $ 584 $ 437 $ 1,368 Gross amounts not offset in the condensed consolidated balance sheets Financial instruments (352) (374) (352) (374) Cash collateral received/pledged (483) (109) (48) (551) Net amount $ 193 $ 101 $ 37 $ 443
Derivative Contracts Impact on the Condensed Consolidated Statements of Earnings and Other Comprehensive Earnings	For the six months ended June 30, 2024 and 2023, PMI's derivative contracts impacted the condensed consolidated statements of earnings and comprehensive earnings as follows: (pre-tax, in millions) For the Six Months Ended June 30, Amount of Gain/(Loss) Recognized in Other Comprehensive Earnings/(Losses) on Derivatives Statement of Earnings Amount of Gain/(Loss) Reclassified from Other Comprehensive Earnings/(Losses) into Earnings Amount of Gain/(Loss) Recognized in Earnings 2024 2023 2024 2023 2024 2023 Derivative contracts designated as hedging instruments: Cash flow hedges: Foreign exchange contracts $ 288 $ 223 Net revenues $ 90 $ 39 Cost of sales — — Marketing, administration and research costs 7 71 Interest expense, net (5) (6) Interest rate contracts 54 72 Interest expense, net 25 22 Commodity contracts (1) (1) Cost of sales — — Fair value hedges: Interest rate contracts Interest expense, net (a) $ (17) $ (14) Net investment hedges (b) : Foreign exchange contracts 578 (439) Interest expense, net (c) 147 127 Derivative contracts not designated as hedging instruments: Foreign exchange contracts Interest expense, net 99 152 Marketing, administration and research costs (d) 432 (104) Total $ 919 $ (145) $ 117 $ 126 $ 661 $ 161 (a) The gains (losses) from these contracts are offset by the changes in the fair value of the hedged item (b) Amount of gains (losses) on hedges of net investments principally related to changes in foreign currency exchange and interest rates between the Euro and U.S. dollar (c) Represent the gains for amounts excluded from the effectiveness testing (d) The gains (losses) from these contracts attributable to changes in foreign currency exchange rates are partially offset by the (losses) and gains generated by the underlying intercompany and third-party loans being hedged For the three months ended June 30, 2024 and 2023, PMI's derivative contracts impacted the condensed consolidated statements of earnings and comprehensive earnings as follows: (pre-tax, in millions) For the Three Months Ended June 30, Amount of Gain/(Loss) Recognized in Other Comprehensive Earnings/(Losses) on Derivatives Statement of Earnings Amount of Gain/(Loss) Reclassified from Other Comprehensive Earnings/(Losses) into Earnings Amount of Gain/(Loss) Recognized in Earnings 2024 2023 2024 2023 2024 2023 Derivative contracts designated as hedging instruments: Cash flow hedges: Foreign exchange contracts $ 122 $ 213 Net revenues $ 61 $ 27 Cost of sales — — Marketing, administration and research costs (17) 55 Interest expense, net (2) (3) Interest rate contracts — 7 Interest expense, net 13 12 Commodity contracts 2 (1) Cost of sales — — Fair value hedges: Interest rate contracts Interest expense, net (a) $ (6) $ (17) Net investment hedges (b) : Foreign exchange contracts 125 (181) Interest expense, net (c) 75 64 Derivative contracts not designated as hedging instruments: Foreign exchange contracts Interest expense, net 55 62 Marketing, administration and research costs (d) (80) (88) Total $ 249 $ 38 $ 55 $ 91 $ 44 $ 21 (a) The gains (losses) from these contracts are offset by the changes in the fair value of the hedged item (b) Amount of gains (losses) on hedges of net investments principally related to changes in foreign currency exchange and interest rates between the Euro and U.S. dollar (c) Represent the gains for amounts excluded from the effectiveness testing (d) The gains (losses) from these contracts attributable to changes in foreign currency exchange rates are partially offset by the (losses) and gains generated by the underlying intercompany and third-party loans being hedged
Qualifying Hedging Activity Reported in Accumulated Other Comprehensive Earnings (Losses), Net of Income Taxes	Hedging activity affected accumulated other comprehensive losses, net of income taxes, as follows: (in millions) For the Six Months Ended June 30, For the Three Months Ended June 30, 2024 2023 2024 2023 Gain/(loss) as of beginning of period, $ 241 $ 266 $ 373 $ 296 Derivative (gains)/losses transferred to earnings (94) (104) (48) (75) Change in fair value 286 246 108 187 Gain/(loss) as of June 30, $ 433 $ 408 $ 433 $ 408

Earnings Per Share_ (Tables)

Earnings Per Share: (Tables)	6 Months Ended
	Jun. 30, 2024
Earnings Per Share [Abstract]
Calculation of Basic and Diluted EPS	Basic and diluted earnings per share (“EPS”) were calculated using the following: (in millions) For the Six Months Ended June 30, For the Three Months Ended June 30, 2024 2023 2024 2023 Net earnings attributable to PMI $ 4,554 $ 3,563 $ 2,406 $ 1,568 Less distributed and undistributed earnings attributable to share-based payment awards 14 11 7 5 Net earnings for basic and diluted EPS $ 4,540 $ 3,552 $ 2,399 $ 1,563 Weighted-average shares for basic EPS 1,554 1,552 1,555 1,552 Plus contingently issuable performance stock units (PSUs) (1) 2 1 1 1 Weighted-average shares for diluted EPS 1,556 1,553 1,556 1,553 (1)

Segment Reporting_ (Tables)

Segment Reporting: (Tables)	6 Months Ended
	Jun. 30, 2024
Segment Reporting [Abstract]
Segment Data	Segment data were as follows: (in millions) For the Six Months Ended June 30, For the Three Months Ended June 30, 2024 2023 2024 2023 Net revenues: Europe $ 7,180 $ 6,642 $ 3,815 $ 3,574 SSEA, CIS & MEA 5,429 5,145 2,771 2,668 EA, AU & PMI DF 3,357 3,200 1,673 1,680 Americas 2,125 1,837 1,129 969 Wellness and Healthcare 170 162 80 76 Net revenues $ 18,261 $ 16,986 $ 9,468 $ 8,967 Operating income (loss): Europe $ 3,116 $ 2,834 $ 1,660 $ 1,619 SSEA, CIS & MEA 1,663 1,614 891 880 EA, AU & PMI DF 1,516 1,194 753 557 Americas 282 426 183 243 Wellness and Healthcare (88) (771) (43) (733) Operating income $ 6,489 $ 5,297 $ 3,444 $ 2,566 PMI's net revenues by product category were as follows: (in millions) For the Six Months Ended June 30, For the Three Months Ended June 30, 2024 2023 2024 2023 Net revenues: Combustible tobacco: Europe $ 4,145 $ 3,924 $ 2,214 $ 2,108 SSEA, CIS & MEA 4,778 4,504 2,432 2,350 EA, AU & PMI DF 1,217 1,412 620 724 Americas 1,126 1,173 592 608 Total combustible tobacco 11,265 11,013 5,858 5,790 Smoke-free: Smoke-free excluding Wellness and Healthcare: Europe 3,035 2,718 1,601 1,466 SSEA, CIS & MEA 651 641 339 318 EA, AU & PMI DF 2,140 1,788 1,053 956 Americas 999 664 537 361 Total Smoke-free excluding Wellness and Healthcare 6,826 5,811 3,530 3,101 Wellness and Healthcare 170 162 80 76 Total Smoke-free 6,996 5,973 3,610 3,177 Total PMI net revenues $ 18,261 $ 16,986 $ 9,468 $ 8,967 Note: Sum of product categories or Regions might not foot to total PMI due to roundings.

Indebtedness_ (Tables)

Indebtedness: (Tables)	6 Months Ended
	Jun. 30, 2024
Debt Disclosure [Abstract]
Schedule of Short-Term Debt	At June 30, 2024 and December 31, 2023, PMI’s short-term borrowings and related average interest rates consisted of the following: June 30, 2024 December 31, 2023 (in millions) Amount Outstanding Average Rate Amount Outstanding Average Rate Commercial paper $ — — % $ 1,685 5.6 % Bank loans 139 11.6 283 8.9 $ 139 $ 1,968
Long-Term Debt	At June 30, 2024 and December 31, 2023, PMI’s long-term debt consisted of the following: (in millions) June 30, 2024 December 31, 2023 U.S. dollar notes, 0.875% to 6.375% (average interest rate 4.572%), due through 2044 $ 34,059 $ 30,272 Foreign currency obligations: Euro notes, 0.125% to 3.750% (average interest rate 1.921%), due through 2039 8,103 8,526 Swiss franc note, 1.625%, due 2024 — 299 Euro credit facility borrowings related to Swedish Match AB acquisition, (average interest rate 4.194%), due through 2027 5,887 6,121 Swedish krona notes, 1.395% to 2.710% (average interest rate 2.016%), due through 2029 224 236 Other (average interest rate 6.131%), due through 2032 (a) 727 487 Carrying value of long-term debt 49,000 45,941 Less current portion of long-term debt 4,353 4,698 $ 44,647 $ 41,243 (a)
Aggregate Fair Values of PMI's Debt, Excluding Finance Leases	At June 30, 2024, the fair value of PMI's outstanding long-term debt, excluding the aforementioned finance leases, was as follows: (in millions) June 30, 2024 Level 1 $ 40,607 Level 2 6,693
Schedule of Debt Issuances During Current Period	PMI's debt issuances in the first six months of 2024 were as follows: (in millions) Type Face Value Interest Rate Issuance Maturity U.S. dollar notes (a) $750 4.750% February 2024 February 2027 U.S. dollar notes (a) $1,000 4.875% February 2024 February 2029 U.S. dollar notes (a) $1,250 5.125% February 2024 February 2031 U.S. dollar notes (a) $1,750 5.250% February 2024 February 2034 Euro notes (b) (c) €500 (approximately $543) 3.750% June 2024 January 2031 (a) Interest is payable semi-annually, commencing in August 2024 (b) Interest is payable annually, commencing in January 2025 (c) USD equivalents for foreign currency notes were calculated based on exchange rates on the date of issuance.
Schedule of Committed Credit Facilities	At June 30, 2024, PMI's total committed revolving credit facilities were as follows: (in billions) Type Committed 364-day revolving credit, expiring January 28, 2025 $ 1.7 Multi-year revolving credit, expiring February 10, 2026 (1) 2.0 Multi-year revolving credit, expiring September 29, 2026 (2) (3) 2.5 Total facilities $ 6.2 (1) On January 28, 2022, PMI entered into an agreement, effective February 10, 2022, to amend and extend the term of its $2.0 billion multi-year revolving credit facility, for an additional year covering the period February 11, 2026 to February 10, 2027, in the amount of $1.9 billion. (2) Includes pricing adjustments that may result in the reduction or increase in both the interest rate and commitment fee under the credit agreement if PMI achieves, or fails to achieve, certain specified targets. (3)

Accumulated Other Comprehensi_2

Accumulated Other Comprehensive Losses: (Tables)	6 Months Ended
	Jun. 30, 2024
Accumulated Other Comprehensive Income (Loss), Net of Tax [Abstract]
Components of Accumulated Other Comprehensive Earnings (Losses), Net of Taxes	PMI’s accumulated other comprehensive losses, net of taxes, consisted of the following: (Losses) Earnings At At At (in millions) June 30, 2024 December 31, 2023 June 30, 2023 Currency translation adjustments $ (8,841) $ (9,467) $ (8,678) Pension and other benefits (2,522) (2,589) (1,775) Derivatives accounted for as hedges 433 241 408 Total accumulated other comprehensive losses $ (10,930) $ (11,815) $ (10,045)

Related Parties - Equity Inve_2

Related Parties - Equity Investments and Other: (Tables)	6 Months Ended
	Jun. 30, 2024
Equity Method Investments and Joint Ventures [Abstract]
Earnings and Balance Sheet Activities with Related Parties - Equity Investments and Other	PMI’s net revenues and expenses with the above related parties were as follows: For the Six Months Ended June 30, For the Three Months Ended June 30, (in millions) 2024 2023 2024 2023 Net revenues: Megapolis Group $ 1,096 $ 1,184 $ 576 $ 596 Other 725 590 385 305 Net revenues (a) $ 1,821 $ 1,774 $ 961 $ 901 Expenses: Other $ 73 $ 113 $ 33 $ 63 Expenses $ 73 $ 113 $ 33 $ 63 (a) Net revenues exclude excise taxes and VAT billed to customers. PMI’s balance sheet activity with the above related parties was as follows: (in millions) At June 30, 2024 At December 31, 2023 Receivables: Megapolis Group $ 535 $ 474 Other 299 236 Receivables $ 834 $ 710 Payables: Other $ 28 $ 18 Payables $ 28 $ 18

Sale of Accounts Receivable_ (T

Sale of Accounts Receivable: (Tables)	6 Months Ended
	Jun. 30, 2024
Sale of Accounts Receivable [Abstract]
Loss on Sale of Trade Receivables	The loss on sale of trade receivables was as follows: (in millions) For the Six Months Ended June 30, For the Three Months Ended June 30, 2024 $ 22 $ 10 2023 $ 24 $ 14

Product Warranty_ (Tables)

Product Warranty: (Tables)	6 Months Ended
	Jun. 30, 2024
Guarantees and Product Warranties [Abstract]
Schedule of Accrued Product Warranties	At June 30, 2024 and December 31, 2023, these amounts were as follows: (in millions) As of and For the Six Months Ended June 30, 2024 As of and For the Year Ended December 31, 2023 Balance at beginning of period $ 80 $ 104 Changes due to: Warranties issued 45 60 Settlements (38) (83) Currency/Other — (1) Balance at end of period $ 87 $ 80

Asset Impairment and Exit Cos_2

Asset Impairment and Exit Costs: (Tables)	6 Months Ended
	Jun. 30, 2024
Restructuring and Related Activities [Abstract]
Pre-Tax Asset Impairment and Exit Costs by Segment	PMI recorded the following pre-tax asset impairment and exit costs by segment: (in millions) For the Six Months Ended June 30, 2024 2023 Reclassification of accumulated foreign currency translation losses from other comprehensive losses: Americas $ 38 $ — Total reclassification of accumulated foreign currency translation losses from other comprehensive losses 38 — Contract termination charges: Europe — 34 SSEA, CIS & MEA — 23 EA, AU & PMI DF — 14 Americas 65 7 Total contract termination charges 65 78 Asset impairment charges: Europe — 13 SSEA, CIS & MEA — 9 EA, AU & PMI DF — 5 Americas 65 4 Total asset impairment charges 65 31 Asset impairment and exit costs $ 168 $ 109
Movement in Exit Cost Liabilities	The movement in exit cost liabilities for the six months ended June 30, 2024 was as follows: (in millions) Liability balance, January 1, 2024 $ 29 Charges, net 65 Cash spent (32) Prepaid commitments (20) Currency/other 1 Liability balance, June 30, 2024 $ 43

Leases_ (Tables)

Leases: (Tables)	6 Months Ended
	Jun. 30, 2024
Leases [Abstract]
Lease Cost Components	The components of PMI’s lease cost were as follows for the six months and three months ended June 30, 2024 and 2023: For the Six Months Ended June 30, For the Three Months Ended June 30, (in millions) 2024 2023 2024 2023 Operating lease cost $ 138 $ 133 $ 72 $ 66 Finance lease cost: Amortization of right-of-use assets 37 28 12 14 Interest on lease liabilities 1 — 1 — Short-term lease cost 32 29 16 15 Variable lease cost 13 14 6 7 Total lease cost $ 221 $ 204 $ 107 $ 102

Acquisitions_ (Tables)

Acquisitions: (Tables)	6 Months Ended
	Jun. 30, 2024
Business Combination, Asset Acquisition, and Joint Venture Formation [Abstract]
Schedule of Purchase Price Allocation	The following table summarizes the preliminary purchase price allocation for the fair value of assets acquired and liabilities assumed as of the date of the acquisition, which includes previously held interest: (in millions) Cash and cash equivalent $ 74 Current assets, including receivables and inventories 11 Other intangible assets - Tobacco manufacturing license 211 Other non-current assets, including property, plant and equipment 16 Current liabilities (8) Identifiable net assets acquired 304 Noncontrolling interest (159) Goodwill 510 Acquisition fair value $ 655

Background and Basis of Prese_3

Background and Basis of Presentation: (Details)	6 Months Ended
	Jun. 30, 2024 segment
Geographical Segment
Product Information [Line Items]
Number of reportable segments	4

Stock Plans_ (Narrative) (Detai

Stock Plans: (Narrative) (Details) $ in Millions	6 Months Ended
	Jun. 30, 2024 USD ($) year metric shares	May 31, 2022 shares	May 31, 2017 shares
Restricted Stock Units (RSUs)
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Total unrecognized compensation cost | $	$ 228
Award requisite service period	3 years
Minimum retirement age | year	58
Restricted stock units vested (in shares)	1,741,966
Restricted Stock Units (RSUs) | Grant Date Fair Value
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Fair value of vested stock awards | $	$ 148
Restricted Stock Units (RSUs) | Total Fair Value
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Fair value of vested stock awards | $	159
Performance Shares
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Total unrecognized compensation cost | $	$ 55
Minimum retirement age | year	58
Restricted stock units vested (in shares)	916,452
Length of performance cycle period	3 years
Absolute basis (as a percent)	40%
Currency-neutral compound annual adjusted diluted earnings per share growth rate (as a percent)	30%
Product sustainability weight	20%
Operational sustainability weight	10%
Performance metrics predefined at time of grant | metric	3
Aggregate weighted performance factor	100%
Shares of common stock issued for each vested performance stock unit (in shares)	1
Performance Shares | Minimum
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Award vesting rights, percentage	0%
Performance Shares | Maximum
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Award vesting rights, percentage	200%
Performance Shares | Grant Date Fair Value
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Fair value of vested stock awards | $	$ 86
Performance Shares | Total Fair Value
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Fair value of vested stock awards | $	$ 83
2022 Performance Incentive Plan
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Estimated common stock to be awarded under a stock benefit plan, maximum limit (in shares)		25,000,000
Shares available for grant under the plan (in shares)	19,161,366
Non Employee Directors Plan
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Estimated common stock to be awarded under a stock benefit plan, maximum limit (in shares)			1,000,000
Shares available for grant under the plan (in shares)	855,920
Percentage of voting shares that PMI may own, used in determining non-employee director status			50%

Stock Plans_ (RSU Awards) (Deta

Stock Plans: (RSU Awards) (Details) - Restricted Stock Units (RSUs) - USD ($) $ / shares in Units, $ in Millions	3 Months Ended		6 Months Ended
	Jun. 30, 2024	Jun. 30, 2023	Jun. 30, 2024	Jun. 30, 2023
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Number of shares granted (in shares)			1,976,920	1,752,050
Weighted-average grant date fair value per RSU award granted (in dollars per share)			$ 89.05	$ 101.98
Compensation Expense Related to RSU Awards	$ 37	$ 36	$ 84	$ 86

Stock Plans_ (PSU Awards) (Deta

Stock Plans: (PSU Awards) (Details) - USD ($) $ / shares in Units, $ in Millions	3 Months Ended		6 Months Ended
	Jun. 30, 2024	Jun. 30, 2023	Jun. 30, 2024	Jun. 30, 2023
Performance Shares
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Number of shares granted (in shares)			543,560	482,360
Average risk-free interest rate			4.20%	4.10%
Average expected volatility			19.90%	24.30%
Compensation Expense Related to PSU Awards	$ 18	$ 18	$ 49	$ 45
Performance Share Units, Other Performance Metrics
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Weighted-average PSU grant date fair value subject to specific factors (in dollars per share)			$ 89.01	$ 102.02
Performance Share Units, TSR Performance Metric
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Weighted-average PSU grant date fair value subject to specific factors (in dollars per share)			$ 85.72	$ 133.54

Benefit Plans_ (Components of P

Benefit Plans: (Components of Pension and Other Employee Benefits Costs) (Details) - USD ($) $ in Millions	3 Months Ended		6 Months Ended
	Jun. 30, 2024	Jun. 30, 2023	Jun. 30, 2024	Jun. 30, 2023
Defined Benefit Plans and Other Postretirement Benefit Plans Table Text Block [Line Items]
Total pension and other employee benefit costs	$ 14	$ 6	$ 29	$ 28
Pension Plan
Defined Benefit Plans and Other Postretirement Benefit Plans Table Text Block [Line Items]
Total pension and other employee benefit costs	(20)	(25)	(39)	(37)
Postemployment Benefit Plans
Defined Benefit Plans and Other Postretirement Benefit Plans Table Text Block [Line Items]
Total pension and other employee benefit costs	31	29	62	59
Postretirement Benefit Costs
Defined Benefit Plans and Other Postretirement Benefit Plans Table Text Block [Line Items]
Total pension and other employee benefit costs	$ 3	$ 2	$ 6	$ 6

Benefit Plans_ (Components of N

Benefit Plans: (Components of Net Periodic Benefit Cost) (Details) - Pension Plan - USD ($) $ in Millions	3 Months Ended		6 Months Ended
	Jun. 30, 2024	Jun. 30, 2023	Jun. 30, 2024	Jun. 30, 2023
Defined Benefit Plan Disclosure [Line Items]
Service cost	$ 54	$ 42	$ 109	$ 85
Interest cost	57	63	116	129
Expected return on plan assets	(99)	(91)	(200)	(181)
Amortization:
Net loss	23	4	46	16
Prior service cost (credit)	(1)	(1)	(1)	(1)
Net periodic pension cost	$ 34	$ 17	$ 70	$ 48

Benefit Plans_ (Narrative) (Det

Benefit Plans: (Narrative) (Details) $ in Millions	6 Months Ended
	Jun. 30, 2024 USD ($)
Retirement Benefits [Abstract]
Employer contributions	$ 55
Anticipated additional employer contributions during the remainder of the current fiscal year	$ 66

Goodwill and Other Intangible_3

Goodwill and Other Intangible Assets, net: (Narrative) (Details) - USD ($)	3 Months Ended			6 Months Ended
	Jun. 30, 2024	Mar. 31, 2024	Jun. 30, 2023	Jun. 30, 2024	Jun. 30, 2023	Dec. 31, 2023
Finite-Lived Intangible Assets [Line Items]
Impairment of goodwill and other intangibles	$ 0		$ 680,000,000	$ 27,000,000	$ 680,000,000
Total assets	65,782,000,000			65,782,000,000		$ 65,304,000,000
Cash and cash equivalents	4,807,000,000			4,807,000,000		$ 3,060,000,000
Non-amortizable intangible assets, decrease in currency movements				181,000,000
Finite lived intangible asset, currency movements increase (decrease)				(203,000,000)
Amortization of Intangible Assets				332,000,000
Change in accumulated amortization, currency movements				62,000,000
Estimated amortization expense, year one, assuming no additional transactions occur that require the amortization of intangible assets	1,031,000,000			1,031,000,000
Estimated amortization expense, year two, assuming no additional transactions occur that require the amortization of intangible assets	1,031,000,000			1,031,000,000
Estimated amortization expense, year three, assuming no additional transactions occur that require the amortization of intangible assets	1,031,000,000			1,031,000,000
Estimated amortization expense, year four, assuming no additional transactions occur that require the amortization of intangible assets	1,031,000,000			1,031,000,000
Estimated amortization expense, year five, assuming no additional transactions occur that require the amortization of intangible assets	1,031,000,000			1,031,000,000
Impairment of goodwill	$ 0		665,000,000	$ 0	665,000,000
Megapolis Group
Finite-Lived Intangible Assets [Line Items]
Ownership percentage	23%			23%
RUSSIAN FEDERATION | War In Ukraine
Finite-Lived Intangible Assets [Line Items]
Total assets	$ 2,800,000,000			$ 2,800,000,000
Cash and cash equivalents	$ 700,000,000			$ 700,000,000
Wellness & Healthcare
Finite-Lived Intangible Assets [Line Items]
Excess of fair value over carrying value (less than)	20%			20%
Wellness & Healthcare
Finite-Lived Intangible Assets [Line Items]
Impairment of goodwill			665,000,000		665,000,000
In Process Research and Development
Finite-Lived Intangible Assets [Line Items]
Non-amortizable intangible asset impairment		$ 27,000,000	$ 15,000,000	$ 27,000,000	$ 15,000,000
Cost of sales
Finite-Lived Intangible Assets [Line Items]
Amortization of Intangible Assets				32,000,000
Marketing, administration and research costs
Finite-Lived Intangible Assets [Line Items]
Amortization of Intangible Assets				$ 300,000,000

Goodwill and Other Intangible_4

Goodwill and Other Intangible Assets, net: (Movement in Goodwill) (Details) $ in Millions	6 Months Ended
	Jun. 30, 2024 USD ($)
Goodwill [Roll Forward]
Beginning balance	$ 16,779
Changes due to:
Acquisitions	510
Currency	(470)
Ending balance	16,819
Europe
Goodwill [Roll Forward]
Beginning balance	4,173
Changes due to:
Acquisitions	0
Currency	(228)
Ending balance	3,945
SSEA, CIS & MEA
Goodwill [Roll Forward]
Beginning balance	2,877
Changes due to:
Acquisitions	510
Currency	(159)
Ending balance	3,228
EA, AU & PMI DF
Goodwill [Roll Forward]
Beginning balance	492
Changes due to:
Acquisitions	0
Currency	(27)
Ending balance	465
Americas
Goodwill [Roll Forward]
Beginning balance	8,847
Changes due to:
Acquisitions	0
Currency	(49)
Ending balance	8,798
Wellness & Healthcare
Goodwill [Roll Forward]
Beginning balance	390
Changes due to:
Acquisitions	0
Currency	(7)
Ending balance	$ 383

Goodwill and Other Intangible_5

Goodwill and Other Intangible Assets, net: (Other Intangible Assets) (Details) - USD ($) $ in Millions	Jun. 30, 2024	Dec. 31, 2023
Goodwill and Intangible Assets Disclosure [Abstract]
Non-amortizable intangible assets	$ 4,541	$ 4,543
Finite-Lived Intangible Assets [Line Items]
Amortizable intangible assets, accumulated amortization	1,833	1,563
Total other intangible assets, gross	14,004	11,427
Total other intangible assets, net	$ 12,171	9,864
Trademarks
Finite-Lived Intangible Assets [Line Items]
Weighted-average remaining useful life	16 years
Amortizable intangible assets, gross carrying amount	$ 2,179	2,267
Amortizable intangible assets, accumulated amortization	812	784
Amortizable intangible assets, net	$ 1,367	1,483
Reacquired commercialization rights for IQOS in the U.S.
Finite-Lived Intangible Assets [Line Items]
Weighted-average remaining useful life	5 years
Amortizable intangible assets, gross carrying amount	$ 2,777	0
Amortizable intangible assets, accumulated amortization	93	0
Amortizable intangible assets, net	$ 2,684	0
Developed technology, including patents
Finite-Lived Intangible Assets [Line Items]
Weighted-average remaining useful life	6 years
Amortizable intangible assets, gross carrying amount	$ 750	774
Amortizable intangible assets, accumulated amortization	349	329
Amortizable intangible assets, net	$ 401	445
Customer relationships and other
Finite-Lived Intangible Assets [Line Items]
Weighted-average remaining useful life	11 years
Amortizable intangible assets, gross carrying amount	$ 3,757	3,843
Amortizable intangible assets, accumulated amortization	579	450
Amortizable intangible assets, net	$ 3,178	$ 3,393

Financial Instruments_ (Notiona

Financial Instruments: (Notional Amounts of Outstanding Derivative Instruments) (Details) - USD ($) $ in Millions	Jun. 30, 2024	Dec. 31, 2023
Derivative [Line Items]
Notional amount	$ 41,379	$ 43,265
Designated as Hedging Instrument | Foreign exchange contracts
Derivative [Line Items]
Notional amount	22,826	21,987
Designated as Hedging Instrument | Interest rate contracts
Derivative [Line Items]
Notional amount	1,000	3,600
Designated as Hedging Instrument | Commodity contracts
Derivative [Line Items]
Notional amount	13	20
Not Designated as Hedging Instrument | Foreign exchange contracts
Derivative [Line Items]
Notional amount	$ 17,540	$ 17,658

Financial Instruments_ (Fair Va

Financial Instruments: (Fair Value of Derivative Contracts) (Details) - USD ($) $ in Millions	Jun. 30, 2024	Dec. 31, 2023
Derivatives, Fair Value [Line Items]
Derivative asset fair value	$ 1,028	$ 584
Gross amounts not offset in the condensed consolidated balance sheets - financial instruments	(352)	(374)
Gross amounts not offset in the condensed consolidated balance sheets - cash collateral received / pledged	(483)	(109)
Net amount	193	101
Derivative liability fair value	437	1,368
Gross amounts not offset in the condensed consolidated balance sheets - financial instruments	(352)	(374)
Gross amounts not offset in the condensed consolidated balance sheets - cash collateral received / pledged	(48)	(551)
Net amount	37	443
Foreign exchange contracts | Foreign exchange contracts | Other current assets
Derivatives, Fair Value [Line Items]
Derivative asset fair value	590	345
Foreign exchange contracts | Foreign exchange contracts | Other assets
Derivatives, Fair Value [Line Items]
Derivative asset fair value	292	153
Foreign exchange contracts | Foreign exchange contracts | Other accrued liabilities
Derivatives, Fair Value [Line Items]
Derivative liability fair value	50	249
Foreign exchange contracts | Foreign exchange contracts | Income taxes and other liabilities
Derivatives, Fair Value [Line Items]
Derivative liability fair value	167	449
Foreign exchange contracts | Not Designated as Hedging Instrument | Other current assets
Derivatives, Fair Value [Line Items]
Derivative asset fair value	144	85
Foreign exchange contracts | Not Designated as Hedging Instrument | Other assets
Derivatives, Fair Value [Line Items]
Derivative asset fair value	2	0
Foreign exchange contracts | Not Designated as Hedging Instrument | Other accrued liabilities
Derivatives, Fair Value [Line Items]
Derivative liability fair value	61	425
Foreign exchange contracts | Not Designated as Hedging Instrument | Income taxes and other liabilities
Derivatives, Fair Value [Line Items]
Derivative liability fair value	99	143
Interest rate contracts | Foreign exchange contracts | Other current assets
Derivatives, Fair Value [Line Items]
Derivative asset fair value	0	1
Interest rate contracts | Foreign exchange contracts | Other assets
Derivatives, Fair Value [Line Items]
Derivative asset fair value	0	0
Interest rate contracts | Foreign exchange contracts | Other accrued liabilities
Derivatives, Fair Value [Line Items]
Derivative liability fair value	41	78
Interest rate contracts | Foreign exchange contracts | Income taxes and other liabilities
Derivatives, Fair Value [Line Items]
Derivative liability fair value	16	18
Commodity contracts | Foreign exchange contracts | Other current assets
Derivatives, Fair Value [Line Items]
Derivative asset fair value	0	0
Commodity contracts | Foreign exchange contracts | Other assets
Derivatives, Fair Value [Line Items]
Derivative asset fair value	0	0
Commodity contracts | Foreign exchange contracts | Other accrued liabilities
Derivatives, Fair Value [Line Items]
Derivative liability fair value	3	5
Commodity contracts | Foreign exchange contracts | Income taxes and other liabilities
Derivatives, Fair Value [Line Items]
Derivative liability fair value	$ 0	$ 1

Financial Instruments_ (Cash Fl

Financial Instruments: (Cash Flow and Net Investment Hedging Activities Effect on Condensed Consolidated Statements of Earnings and Other Comprehensive Earnings) (Details) - USD ($) $ in Millions	3 Months Ended		6 Months Ended
	Jun. 30, 2024	Jun. 30, 2023	Jun. 30, 2024	Jun. 30, 2023
Derivative Instruments, Gain (Loss) [Line Items]
Total	$ 249	$ 38	$ 919	$ (145)
Derivative, Excluded Component, Gain (Loss), Statement of Income or Comprehensive Income [Extensible Enumeration]	Interest Income (Expense), Nonoperating		Interest Income (Expense), Nonoperating
Foreign exchange contracts
Derivative Instruments, Gain (Loss) [Line Items]
Foreign exchange contracts	$ 122	213	$ 288	223
Net investment hedges	125	(181)	578	(439)
Amount of Gain/(Loss) Reclassified from Other Comprehensive Earnings/(Losses) into Earnings	55	91	117	126
Foreign exchange contracts | Foreign exchange contracts
Derivative Instruments, Gain (Loss) [Line Items]
Amount of Gain/(Loss) Recognized in Earnings	75	64	147	127
Foreign exchange contracts | Not Designated as Hedging Instrument
Derivative Instruments, Gain (Loss) [Line Items]
Amount of Gain/(Loss) Recognized in Earnings	44	21	661	161
Foreign exchange contracts | Net revenues
Derivative Instruments, Gain (Loss) [Line Items]
Amount of Gain/(Loss) Reclassified from Other Comprehensive Earnings/(Losses) into Earnings	61	27	90	39
Foreign exchange contracts | Cost of sales
Derivative Instruments, Gain (Loss) [Line Items]
Amount of Gain/(Loss) Reclassified from Other Comprehensive Earnings/(Losses) into Earnings	0	0	0	0
Foreign exchange contracts | Marketing, administration and research costs
Derivative Instruments, Gain (Loss) [Line Items]
Amount of Gain/(Loss) Reclassified from Other Comprehensive Earnings/(Losses) into Earnings	(17)	55	7	71
Foreign exchange contracts | Marketing, administration and research costs | Not Designated as Hedging Instrument
Derivative Instruments, Gain (Loss) [Line Items]
Amount of Gain/(Loss) Recognized in Earnings	(80)	(88)	432	(104)
Foreign exchange contracts | Interest expense, net
Derivative Instruments, Gain (Loss) [Line Items]
Amount of Gain/(Loss) Reclassified from Other Comprehensive Earnings/(Losses) into Earnings	(2)	(3)	(5)	(6)
Foreign exchange contracts | Interest expense, net | Not Designated as Hedging Instrument
Derivative Instruments, Gain (Loss) [Line Items]
Amount of Gain/(Loss) Recognized in Earnings	55	62	99	152
Interest rate contracts
Derivative Instruments, Gain (Loss) [Line Items]
Foreign exchange contracts	0	7	54	72
Interest rate contracts | Interest expense, net
Derivative Instruments, Gain (Loss) [Line Items]
Amount of Gain/(Loss) Reclassified from Other Comprehensive Earnings/(Losses) into Earnings	13	12	25	22
Interest rate contracts | Interest expense, net | Foreign exchange contracts
Derivative Instruments, Gain (Loss) [Line Items]
Amount of Gain/(Loss) Recognized in Earnings	(6)	(17)	(17)	(14)
Commodity contracts
Derivative Instruments, Gain (Loss) [Line Items]
Foreign exchange contracts	2	(1)	(1)	(1)
Commodity contracts | Cost of sales
Derivative Instruments, Gain (Loss) [Line Items]
Amount of Gain/(Loss) Reclassified from Other Comprehensive Earnings/(Losses) into Earnings	$ 0	$ 0	$ 0	$ 0

Financial Instruments_ (Narrati

Financial Instruments: (Narrative) (Details) - USD ($) $ in Millions	3 Months Ended		6 Months Ended
	Jun. 30, 2024	Jun. 30, 2023	Jun. 30, 2024	Jun. 30, 2023
Derivative [Line Items]
Fair value hedge amount	$ 941		$ 941
Cumulative fair value gain (loss) of hedged liability	57		57
Long-Term Debt And Lease Obligation, Current
Derivative [Line Items]
Fair value hedge amount	336		336
Long-Term Debt And Lease Obligation
Derivative [Line Items]
Fair value hedge amount	605		605
Level 1
Derivative [Line Items]
Other investments	144		144
Net Investment Hedging | Foreign Debt
Derivative [Line Items]
Foreign currency gain (loss)	0	$ 23	5	$ 24
Foreign exchange contracts
Derivative [Line Items]
Derivative instruments, gains to be reclassified to earnings	$ 197		$ 197

Financial Instruments_ (Qualify

Financial Instruments: (Qualifying Hedging Activity Reported in Accumulated Other Comprehensive Earnings (Losses) Net of Income Taxes) (Details) - USD ($) $ in Millions	3 Months Ended		6 Months Ended
	Jun. 30, 2024	Jun. 30, 2023	Jun. 30, 2024	Jun. 30, 2023
AOCI Including Portion Attributable to Noncontrolling Interest, Net of Tax [Roll Forward]
Derivative (gains)/losses transferred to earnings	$ (48)	$ (75)	$ (94)	$ (104)
Change in fair value	108	187	286	246
Other Comprehensive Income (Loss)
AOCI Including Portion Attributable to Noncontrolling Interest, Net of Tax [Roll Forward]
Gain/(loss) as of beginning of period,	373	296	241	266
Derivative (gains)/losses transferred to earnings	(48)	(75)	(94)	(104)
Change in fair value	108	187	286	246
Gain/(loss) as of June 30,	$ 433	$ 408	$ 433	$ 408

Earnings Per Share_ (Details)

Earnings Per Share: (Details) - USD ($) $ in Millions	3 Months Ended		6 Months Ended
	Jun. 30, 2024	Jun. 30, 2023	Jun. 30, 2024	Jun. 30, 2023
Earnings Per Share [Abstract]
Net earnings attributable to PMI	$ 2,406	$ 1,568	$ 4,554	$ 3,563
Less distributed and undistributed earnings attributable to share-based payment awards	7	5	14	11
Net earnings for basic EPS	2,399	1,563	4,540	3,552
Net earnings for diluted EPS	$ 2,399	$ 1,563	$ 4,540	$ 3,552
Weighted-average shares for basic EPS (in shares)	1,555,000,000	1,552,000,000	1,554,000,000	1,552,000,000
Plus contingently issuable performance stock units (PSUs), (in shares)	1,000,000	1,000,000	2,000,000	1,000,000
Weighted-average shares for diluted EPS (in shares)	1,556,000,000	1,553,000,000	1,556,000,000	1,553,000,000
Antidilutive stock awards (in shares)	0	0	0	0

Segment Reporting_ (Narrative)

Segment Reporting: (Narrative) (Details) $ in Millions	3 Months Ended		6 Months Ended
	Jun. 30, 2023 USD ($)	Mar. 31, 2023 USD ($)	Jun. 30, 2024 segment	Jun. 30, 2023 USD ($)
Swedish Match AB
Segment Reporting Information [Line Items]
Business combination fair value adjustment to inventories		$ 18
Geographical Segment
Segment Reporting Information [Line Items]
Number of reportable segments | segment			4
EA, AU & PMI DF | Korea
Segment Reporting Information [Line Items]
Non-cash pre-tax charge	$ 204			$ 204
SSEA, CIS & MEA | Net Revenues
Segment Reporting Information [Line Items]
Pre tax charge on termination		$ 80

Segment Reporting_ (Segment Dat

Segment Reporting: (Segment Data) (Details) - USD ($) $ in Millions	3 Months Ended				6 Months Ended
	Jun. 30, 2024		Jun. 30, 2023		Jun. 30, 2024		Jun. 30, 2023
Segment Reporting Information [Line Items]
Net revenues	$ 9,468	[1],[2]	$ 8,967	[1],[2]	$ 18,261	[3],[4]	$ 16,986	[3],[4]
Operating income	3,444		2,566		6,489		5,297
Europe
Segment Reporting Information [Line Items]
Net revenues	3,815		3,574		7,180		6,642
Operating income	1,660		1,619		3,116		2,834
SSEA, CIS & MEA
Segment Reporting Information [Line Items]
Net revenues	2,771		2,668		5,429		5,145
Operating income	891		880		1,663		1,614
EA, AU & PMI DF
Segment Reporting Information [Line Items]
Net revenues	1,673		1,680		3,357		3,200
Operating income	753		557		1,516		1,194
Americas
Segment Reporting Information [Line Items]
Net revenues	1,129		969		2,125		1,837
Operating income	183		243		282		426
Wellness & Healthcare
Segment Reporting Information [Line Items]
Net revenues	80		76		170		162
Operating income	(43)		(733)		(88)		(771)
Combustible Tobacco Products
Segment Reporting Information [Line Items]
Net revenues	5,858		5,790		11,265		11,013
Combustible Tobacco Products | Europe
Segment Reporting Information [Line Items]
Net revenues	2,214		2,108		4,145		3,924
Combustible Tobacco Products | SSEA, CIS & MEA
Segment Reporting Information [Line Items]
Net revenues	2,432		2,350		4,778		4,504
Combustible Tobacco Products | EA, AU & PMI DF
Segment Reporting Information [Line Items]
Net revenues	620		724		1,217		1,412
Combustible Tobacco Products | Americas
Segment Reporting Information [Line Items]
Net revenues	592		608		1,126		1,173
Smoke-Free Products
Segment Reporting Information [Line Items]
Net revenues	3,610		3,177		6,996		5,973
Smoke-Free Products | Smoke-free excluding Wellness and Healthcare:
Segment Reporting Information [Line Items]
Net revenues	3,530		3,101		6,826		5,811
Smoke-Free Products | Europe
Segment Reporting Information [Line Items]
Net revenues	1,601		1,466		3,035		2,718
Smoke-Free Products | SSEA, CIS & MEA
Segment Reporting Information [Line Items]
Net revenues	339		318		651		641
Smoke-Free Products | EA, AU & PMI DF
Segment Reporting Information [Line Items]
Net revenues	1,053		956		2,140		1,788
Smoke-Free Products | Americas
Segment Reporting Information [Line Items]
Net revenues	537		361		999		664
Smoke-Free Products | Wellness & Healthcare
Segment Reporting Information [Line Items]
Net revenues	$ 80		$ 76		$ 170		$ 162
[1]Includes net revenues from related parties of $961 million and $901 million for the three months ended June 30, 2024 and 2023, respectively.[2]Net of excise taxes of $12,923 million and $12,749 million for the three months ended June 30, 2024 and 2023, respectively.[3]Includes net revenues from related parties of $1,821 million and $1,774 million for the six months ended June 30, 2024 and 2023, respectively.[4]Net of excise tax on products of $24,762 million and $24,048 million for the six months ended June 30, 2024 and 2023, respectively.

Contingencies_ (Tobacco-Related

Contingencies: (Tobacco-Related Litigation) (Details) - Canada $ in Thousands, $ in Thousands							1 Months Ended		3 Months Ended
	Mar. 01, 2019 CAD ($)	Mar. 01, 2019 USD ($)	May 27, 2015 CAD ($) plaintiff manufacturer	May 27, 2015 USD ($) plaintiff manufacturer	Jun. 20, 2012 cigarette	Jul. 10, 2009 cigarette	Oct. 30, 2015 CAD ($)	Oct. 30, 2015 USD ($)	Dec. 31, 2019 USD ($)
Adams | Pending Litigation
Loss Contingencies [Line Items]
Minimum number of cigarettes smoked | cigarette						25,000
Suzanne Jacklin | Pending Litigation
Loss Contingencies [Line Items]
Minimum number of cigarettes smoked | cigarette					25,000
Smoking And Health Class Actions | Conseil Quebecois Sur Le Tabac Et La Sante and Jean-Yves Blais
Loss Contingencies [Line Items]
Number of additional manufacturers found liable | manufacturer			2	2
Court-estimated number of members in class | plaintiff			99,957	99,957
Smoking And Health Class Actions | Conseil Quebecois Sur Le Tabac Et La Sante and Jean-Yves Blais | Judicial Ruling | Imperial Tobacco Ltd., Rothmans, Benson And Hedges Inc., And JTI Macdonald Corp.
Loss Contingencies [Line Items]
Compensatory damages awarded			$ 15,500,000	$ 11,300,000
Punitive damages awarded			90	65
Damages, reduced amount	$ 13,500,000	$ 9,800,000
Smoking And Health Class Actions | Conseil Quebecois Sur Le Tabac Et La Sante and Jean-Yves Blais | Judicial Ruling | RBH
Loss Contingencies [Line Items]
Compensatory damages awarded	$ 2,700,000	$ 2,000,000	$ 3,100,000	$ 2,300,000
Damages allocated to subsidiary	20%	20%	20%	20%
Punitive damages awarded			$ 30	$ 22
Smoking And Health Class Actions | Cecilia Letourneau & Conseil Quebecois Sur La Tabac Et La Sante and Jean-Yves Blais Cases | Judicial Ruling | Imperial Tobacco Ltd., Rothmans, Benson And Hedges Inc., And JTI Macdonald Corp.
Loss Contingencies [Line Items]
Amount to be deposited into trust	$ 1,100,000	$ 799,000
Payment period	60 days	60 days
Smoking And Health Class Actions | Cecilia Letourneau & Conseil Quebecois Sur La Tabac Et La Sante and Jean-Yves Blais Cases | Appellate Ruling | RBH
Loss Contingencies [Line Items]
Motion for security ordered by appeals court, paid by defendant							$ 226,000	$ 164,000
Amount of security ordered, funded by defendant	$ 257,000	$ 194,000
Amount of litigation charge | $									$ 194,000
Amount of litigation charge net of tax | $									$ 142,000
Smoking And Health Class Actions | Cecilia Letourneau & Conseil Quebecois Sur La Tabac Et La Sante and Jean-Yves Blais Cases | Appellate Ruling | Imperial Tobacco Ltd.
Loss Contingencies [Line Items]
Motion for security ordered by appeals court							$ 758,000	$ 551,000
Smoking And Health Class Actions | Cecilia Letourneau
Loss Contingencies [Line Items]
Number of additional manufacturers found liable | manufacturer			2	2
Court-estimated number of members in class | plaintiff			918,000	918,000
Smoking And Health Class Actions | Cecilia Letourneau | Judicial Ruling | Imperial Tobacco Ltd., Rothmans, Benson And Hedges Inc., And JTI Macdonald Corp.
Loss Contingencies [Line Items]
Punitive damages awarded			$ 131,000	$ 95,000
Smoking And Health Class Actions | Cecilia Letourneau | Judicial Ruling | RBH
Loss Contingencies [Line Items]
Punitive damages awarded			$ 46,000	$ 33,000
Punitive damages, value	$ 57,000	$ 41,000

Contingencies_ (Combustible Tob

Contingencies: (Combustible Tobacco Products Litigation) (Details) - Combustible Products - Combustible Tobacco Products	354 Months Ended
	Jun. 30, 2024 case
Loss Contingencies [Line Items]
Cases brought against PM	622
Number of cases dismissed	552
Pending cases	70
Claims on appeal, subject to an appeal	4
Claims on final resolution with no material impact	2

Contingencies_ (Smoking and Hea

Contingencies: (Smoking and Health Litigation) (Details) - Combustible Products - case	Jun. 30, 2024	Jun. 30, 2023
Individual Smoking And Health Cases
Loss Contingencies [Line Items]
Cases brought against PM	39	50
Individual Smoking And Health Cases | Argentina
Loss Contingencies [Line Items]
Cases brought against PM	27
Individual Smoking And Health Cases | Canada
Loss Contingencies [Line Items]
Cases brought against PM	2
Individual Smoking And Health Cases | Chile
Loss Contingencies [Line Items]
Cases brought against PM	9
Individual Smoking And Health Cases | Turkey
Loss Contingencies [Line Items]
Cases brought against PM	1
Smoking And Health Class Actions
Loss Contingencies [Line Items]
Cases brought against PM	9	9

Contingencies_ (Health Care Cos

Contingencies: (Health Care Cost Recovery Litigation) (Details) - Health Care Cost Recovery Actions	Apr. 14, 2014 patient	Oct. 17, 2008	Mar. 13, 2008	Feb. 26, 2008	May 25, 2007	May 09, 2007	Jun. 30, 2024 case	Jun. 30, 2023 case
Korea
Loss Contingencies [Line Items]
Damages sought, number of patients | patient	3,484
Nigeria | Pending Litigation | The Attorney General Of Lagos State
Loss Contingencies [Line Items]
Damages sought, period of past reimbursements			20 years
Damages sought, period of future reimbursements			20 years
Nigeria | Pending Litigation | The Attorney General Of Kano State
Loss Contingencies [Line Items]
Damages sought, period of past reimbursements						20 years
Damages sought, period of future reimbursements						20 years
Nigeria | Pending Litigation | The Attorney General Of Gombe State
Loss Contingencies [Line Items]
Damages sought, period of past reimbursements		20 years
Damages sought, period of future reimbursements		20 years
Nigeria | Pending Litigation | The Attorney General Of Oyo State
Loss Contingencies [Line Items]
Damages sought, period of past reimbursements					20 years
Damages sought, period of future reimbursements					20 years
Nigeria | Pending Litigation | The Attorney General Of Ogun State
Loss Contingencies [Line Items]
Damages sought, period of past reimbursements				20 years
Damages sought, period of future reimbursements				20 years
Combustible Products
Loss Contingencies [Line Items]
Cases brought against PM							17	17
Combustible Products | Brazil
Loss Contingencies [Line Items]
Cases brought against PM							1
Combustible Products | Canada
Loss Contingencies [Line Items]
Cases brought against PM							10
Combustible Products | Korea
Loss Contingencies [Line Items]
Cases brought against PM							1
Combustible Products | Nigeria
Loss Contingencies [Line Items]
Cases brought against PM							5

Contingencies_ (Label-Related C

Contingencies: (Label-Related Cases) (Details) - Individual Label Related Cases - Combustible Products - case	Jun. 30, 2024	Jun. 30, 2023
Loss Contingencies [Line Items]
Cases brought against PM	4	5
Italy
Loss Contingencies [Line Items]
Cases brought against PM	1
Chile
Loss Contingencies [Line Items]
Cases brought against PM	3

Contingencies_ (Public Civil Ac

Contingencies: (Public Civil Actions) (Details) - Public Civil Actions - Combustible Products - case	Jun. 30, 2024	Jun. 30, 2023
Loss Contingencies [Line Items]
Cases brought against PM	1	1
Venezuela
Loss Contingencies [Line Items]
Cases brought against PM	1

Contingencies_ (Other Litigatio

Contingencies: (Other Litigation) (Details) € in Millions, ฿ in Millions, $ in Millions

1 Months Ended

Jun. 01, 2022 THB (฿)

Jun. 01, 2022 USD ($)

Sep. 22, 2021 USD ($)

Sep. 22, 2021 EUR (€)

Jan. 26, 2017 THB (฿)

Jan. 26, 2017 USD ($)

Jan. 18, 2016 THB (฿) defendant

Jan. 18, 2016 USD ($) defendant

Jul. 31, 2020 defendant

Mar. 31, 2020 THB (฿)

Mar. 31, 2020 USD ($)

Nov. 30, 2019 THB (฿)

Nov. 30, 2019 USD ($)

Jun. 30, 2024

Megapolis Group

Loss Contingencies [Line Items]

Ownership percentage

23%

Public Prosecutor's Office Of Rome, Italy Vs. Philip Morris Italia S.r.l.

Loss Contingencies [Line Items]

Number of defendants

3

British American Tobacco p.l.c Vs. Philip Morris Italia S.r.l.

Loss Contingencies [Line Items]

Damages sought

$ 54.3

€ 50

Thailand | Other Litigation | The Department of Special Investigations of the Government of Thailand

Loss Contingencies [Line Items]

Fines sought

฿ 122

$ 3.4

฿ 19,800

$ 545

฿ 80,800

$ 2,200

฿ 130

$ 3.6

฿ 1,200

$ 33

Pending Litigation | Thailand | Other Litigation | The Department of Special Investigations of the Government of Thailand

Loss Contingencies [Line Items]

Number of defendants

7

7

Income Taxes_ (Details)

Income Taxes: (Details) $ in Millions, Rp in Trillions	3 Months Ended		6 Months Ended
	Jun. 30, 2024 USD ($)	Jun. 30, 2023 USD ($)	Jun. 30, 2024 USD ($)	Jun. 30, 2024 IDR (Rp)	Jun. 30, 2023 USD ($)
Income Taxes [Line Items]
Effective tax rate (as a percent)	23.70%	24.70%	24.20%	24.20%	20.80%
Income tax expense (benefit)	$ (734)	$ (560)	$ (1,410)		$ (988)
Other tax benefit			(77)
Amount assessed by taxing authorities			238	Rp 3.9
Venezuela Plan
Income Taxes [Line Items]
Income tax expense (benefit)			47
Swedish Match AB
Income Taxes [Line Items]
Income tax expense (benefit)			$ (142)		$ 96
Minimum
Income Taxes [Line Items]
Statute of limitations term			3 years	3 years
Maximum
Income Taxes [Line Items]
Statute of limitations term			5 years	5 years

Indebtedness_ (Short-Term Borro

Indebtedness: (Short-Term Borrowings) (Details) - USD ($) $ in Millions	Jun. 30, 2024	Dec. 31, 2023
Short-term Debt [Line Items]
Amount Outstanding	$ 139	$ 1,968
Commercial paper
Short-term Debt [Line Items]
Amount Outstanding	$ 0	$ 1,685
Average Rate	0%	5.60%
Bank loans
Short-term Debt [Line Items]
Amount Outstanding	$ 139	$ 283
Average Rate	11.60%	8.90%

Indebtedness_ (Schedule of Long

Indebtedness: (Schedule of Long-Term Debt) (Details) - USD ($) $ in Millions	6 Months Ended
	Jun. 30, 2024	Dec. 31, 2023
Debt Instrument [Line Items]
Long-term debt, including current maturities	$ 49,000	$ 45,941
Less current portion of long-term debt	4,353	4,698
Long-term debt	44,647	41,243
Finance lease, liability	$ 43	53
U.S. Dollar Notes
Debt Instrument [Line Items]
Average interest rate	4.572%
Long-term debt, including current maturities	$ 34,059	30,272
U.S. Dollar Notes | Minimum
Debt Instrument [Line Items]
Interest rate, stated percentage	0.875%
U.S. Dollar Notes | Maximum
Debt Instrument [Line Items]
Interest rate, stated percentage	6.375%
Euro Notes | Foreign Currency Obligations
Debt Instrument [Line Items]
Average interest rate	1.921%
Long-term debt, including current maturities	$ 8,103	8,526
Euro Notes | Foreign Currency Obligations | Minimum
Debt Instrument [Line Items]
Interest rate, stated percentage	0.125%
Euro Notes | Foreign Currency Obligations | Maximum
Debt Instrument [Line Items]
Interest rate, stated percentage	3.75%
Swiss Franc Notes | Foreign Currency Obligations
Debt Instrument [Line Items]
Average interest rate	1.625%
Long-term debt, including current maturities	$ 0	299
Euro Bank Loan | Foreign Currency Obligations
Debt Instrument [Line Items]
Average interest rate	4.194%
Long-term debt, including current maturities	$ 5,887	6,121
Swedish Krona Notes | Foreign Currency Obligations
Debt Instrument [Line Items]
Average interest rate	2.016%
Long-term debt, including current maturities	$ 224	236
Swedish Krona Notes | Foreign Currency Obligations | Minimum
Debt Instrument [Line Items]
Interest rate, stated percentage	1.395%
Swedish Krona Notes | Foreign Currency Obligations | Maximum
Debt Instrument [Line Items]
Interest rate, stated percentage	2.71%
Other | Foreign Currency Obligations
Debt Instrument [Line Items]
Average interest rate	6.131%
Long-term debt, including current maturities	$ 727	$ 487

Indebtedness_ (Schedule of Fair

Indebtedness: (Schedule of Fair Value) (Details) $ in Millions	Jun. 30, 2024 USD ($)
Level 1
Debt Instrument [Line Items]
Fair value of outstanding long-term debt	$ 40,607
Level 2
Debt Instrument [Line Items]
Fair value of outstanding long-term debt	$ 6,693

Indebtedness_ (Narrative) (Deta

Indebtedness: (Narrative) (Details) € in Billions

6 Months Ended

Feb. 17, 2023 USD ($)

Nov. 21, 2022 USD ($)

Nov. 10, 2022 USD ($)

Nov. 10, 2022 USD ($)

Nov. 07, 2022 USD ($)

Jun. 23, 2022 USD ($)

May 11, 2022 USD ($)

Jun. 30, 2024 USD ($)

Jun. 30, 2023 USD ($)

Jun. 30, 2024 EUR (€)

Dec. 31, 2023 USD ($)

Dec. 31, 2023 EUR (€)

Dec. 31, 2022

Nov. 11, 2022

Jun. 23, 2022 EUR (€)

Debt Instrument [Line Items]

Principal amount

$ 6,200,000,000

Repayments under credit facilities related to acquisition

0

$ 4,430,000,000

Long-term debt, including current maturities

49,000,000,000

$ 45,941,000,000

Borrowings under credit facilities

0

Amount Outstanding

139,000,000

1,968,000,000

Bank loans

Debt Instrument [Line Items]

Amount Outstanding

139,000,000

283,000,000

Short Term Credit Arrangement

Debt Instrument [Line Items]

Principal amount

2,100,000,000

2,700,000,000

Swedish Match AB

Debt Instrument [Line Items]

Interest acquired

100%

94.81%

85.87%

Senior Unsecured Bridge Facility

Debt Instrument [Line Items]

Debt instrument, term

364 days

Principal amount

$ 11,000,000,000

$ 17,000,000,000

Senior Unsecured Bridge Facility | Swedish Match AB

Debt Instrument [Line Items]

Borrowings under credit facilities related to acquisition

$ 8,400,000,000

$ 500,000,000

$ 7,900,000,000

Repayments under credit facilities related to acquisition

$ 4,400,000,000

$ 4,000,000,000

Senior Unsecured Term Loan

Debt Instrument [Line Items]

Principal amount

$ 5,800,000,000

€ 5.5

Senior Unsecured Term Loan | Swedish Match AB

Debt Instrument [Line Items]

Long-term debt, including current maturities

$ 6,000,000,000

€ 5.5

$ 6,000,000,000

€ 5.5

Senior Unsecured Term Loan | Three year tranche

Debt Instrument [Line Items]

Debt instrument, term

3 years

Principal amount

$ 3,200,000,000

3

Senior Unsecured Term Loan | Five year tranche

Debt Instrument [Line Items]

Principal amount

$ 2,600,000,000

€ 2.5

Indebtedness_ (Debt Issuances O

Indebtedness: (Debt Issuances Outstanding) (Details) € in Millions, $ in Millions	Jun. 30, 2024 USD ($)	Jun. 30, 2024 EUR (€)
US Dollar Notes, 4.750%, Due February 2027
Debt Instrument [Line Items]
Face Value	$ 750
Interest Rate	4.75%	4.75%
US Dollar Notes, 4.875%, Due February 2029
Debt Instrument [Line Items]
Face Value	$ 1,000
Interest Rate	4.875%	4.875%
US Dollar Notes, 5.125%, Due February 2031
Debt Instrument [Line Items]
Face Value	$ 1,250
Interest Rate	5.125%	5.125%
US Dollar Notes, 5.250%, Due February 2034
Debt Instrument [Line Items]
Face Value	$ 1,750
Interest Rate	5.25%	5.25%
Euro Notes, 3.750% Due January 2031
Debt Instrument [Line Items]
Face Value	$ 543	€ 500
Interest Rate	3.75%	3.75%

Indebtedness_ (Schedule of Cred

Indebtedness: (Schedule of Credit Facilities) (Details) - USD ($)	6 Months Ended
	Jun. 30, 2024	Sep. 20, 2023	Jan. 28, 2022
Line of Credit Facility [Line Items]
Committed credit facilities	$ 6,200,000,000
Three Hundred Sixty-Four Day Revolving Credit Expiring January 28, 2025
Line of Credit Facility [Line Items]
Debt instrument, term	364 days
Committed credit facilities	$ 1,700,000,000
Multi-year Revolving Credit Facility, Expiring February 10, 2026
Line of Credit Facility [Line Items]
Committed credit facilities	2,000,000,000
Multi-year Revolving Credit Facility, Expiring September 29, 2026
Line of Credit Facility [Line Items]
Committed credit facilities	$ 2,500,000,000
Multi-year Revolving Credit Facility, Expiring February 10, 2027
Line of Credit Facility [Line Items]
Committed credit facilities			$ 1,900,000,000
Multi-year Revolving Credit Facility, Expiring September 29, 2027
Line of Credit Facility [Line Items]
Committed credit facilities		$ 2,300,000,000

Accumulated Other Comprehensi_3

Accumulated Other Comprehensive Losses: (Details) - USD ($) $ in Millions	Jun. 30, 2024	Mar. 31, 2024	Dec. 31, 2023	Jun. 30, 2023	Mar. 31, 2023	Dec. 31, 2022
Reclassification Adjustment out of Accumulated Other Comprehensive Income on Derivatives [Line Items]
Total accumulated other comprehensive losses	$ (7,942)	$ (8,563)	$ (9,446)	$ (7,960)	$ (7,053)	$ (6,311)
Accumulated Other Comprehensive Losses
Reclassification Adjustment out of Accumulated Other Comprehensive Income on Derivatives [Line Items]
Total accumulated other comprehensive losses	(10,930)	$ (11,065)	(11,815)	(10,045)	$ (9,614)	$ (9,559)
Currency translation adjustments
Reclassification Adjustment out of Accumulated Other Comprehensive Income on Derivatives [Line Items]
Total accumulated other comprehensive losses	(8,841)		(9,467)	(8,678)
Pension and other benefits
Reclassification Adjustment out of Accumulated Other Comprehensive Income on Derivatives [Line Items]
Total accumulated other comprehensive losses	(2,522)		(2,589)	(1,775)
Derivatives accounted for as hedges
Reclassification Adjustment out of Accumulated Other Comprehensive Income on Derivatives [Line Items]
Total accumulated other comprehensive losses	$ 433		$ 241	$ 408

Related Parties - Equity Inve_3

Related Parties - Equity Investments and Other: (Narrative) (Details) - USD ($) $ in Millions	6 Months Ended	12 Months Ended
	Jun. 30, 2024	Dec. 31, 2023	May 31, 2024	Apr. 30, 2023	Mar. 22, 2019
Schedule of Equity Method Investments [Line Items]
Equity method investments	$ 1,145	$ 1,309
Difference between equity method investment carrying value and book value	1,075	907
Dividends from unconsolidated subsidiaries	0	57
Equity securities, unrealized gain (loss)	319
Equity securities, unrealized gain (loss), net	242
Definite-Lived Intangibles And Other Assets
Schedule of Equity Method Investments [Line Items]
Difference between equity method investment carrying value and book value	153	$ 31
Level 1
Schedule of Equity Method Investments [Line Items]
Equity securities, noncurrent	$ 694
IPM India
Schedule of Equity Method Investments [Line Items]
Parent ownership percentage	56.30%
TTI | PMM
Schedule of Equity Method Investments [Line Items]
Noncontrolling ownership percentage	33%
Megapolis Group
Schedule of Equity Method Investments [Line Items]
Equity method investments	$ 431
Ownership percentage	23%
Cumulative foreign currency translation losses	$ 540
EITA
Schedule of Equity Method Investments [Line Items]
Ownership percentage	49%
STAEM
Schedule of Equity Method Investments [Line Items]
Ownership percentage	25%
STAEM | EITA
Schedule of Equity Method Investments [Line Items]
Ownership percentage	51%
STAEM | Management Et Developpement Des Actifs Et Des Ressources Holding (MADAR Holding)
Schedule of Equity Method Investments [Line Items]
Ownership percentage	49%
RBH
Schedule of Equity Method Investments [Line Items]
Equity securities					$ 3,280
UTC
Schedule of Equity Method Investments [Line Items]
Ownership percentage				25%
Eastern
Schedule of Equity Method Investments [Line Items]
Ownership percentage			14.70%

Related Parties - Equity Inve_4

Related Parties - Equity Investments and Other: (Balance Sheet and Earnings Activity) (Details) - USD ($) $ in Millions		3 Months Ended				6 Months Ended
		Jun. 30, 2024		Jun. 30, 2023		Jun. 30, 2024		Jun. 30, 2023		Dec. 31, 2023
Schedule of Equity Method Investments [Line Items]
Net revenues		$ 9,468	[1],[2]	$ 8,967	[1],[2]	$ 18,261	[3],[4]	$ 16,986	[3],[4]
Expenses		33		63		73		113
Trade receivables, related parties	[5]	4,240				4,240				$ 3,461
Payables		3,591				3,591				4,143
Related Party
Schedule of Equity Method Investments [Line Items]
Net revenues		961		901		1,821		1,774
Trade receivables, related parties		834				834				710
Payables		28				28				18
Megapolis Group | Related Party
Schedule of Equity Method Investments [Line Items]
Net revenues		576		596		1,096		1,184
Trade receivables, related parties		535				535				474
Other
Schedule of Equity Method Investments [Line Items]
Expenses		33		63		73		113
Other | Related Party
Schedule of Equity Method Investments [Line Items]
Net revenues		385		$ 305		725		$ 590
Trade receivables, related parties		299				299				236
Payables		$ 28				$ 28				$ 18
[1]Includes net revenues from related parties of $961 million and $901 million for the three months ended June 30, 2024 and 2023, respectively.[2]Net of excise taxes of $12,923 million and $12,749 million for the three months ended June 30, 2024 and 2023, respectively.[3]Includes net revenues from related parties of $1,821 million and $1,774 million for the six months ended June 30, 2024 and 2023, respectively.[4]Net of excise tax on products of $24,762 million and $24,048 million for the six months ended June 30, 2024 and 2023, respectively.[5] Includes trade receivables from related parties of $834 million and $710 million as of June 30, 2024, and December 31, 2023, respectively. For further details, see Note 12. Related Parties - Equity Investments and Other.

Sale of Accounts Receivable_ (N

Sale of Accounts Receivable: (Narrative) (Details) $ in Millions	3 Months Ended		6 Months Ended
	Jun. 30, 2024 USD ($) arrangement	Jun. 30, 2023 USD ($)	Jun. 30, 2024 USD ($) arrangement	Jun. 30, 2023 USD ($)
Sale of Accounts Receivable [Abstract]
Trade receivable, arrangement | arrangement	2		2
Cumulative trade receivables sold			$ 5,600	$ 6,100
Trade receivables sold and derecognized that remain uncollected	$ 700	$ 700	700	700
Loss on sale of accounts receivable	$ 10	$ 14	$ 22	$ 24

Sale of Accounts Receivable_ Lo

Sale of Accounts Receivable: Loss on Sale of Trade Receivables (Details) - USD ($) $ in Millions	3 Months Ended		6 Months Ended
	Jun. 30, 2024	Jun. 30, 2023	Jun. 30, 2024	Jun. 30, 2023
Sale of Accounts Receivable [Abstract]
Loss on sale of trade receivables	$ 10	$ 14	$ 22	$ 24

Product Warranty_ (Narrative) (

Product Warranty: (Narrative) (Details)	6 Months Ended
	Jun. 30, 2024
Guarantees and Product Warranties [Abstract]
Standard product warranty term	12 months

Product Warranty_ (Movement in

Product Warranty: (Movement in Product Warranty Obligations) (Details) - USD ($) $ in Millions	6 Months Ended	12 Months Ended
	Jun. 30, 2024	Dec. 31, 2023
Movement in Standard Product Warranty Accrual [Roll Forward]
Balance at beginning of period	$ 80	$ 104
Changes due to:
Warranties issued	45	60
Settlements	(38)	(83)
Currency/Other	0	(1)
Balance at end of period	$ 87	$ 80

Asset Impairment and Exit Cos_3

Asset Impairment and Exit Costs: (Narrative) (Details) - USD ($)	3 Months Ended				6 Months Ended
	Jun. 30, 2024	Mar. 31, 2024	Jun. 30, 2023	Mar. 31, 2023	Dec. 31, 2024	Jun. 30, 2024	Jun. 30, 2023
Restructuring Cost and Reserve [Line Items]
Restructuring and related cost, incurred cost	$ 0		$ 0			$ 168,000,000	$ 109,000,000
Impairment of goodwill and other intangibles	$ 0		680,000,000			27,000,000	680,000,000
Total reclassification of accumulated foreign currency translation losses from other comprehensive losses						38,000,000	0
Future cash payments for exit costs expected to be paid						32,000,000
In Process Research and Development
Restructuring Cost and Reserve [Line Items]
Non-amortizable intangible asset impairment		$ 27,000,000	$ 15,000,000			27,000,000	15,000,000
Forecast
Restructuring Cost and Reserve [Line Items]
Future cash payments for exit costs expected to be paid					$ 32,000,000
e-Vapor Products Manufacturing Optimization
Restructuring Cost and Reserve [Line Items]
Restructuring and related cost, incurred cost				$ 109,000,000
Venezuela Plan
Restructuring Cost and Reserve [Line Items]
Restructuring and related cost, incurred cost		47,000,000
Total reclassification of accumulated foreign currency translation losses from other comprehensive losses		38,000,000
US Restructuring
Restructuring Cost and Reserve [Line Items]
Restructuring and related cost, incurred cost		121,000,000
Contract Termination
Restructuring Cost and Reserve [Line Items]
Restructuring and related cost, incurred cost						65,000,000	78,000,000
Contract Termination | e-Vapor Products Manufacturing Optimization
Restructuring Cost and Reserve [Line Items]
Restructuring and related cost, incurred cost				78,000,000
Contract Termination | Venezuela Plan
Restructuring Cost and Reserve [Line Items]
Restructuring and related cost, incurred cost		4,000,000
Contract Termination | US Restructuring
Restructuring Cost and Reserve [Line Items]
Restructuring and related cost, incurred cost		61,000,000
Finance Lease Termination | e-Vapor Products Manufacturing Optimization
Restructuring Cost and Reserve [Line Items]
Restructuring and related cost, incurred cost				21,000,000
Pre Paid Commitments | US Restructuring
Restructuring Cost and Reserve [Line Items]
Restructuring and related cost, incurred cost		20,000,000
Asset Impairment
Restructuring Cost and Reserve [Line Items]
Restructuring and related cost, incurred cost						$ 65,000,000	$ 31,000,000
Asset Impairment | e-Vapor Products Manufacturing Optimization
Restructuring Cost and Reserve [Line Items]
Restructuring and related cost, incurred cost				$ 31,000,000
Asset Impairment | Venezuela Plan
Restructuring Cost and Reserve [Line Items]
Restructuring and related cost, incurred cost		5,000,000
Asset Impairment | US Restructuring
Restructuring Cost and Reserve [Line Items]
Restructuring and related cost, incurred cost		$ 60,000,000

Asset Impairment and Exit Cos_4

Asset Impairment and Exit Costs: (Asset Impairment and Exit Costs by Segment) (Details) - USD ($)	3 Months Ended		6 Months Ended
	Jun. 30, 2024	Jun. 30, 2023	Jun. 30, 2024	Jun. 30, 2023
Restructuring Cost and Reserve [Line Items]
Total reclassification of accumulated foreign currency translation losses from other comprehensive losses			$ 38,000,000	$ 0
Restructuring and related cost, incurred cost	$ 0	$ 0	168,000,000	109,000,000
Contract Termination
Restructuring Cost and Reserve [Line Items]
Restructuring and related cost, incurred cost			65,000,000	78,000,000
Asset Impairment
Restructuring Cost and Reserve [Line Items]
Restructuring and related cost, incurred cost			65,000,000	31,000,000
Americas | Operating Segments
Restructuring Cost and Reserve [Line Items]
Total reclassification of accumulated foreign currency translation losses from other comprehensive losses			38,000,000	0
Americas | Operating Segments | Contract Termination
Restructuring Cost and Reserve [Line Items]
Restructuring and related cost, incurred cost			65,000,000	7,000,000
Americas | Operating Segments | Asset Impairment
Restructuring Cost and Reserve [Line Items]
Restructuring and related cost, incurred cost			65,000,000	4,000,000
Europe | Operating Segments | Contract Termination
Restructuring Cost and Reserve [Line Items]
Restructuring and related cost, incurred cost			0	34,000,000
Europe | Operating Segments | Asset Impairment
Restructuring Cost and Reserve [Line Items]
Restructuring and related cost, incurred cost			0	13,000,000
SSEA, CIS & MEA | Operating Segments | Contract Termination
Restructuring Cost and Reserve [Line Items]
Restructuring and related cost, incurred cost			0	23,000,000
SSEA, CIS & MEA | Operating Segments | Asset Impairment
Restructuring Cost and Reserve [Line Items]
Restructuring and related cost, incurred cost			0	9,000,000
EA, AU & PMI DF | Operating Segments | Contract Termination
Restructuring Cost and Reserve [Line Items]
Restructuring and related cost, incurred cost			0	14,000,000
EA, AU & PMI DF | Operating Segments | Asset Impairment
Restructuring Cost and Reserve [Line Items]
Restructuring and related cost, incurred cost			$ 0	$ 5,000,000

Asset Impairment and Exit Cos_5

Asset Impairment and Exit Costs: (Movement in Exit Cost Liabilities) (Details) $ in Millions	6 Months Ended
	Jun. 30, 2024 USD ($)
Movement in exit cost liabilities
Liability balance, January 1, 2024	$ 29
Charges, net	65
Cash spent	(32)
Prepaid commitments	(20)
Currency/other	1
Liability balance, June 30, 2024	$ 43

Leases_ (Details)

Leases: (Details) - USD ($) $ in Millions	3 Months Ended		6 Months Ended
	Jun. 30, 2024	Jun. 30, 2023	Jun. 30, 2024	Jun. 30, 2023
Leases [Abstract]
Operating lease cost	$ 72	$ 66	$ 138	$ 133
Amortization of right-of-use assets	12	14	37	28
Interest on lease liabilities	1	0	1	0
Short-term lease cost	16	15	32	29
Variable lease cost	6	7	13	14
Total lease cost	$ 107	$ 102	$ 221	$ 204

Supply Chain Financing_ (Detail

Supply Chain Financing: (Details) - USD ($) $ in Billions	Jun. 30, 2024	Dec. 31, 2023
Supplier Finance Program [Line Items]
Supply chain payment terms	120 days
Supply Chain Financing Program
Supplier Finance Program [Line Items]
Supply chain financing, obligation, current	$ 0.8	$ 0.9

Acquisitions_ (Narrative) (Deta

Acquisitions: (Narrative) (Details) - USD ($) $ in Millions		1 Months Ended	3 Months Ended			6 Months Ended
	May 16, 2024	Jan. 31, 2023	Jun. 30, 2024	Jun. 30, 2023	Mar. 31, 2022	Jun. 30, 2024	Jun. 30, 2023	Jul. 14, 2023	Apr. 30, 2023	Oct. 20, 2022
Business Acquisition [Line Items]
Proceeds from sale of holdings		$ 258
Cumulative foreign currency translation losses			$ 113	$ 2		$ 155	$ 2
UTC
Business Acquisition [Line Items]
Ownership percentage									25%
Altria Group
Business Acquisition [Line Items]
Commercial agreement, total cash consideration										$ 2,800
Commercial agreement, initial payment										$ 1,000
Commercial agreement, payment								$ 1,800
Altria Group | Other
Business Acquisition [Line Items]
Acquired intangible assets, estimated useful life						5 years
Additional Paid-in Capital
Business Acquisition [Line Items]
Purchase of subsidiary shares from noncontrolling interests					$ 30
Sale of subsidiary shares from noncontrolling interests		36
Accumulated Other Comprehensive Losses
Business Acquisition [Line Items]
Purchase of subsidiary shares from noncontrolling interests					$ 171
Sale of subsidiary shares from noncontrolling interests		$ 179
Noncontrolling Interest Purchase Philip Morris Tütün Mamulleri Sanayi ve Ticaret A.Ş.
Business Acquisition [Line Items]
Interest acquired					25%
Noncontrolling Interest Purchase Philip Morris Pazarlama ve Satış A.Ş.
Business Acquisition [Line Items]
Interest acquired					24.75%
Noncontrolling interest purchase
Business Acquisition [Line Items]
Payments to acquire noncontrolling interests					$ 223
Ownership percentage					100%
EIH
Business Acquisition [Line Items]
Interest acquired									66.73%
UTC
Business Acquisition [Line Items]
Book value of investment	$ 312
Percentage of indirect economic interest	54.25%
Cumulative foreign currency translation losses	$ 112
Total purchase price for the incremental equity interest	315
Payments to acquire noncontrolling interests	30
UTC | Contingent Consideration
Business Acquisition [Line Items]
Liabilities incurred	22
UTC | Borrowings
Business Acquisition [Line Items]
Liabilities incurred	$ 263

Acquisitions_ (Purchase Price A

Acquisitions: (Purchase Price Allocation) (Details) - USD ($) $ in Millions	Jun. 30, 2024	May 16, 2024	Dec. 31, 2023
Net assets acquired based on fair values:
Goodwill	$ 16,819		$ 16,779
UTC
Net assets acquired based on fair values:
Cash and cash equivalent		$ 74
Current assets, including receivables and inventories		11
Other intangible assets - Tobacco manufacturing license		211
Other non-current assets, including property, plant and equipment		16
Current liabilities		(8)
Identifiable net assets acquired		304
Noncontrolling interest		(159)
Goodwill		510
Acquisition fair value		$ 655